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1 Abstract 
Cancer cells frequently escape from immune surveillance by down-regulating two 
important components of the immune defence: antigen-presenting MHC and 
costimulatory molecules. Therefore several novel anti-tumour compounds that aim to 
assist the immune system in recognising and fighting cancer are currently under 
development. Recombinant bispecific antibodies represent one group of such novel 
therapeutics. They target two different antigens and recruit cytotoxic effector cells to 
tumour cells. For cancer immunotherapy, bispecific T cell-engaging antibodies are 
already well characterised. These antibodies target a tumour-associated antigen and 
CD3ε, the constant molecule of the T cell receptor complex. 
On the one hand, this study presents the development of a bispecific antibody targeting 
CD3ε and the rhabdomyosarcoma-associated fetal acetylcholine receptor. On the other 
hand, it describes a novel two-part trispecific antibody format for the treatment of 
leukaemia and other haematological malignancies in the context of haematopoietic 
stem cell transplantation (HSCT). 
For HSCT, an HLA-identical donor is preferred, but very rarely available. In an HLA-
mismatched setting, the HLA disparity could be exploited for targeted cancer treatment. 
In the present study, a two-part trispecific HLA-A2 × CD45 × CD3 antibody was 
developed for potential cases in which the patient is HLA-A2-positive, but the donor is 
not. This holds true for about half the cases in Germany, since HLA-A2 is the most 
common HLA molecule found here. Combinatorial targeting of HLA-A2 and the 
leucocyte-common antigen CD45 allows for highly specific dual-antigen restricted 
tumour targeting. 
More precisely, two single-chain antibody constructs were developed: i) a single-chain 
variable fragment (scFv) specific for HLA-A2, and ii) a scFv against CD45, both linked 
to the VL and the VH domain of a CD3ε-specific antibody, respectively. It turned out 
that, after the concomitant binding of these constructs to the same HLA-A2- and CD45-
expressing cell, the unpaired variable domains of a CD3ε-specific antibody assembled 
to a functional scFv. In a therapeutic situation, this assembly should exclusively occur 
on the recipient’s blood cancer cells, leading to T cell-mediated cancer cell destruction. 
In this way, a relapse of disease might be prevented, and standard therapy (radiation 
and chemotherapy) might be omitted. 
For both approaches, the antibody constructs were periplasmically expressed in E. coli, 
purified via His tag, and biochemically characterised. Their binding to the respective 
targets was proven by flow cytometry. The stimulatory properties of the antibodies were 
assayed by measuring IL-2 release after incubation with T cells and antigen-expressing 
target cells. Both the bispecific antibody against rhabdomyosarcoma and the 
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assembled trispecific antibody against blood cancer mediated T-cell activation in 
a concentration-dependent manner at nanomolar concentrations. For the trispecific 
antibody, this effect indeed proved to be dual antigen-restricted, as it could be blocked 
by prior incubation of either HLA-A2- or CD45-specific scFv and did not occur on 
single-positive (CD45+) or double-negative (HLA-A2- CD45-) target cells. Furthermore, 
antibodies from both approaches recruited T cells for tumour cell destruction in vitro. 
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Kurzbeschreibung 
Krebszellen entgehen der Immunüberwachung oftmals dadurch, dass sie zwei wichtige 
Komponenten der Immunabwehr, nämlich antigenpräsentierende MHC- und 
kostimulatorische Moleküle, herunter regeln. Zurzeit befindet sich daher eine Reihe 
neuartiger Anti-Krebs-Substanzen in der Entwicklung, die darauf abzielen, das 
Immunsystem beim Erkennen und Bekämpfen von Krebs zu unterstützen. 
Rekombinante bispezifische Antikörper stellen eine Gruppe solch neuartiger 
Therapeutika dar. Sie erkennen zwei unterschiedliche Antigene und rekrutieren gezielt 
zytotoxische Effektorzellen zu Tumorzellen. Zur Krebsimmuntherapie sind BiTE-
Antikörper (bispecific T cell engager) bereits gut untersucht. Diese Antikörper sind 
gegen ein tumorassoziiertes Antigen sowie gegen CD3ε, das konstante Molekül des 
T-Zell-Rezeptor-Komplexes, gerichtet. 
Diese Arbeit beschreibt zum einen die Entwicklung eines bispezifischen Antikörpers, 
der CD3ε und den mit Rhabdomyosarkom assoziierten fetalen Acetylcholinrezeptor 
erkennt. Zum anderen präsentiert sie ein neues, zweiteiliges trispezifisches 
Antikörperformat, das zur Behandlung von Leukämie und anderen bösartigen 
Erkrankungen des blutbildenden Systems im Zusammenhang mit hämatopoetischer 
Stammzelltransplantation (HSZT) genutzt werden könnte. 
Für eine HSZT wird ein HLA-identischer Spender bevorzugt. Dieser steht jedoch nur 
sehr selten zur Verfügung. In Fällen mit nur einer Unstimmigkeit in den HLA-
Merkmalen zwischen Patient und Spender könnte diese HLA-Unstimmigkeit nun zur 
gezielten Krebsbehandlung ausgenutzt werden. In dieser Arbeit wurde ein 
trispezifisches HLA-A2 × CD45 × CD3 Antikörperkonstrukt speziell für solche Fälle 
entwickelt, in denen der Patient HLA-A2-positiv ist, der Spender jedoch nicht. Dies trifft 
in Deutschland auf ungefähr die Hälfte aller Fälle zu, da HLA-A2 hier als häufigstes 
HLA-Molekül vorkommt. Mit der Kombination aus HLA-A2 und dem Pan-
Leukozytenmarker CD45 (leucocyte-common antigen) als Ziel, wird eine 
hochspezifische, von zwei Antigenen abhängige, zielgerichtete Tumoransteuerung 
(tumour targeting) möglich. 
Genauer gesagt wurden zwei Einzelketten-Antikörperkonstrukte entwickelt: i) ein 
HLA-A2-spezifisches single-chain variable fragment (scFv) und ii) ein CD45-
spezifisches scFv, jeweils verbunden mit der VL- bzw. der VH-Domäne eines CD3ε-
spezifischen Antikörpers. Es stellte sich heraus, dass nach gleichzeitiger Bindung der 
beiden Konstrukte an dieselbe HLA-A2- und CD45-exprimierende Zelle sich die beiden 
einzelnen, ungepaarten variablen Domänen eines CD3ε-spezifischen Antikörpers zu 
einem funktionellen scFv zusammenfügen. Dieses Zusammenfügen sollte in einer 
therapeutischen Situation ausschließlich auf den Blutkrebszellen des Empfängers 
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geschehen, was zur T-Zell-vermittelten Zerstörung der Krebszellen führen würde. Auf 
diese Weise könnte ein Rückfall der Erkrankung vermieden und eventuell sogar auf die 
Standardtherapie (Bestrahlung und Chemotherapie) verzichtet werden.  
Für die beiden beschriebenen Ansätze wurden die Antikörperkonstrukte 
periplasmatisch in E. coli exprimiert, über einen His-Tag aufgereinigt und biochemisch 
charakterisiert. Ihre Bindung an die jeweiligen Zielantigene wurde mittels 
Durchflusszytometrie nachgewiesen. Die stimulatorischen Eigenschaften der 
Antikörper wurden durch eine Messung der IL-2-Freisetzung nach Inkubation 
zusammen mit T-Zellen und antigenexprimierenden Zielzellen untersucht. Sowohl der 
gegen Rhabdomyosarkom gerichtete BiTE-Antikörper, als auch der zusammengefügte 
trispezifische Antikörper gegen Blutkrebs vermittelten konzentrationsabhängig eine 
T-Zellaktivierung bei nanomolaren Konzentrationen. Für den trispezifischen Antikörper 
erwies sich dieser Effekt tatsächlich als abhängig von zwei Antigenen, da er durch eine 
vorausgehende Inkubation mit entweder einem HLA-A2- oder einem CD45-
spezifischen scFv-Fragment geblockt werden konnte und nicht auf Zellen auftrat, die 
nur ein Antigen (CD45+) oder keins von beiden (HLA-A2- CD45-) tragen. Darüber 
hinaus rekrutierten die Antikörper beider Ansätze T-Zellen zur Zerstörung von 
Tumorzellen in vitro. 
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2 Introduction 
2.1 Cancer Prevalence and Motivation for the Project 
Worldwide, an estimated 12.7 million new cancer cases were diagnosed in 2008 
[Jemal et al., 2011]. Being a leading cause of death, cancer accounted for 7.6 million 
deaths around the world, which corresponds to 13 % of all human deaths, in 2008. In 
Germany, cancer is the second most common cause of death right after cardiovascular 
diseases. The latest appropriate data of the so-called cancer atlas of the Federal 
Republic of Germany provided by the German Cancer Research Centre indicate that of 
all deceased in 2010, 22 % of women and 29 % of men died due to cancer [Becker and 
Wahrendorf, 1998; update on internet www.krebsatlas.de]. The most common cancers 
are principally identical for both sexes. The leading causes of cancer deaths in females 
were breast cancer (19 %), lung cancer (16 %), and colorectal cancer (10 %). For 
males, lung cancer (26 %), colorectal cancer (11 %), and prostate cancer (9 %) were 
the most frequent. Haematological malignancies, including leukaemias, lymphomas, 
and multiple myelomas, were diagnosed in approximately 35,000 cases, which 
accounts for 13.6 % of new cancer diagnoses, leading to about 17,600 deaths (8 %) 
[GEKID atlas on internet www.gekid.de]. On account of the increasing average life 
expectancy of the population in developed countries, the overall cancer mortality rates 
will continue to rise. For years, blood cancer and other cancers have been mostly 
treated with chemotherapy and radiation. Unfortunately, these conventional treatments 
of cancer can have a negative effect on normal cells. Due to their lacking selectivity for 
tumour tissue and their mainly cytotoxic and cytostatic manner of acting on proliferating 
tissues, such treatments often cause severe side effects, thus limiting the administrable 
dose and, in turn, the therapeutical efficiency. Therefore, targeted therapies are gaining 
ground. These aim to target the tumour tissue specifically while leaving the healthy 
tissue unaffected, and ideally induce an immune response against the tumour. 
2.2 Targets in Tumour Therapy 
Tumour cells can express unique antigens and developmentally down-regulated 
antigens, which can be recognised by the immune system either by specific immune 
effector cells and / or by antibodies. Thus, the immune system is able to distinguish 
between normal and malignant cells. For use as targeted cancer therapy, a number of 
potential antigens have been identified. Initially, two main categories of such targets 
have been classified: tumour-specific antigens (TSA) and tumour-associated antigens 
(TAA). TSA are only expressed on tumour cells. TAA are overexpressed on tumour 
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cells, but are also found on some healthy cells, albeit to a lesser extent. However, over 
time many tumour-specific antigens have been found on healthy cells as well, so that 
TAA, although of heterogeneous nature, are nowadays subdivided into four major 
groups by their expression pattern: unique antigens (including mutation antigens and 
viral antigens), cancer/testis antigens, differentiation antigens, and overexpressed 
antigens [Gires and Seliger, 2009]. 
One of the major limitations of using tumour cells as targets in tumour therapy is the 
necessity of the presence of tumour markers which are not expressed on normal 
tissue. On that account, possible targets should be chosen very carefully. 
2.2.1 Fetal Acetylcholine Receptor and Rhabdomyosarcoma 
The nicotinic acetylcholine receptor (AChR) is a transmembrane protein, more 
precisely a cholinergic receptor that forms an ion channel [Silbernagl and Despopoulos, 
2003]. It is located at the neuromuscular junctions on the postsynaptic side and is 
activated by the binding of the neurotransmitter acetylcholine – or nicotine – across the 
synapse. Binding of acetylcholine causes conformational changes and thus an opening 
of the pore, which allows Na+ and K+ ions to diffuse through the receptor, leading to 
a depolarisation of the muscle fibre, the so-called end-plate potential. On that account, 
voltage-gated Na+ channels are opened, and – when a threshold is reached – an action 
potential and finally muscular contraction occurs. 
In humans, the AChR occurs in two isoforms: in a fetal isoform (fAChR) or in an adult 
isoform [Mishina et al., 1986]. The AChR is a glycosylated protein of 290 kDa with 
a total length of about 16 nm. It is composed of five separate but structurally related 
subunits: two α, one β, one δ, and one ε (adult) or γ (fetal) subunit [Unwin, 2000; 2005] 
(Fig. 2.1). Its pentameric structure is further divided into three domains: a large 
N-terminal extracellular ligand-binding domain, a membrane-spanning pore, and 
a smaller intracellular domain [Unwin, 2005]. In the course of the development of the 
neuromuscular junction, the γ subunit of the fetal AChR (α2βγδ) is exchanged by an 
ε subunit, resulting in the mature AChR subtype (α2βεδ) [Mishina et al., 1986; 
Witzemann et al., 1987]. This gradual transition is genetically controlled [Missias et al., 
1996]. After the first postnatal week, the mature AChR is found in nearly all innervated 
muscles, while the fAChR is exclusively expressed into adulthood on a few tissues, 
including extraocular muscle [Horton et al., 1993; Kaminski et al., 1996] and thymic 
myoid cells [Schluep et al., 1987; Marx et al., 1989]. This normal expression aside, 
a high expression of fAChR was found on the vast majority of human 
rhabdomyosarcomas [Gattenloehner et al., 1998], making fAChR a promising tumour 
target for immunotherapy.  
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Fig. 2.1:  The nicotinic acetylcholine receptor (AChR). A) The crystal structure of AChR in top and 
side view. The membrane is indicated by grey horizontal bars. Reprinted from Unwin [2005] 
with permission from Elsevier. B) The AChR is of pentameric structure and composed of either 
α2βγδ (fetal form) or α2βεδ (adult form). Each of the subunits consists of an extracellular, 
a transmembrane, and a cytoplasmic domain. Antibodies found in most patients with 
myasthenia gravis bind to the main immunogenic region, which is different from the 
acetylcholine-binding site. The fetal-specific antibodies that cause arthrogryposis multiplex 
congenita bind close to the acetylcholine binding site and block the function of the fetal AChR. 
E, extracellular; I, intracellular. Adapted from Vincent [2002]. 
Rhabdomyosarcoma comprises a heterogeneous group of the single most soft-tissue 
malignancies in children and adolescents [Newton et al., 1995]. The two major forms of 
rhabdomyosarcoma in children are alveolar and embryonal rhabdomyosarcoma. The 
alveolar form, which typically shows more aggressive clinical behaviour and a poor 
prognosis, can be classified by gene expression profiling [Davicioni et al., 2009]. For 
patients with rhabdomyosarcoma, risk-adapted multimodality therapy is used, including 
surgery, chemotherapy, and usually radiotherapy, depending on the correct pathologic 
diagnosis, histologic subtype, primary site, extent of disease, and extent of resection 
[Gosiengfiao et al., 2012]. Systemic chemotherapy is required in almost all cases, 
though. Due to the new multimodality therapy, rhabdomyosarcoma is now curable in 
most patients with localised disease with more than 70 % surviving five years after 
diagnosis [Walterhouse and Watson, 2007]. However, the prognosis remains poor for 
patients with metastatic or recurrent diseases, resulting in five-year survival rates of 
20 – 30 %. Children over 10 years of age or those with bone and / or bone marrow 
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metastases have an even lower survival rate of about 5 % [Carli et al., 2004; 
Koscielniak et al., 2002]. Hence, there is an urgent need for new therapeutic 
approaches, especially for those with the poorest prognoses. A possible novel 
approach could be a fAChR-targeting immunotherapy. Knowledge of the existence of 
anti-AChR and anti-fAChR antibodies was gained from myasthenia gravis, an 
autoimmune neuromuscular disease most commonly caused by the appearance of 
anti-AChR antibodies [Lindstrom et al., 1976; Vincent, 2002]. In a few cases of 
pregnant women with myasthenia gravis, anti-fAChR antibodies can emerge and pass 
through the placenta to their unborn babies. These antibodies cause arthrogryposis 
multiplex congenita in the unborn babies by blocking the function of the fetal AChR, 
leading to a paralysis of the unborn baby [Riemersma et al., 1996]. As the antibodies 
do not bind adult AChR (see Fig. 2.1), some of these women were entirely unaffected. 
On account of these findings, the use of a fAChR-targeting approach can be assumed 
to be safe; i.e. it is unlikely to induce serious side effects. Additionally, they show that 
the γ subunit of the fAChR bears immunologically available epitopes. Finally, the 
thymus of the above mentioned women appeared to be a beneficial source for the 
successful isolation of human antibodies highly specific for fAChR [Matthews et al., 
2002]. These antibodies, or more precisely Fabs (Fab, fragment antigen-binding), were 
isolated from a thymic combinatorial cDNA library from a myasthenia gravis patient with 
high levels of AChRγ-specific autoantibodies. One of those Fabs, namely Fab35, was 
converted into the single-chain variable fragment (scFv) format in order to generate 
a chimeric antigen receptor (CAR), which is also known as chimeric T-cell receptor 
[Gattenlöhner et al., 2006]. This AChRγ-specific CAR was shown to kill 
rhabdomyosarcoma cell lines that express fAChR in vitro and in vivo, but with 
suboptimal results, as it needed an additive blockade of survivin, an antiapoptotic 
molecule [Simon-Keller et al., 2013]. However, among other obstacles, a routine 
application of such an adoptive T-cell therapy in the clinic is mainly limited by the need 
of ex vivo culture and sophisticated techniques [Neoptolemos et al., 2010]. 
Alternatively, an immunotoxin generated by fusing the same scFv to an exotoxin A 
(scFv35-ETA) has already been generated and tested in vitro and in vivo [Gattenlöhner 
et al., 2010]. 
2.2.2 HLA-A2 and the Function of MHC Molecules 
HLA-A2 is a serotype of the human leucocyte antigen (HLA), the human version of the 
major histocompatibility complex (MHC). MHC molecules are cell-surface glycoproteins 
with a peptide-binding cleft that can bind a wide variety of different peptides and they 
are encoded in a large cluster of genes, known as the MHC, located in humans on 
chromosome 6. MHC molecules are mainly responsible for antigen presentation, which 
is important for the induction and regulation of adaptive immune responses. More 
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precisely, the MHC molecules are involved in the T-cell activation through the T-cell 
receptor (TCR) (see Section 2.4.2) by presenting short peptide fragments of foreign 
proteins (antigens) to TCRs. A combination of polygeny and an extensive 
polymorphism of the MHC leads to a great diversity of MHC molecules and thus to an 
extended range of peptides that can be presented to T cells by each individual and the 
population at large. There are two classes of MHC molecules, which are of similar 
structure (Fig. 2.2), but different in the origin of the peptides they capture and transport 
to the cell surface for the purpose of antigen presentation. MHC class I molecules are 
composed of two polypeptide chains, a membrane-inserted heavy chain α (44 kDa) 
folding into three domains, and β2-microglobulin (β2m, 12 kDa), which associates 
noncovalently and is monomorphic, so it does not vary in sequence between 
individuals. MHC class II molecules are based on a noncovalent complex of two chains 
of similar size, α (34 kDa) and β (29 kDa). The length of MHC molecules is 





Fig. 2.2:  Schematic structure of MHC molecules. A) MHC class I (left) and MHC class II (right). 
B) Crystal structure of the human MHC class I molecule, HLA-A2, without the transmembrane 
region. Image from the RCSB Protein Data Bank (www.pdb.org, Berman et al., 2000) of 
PDB ID 3HLA [Saper et al., 1991]. β2m, β2-microglobulin. 
Their most striking feature is a cleft formed by the two outermost domains, which 
characterises their peptide-binding specificity (Fig. 2.3). Peptide binding, in turn, 
stabilises the molecule’s whole structure. Peptides, so-called T cell epitopes, presented 
by the MHC class I molecules are usually 8 – 10 amino acids (aa) long and derive from 
proteins degraded in the cytosol by the proteasome, a multicatalytic protease complex. 
MHC class II molecules bind peptides from proteins that are degraded in endosomes 
and about 13 – 17 aa long, but the length is not constrained here.  
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Fig. 2.3:  Peptide-binding cleft of human MHC class I molecule. Depicted in complex with an 
antigenic nonapeptide in top view. Image from the RCSB Protein Data Bank (www.pdb.org, 
Berman et al., 2000) of PDB ID 1B0G [Zhao et al., 1999] slightly modified. Assumed binding 
site of the antibody fragment 3PF12 is encircled on the α2 domain of the HLA class I molecule 
HLA-A2 according to Watkins et al. [2000]. 
Having reached the cell surface, the MHC-peptide complexes are recognised by 
different functional classes of T cell by means of their TCRs (see Section 2.4.2, p. 19). 
The two classes of T cell vary in their co-receptors they express, which play an 
important role in the interaction between the MHC-peptide complex and TCR (see Fig. 
2.7, p. 19), and therefore in the activation process of T cells. MHC class I molecules, 
which carry peptides from viruses or other intracellular pathogens, are recognised by 
cytotoxic T cells bearing the co-receptor CD8, which are specialised to kill any infected 
cell that displays the same foreign peptide. MHC class II-peptide complexes are 
recognised by T helper cells, which express the co-receptor CD4. T helper cells are 
specialised to activate other effector cells of the immune system: Macrophages, for 
example, are activated to kill the intravesicular pathogens they harbour, and B cells to 
secrete immunglobulins against foreign molecules. Due to their different functions, 
MHC class I molecules are expressed on most nucleated cells, whereas MHC class II 
molecules are only expressed on immunologically active cells, such as dendritic cells, 
macrophages, or B cells.  
MHC molecules determine the compatibility between donor and recipient for allogeneic 
transplantation. Thus, they are the major reason for graft rejections and graft-versus-
host disease [Kanda et al., 2003]. With the aid of MHC molecules, cancer cells may be 
recognised and eliminated by the immune system. On the other hand, a lack of MHC-
antigen presentation (due to down-regulation by a viral infection) sometimes enables 
cancer cells to escape from immune surveillance. Furthermore, the MHC locus is 
associated with a myriad of autoimmune diseases, such as multiple sclerosis or 
rheumatoid arthritis [Fernando et al., 2008]. 
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Since HLA-A2 belongs to MHC class I molecules, it is expressed on almost all 
nucleated cells, although to a variable extent. While an abundant expression of MHC 
class I molecules is found on immune cells, low expression is found on cells of the 
liver, kidney, and brain [Janeway et al., 2005]. Moreover, HLA-A2 is expressed at 
a high frequency in most population groups (especially Caucasoids) and is the most 
frequently occurring HLA class I allele in Germany (50 %) [Gonzalez-Galarza et al., 
2011]. The high resolution crystal structure of HLA-A2 in complex with an unknown 
peptide was revealed by Bjorkman et al. [1987] and its peptide binding properties are 
also known [Falk et al., 1991]. The fact that HLA-A2 is expressed either at high 
amounts (in HLA-A2-positive individuals) or not at all (in HLA-A2-negative individuals) 
makes it a suitable candidate as a target for combinatorial dual-targeting approaches in 
a transplantation context (see Section 2.6, p. 24). Human anti-HLA antibodies may 
arise during pregnancy, after solid organ transplantation, and after the transfusion of 
HLA-mismatched platelet concentrates or blood [Watkins et al., 2000]. The human 
HLA-A2-specific antibody fragment 3PF12 used in this study was isolated from 
a patient alloimmunised by blood transfusion, selected by V gene phage display 
technology [Watkins et al., 2000]. 
2.2.3 CD45 – Leucocyte-Common Antigen  
CD45 is exclusively expressed on all nucleated haematopoietic cells [Trowbridge and 
Thomas, 1994]. Eight isoforms of CD45 may exist due to alternative splicing of three 
exons encoding the regions A, B, and C, but only five are expressed at significant 
levels: CD45RABC, CD45RAB, CD45RBC, CD45RB, and CD45R0 [Fukuhara et al., 
2002]. The isoforms are differentially expressed on leucocytes and are regulated in 
a cell type and activation state-dependent manner. For example, CD45RABC is 
expressed on B cells, CD45RA and other large isoforms are found on naive T cells, 
and CD45R0 (lacking the exons A, B, and C) is located on memory T cells. Upon 
activation, naive T cells undergo a switch to CD45R0. Myeloid lineage cells generally 
express CD45R0 until activated, when they switch to CD45RA [Hermiston et al., 2009]. 
However, more than one isoform can be expressed on a single leucocyte type. 
CD45 belongs to the protein tyrosine phosphatase family (PTPase) [Charbonneau 
et al., 1988] and is also known as PTPRC, protein tyrosine phosphatase, receptor 
type C. CD45 is a type I transmembrane glycoprotein of 180 – 240 kDa, depending on 
the isoform, and consists of a large extracellular domain, a single transmembrane 
domain, and an extensive cytoplasmic tail (Fig. 2.4) [Thomas, 1989]. The extracellular 
domain consists of the alternatively spliced exons with multiple sites for O-linked 
glycosylation, followed by a cysteine-rich domain and three fibronectin type III domains, 
both comprising multiple sites for N-glycosylation. While the extracellular domain is 
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highly variable, the cytoplasmic part is highly conserved in all mammalian species and 
includes intrinsic PTPase activity. 
CD45RABC












Fig. 2.4:  Schematic structure of CD45 molecules. Multiple isoforms of CD45 are found due to 
alternative splicing of three exons encoding the regions A, B, and C, which are part of the 
extracellular domain. Only two isoforms are shown, CD45RABC and CD45R0. The 
cytoplasmic portion includes intrinsic protein tyrosine phosphatase (PTPase) activity. The 
membrane, key functional domains, and glycosylation sites (O- and N-linked) of CD45 are 
indicated. The membrane is indicated by grey horizontal bars. E, extracellular; I, intracellular; 
PTP, protein tyrosine phosphatase. Adapted from Hermiston et al. [2009]. 
The function of the different isoforms has remained elusive yet. What is known is that 
CD45 is required for receptor signalling in immune cells. CD45 is thought to modulate 
signalling networks mediated by Src-family kinases (SFKs). It can remove the 
phosphate from phosphotyrosines, especially from the inhibitory tyrosine residue of 
SFKs, which, in turn, are associated with antigen receptors and phosphorylate the 
tyrosines in immunoreceptor tyrosine-based activation motifs (ITAMs) [Janeway et al., 
2005]. The key substrates for CD45 in T and B cells are the SFK members Lck and 
Lyn, respectively [Saunders and Johnson, 2010]. By decreasing the threshold of 
antigen receptor signalling in T and B cells, CD45 makes these cells more sensitive to 
stimulation by a specific antigen. CD45 also regulates antigen-triggered Fc-receptor 
signalling in mast cells and Toll-like receptor signalling in dendritic cells. Moreover, 
CD45 may have an impact on immune cell adhesion and migration as well as cytokine 
production. Thus, it seems to be involved in the regulation of adaptive and innate 
immune responses. 
CD45 is one of the most abundant leucocyte cell surface glycoproteins, comprising up 
to 10 % of all cell surface proteins in lymphocytes [Thomas, 1989]. About 200.000 
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CD45 molecules are expressed per cell on average [van der Jagt et al., 1992]. CD45 is 
also expressed on most haematological malignancies, including 85 – 90 % of acute 
leukaemias, while not being found on non-haematopoietic tissues [Matthews et al., 
1991]. Furthermore, CD45 is not internalised or shed upon binding of an anti-CD45 
antibody [Press et al., 1994]. Due to this feature, its abundance, and the fact that it is 
the most specific marker of haematopoietic lineage, CD45 appears as an attractive 
target for developing immunotherapy strategies for the treatment of haematological 
malignancies. New therapeutical approaches are especially required since acute 
myeloid leukaemia (AML), for example, still kills 60 – 70 % of those affected despite 
improvements in induction chemotherapy and haematopoietic stem cell transplantation 
[Lin et al., 2006]. In fact, researchers have already focused on targeting CD45 for 
radioimmunotherapy. A number of radiolabelled CD45-specific antibodies were 
developed for conditioning prior to allogeneic transplantation in AML and 
myelodysplastic syndrome (MDS) and have been tested in clinical studies [Orozco 
et al., 2012], revealing the potency of CD45 as target of blood cancer. For example, an 
131I-labelled anti-CD45 antibody (clone BC8) was used as radioimmunotherapy in 
advanced acute leukaemia and MDS [Matthews et al., 1999]. This CD45-targeted 
radiotherapy could be safely combined with a reduced-intensity conditioning regimen 
leading to encouraging overall survival for older, high-risk patients with AML or MDS 
[Pagel et al., 2009]. In order to enhance the radiation at the malignant CD45-
expressing sites and to diminish it in normal tissues, a pretargeted radioimmunotherapy 
in the form of a recombinant anti-CD45 tetravalent single-chain antibody-streptavidin 
fusion protein (scFv4SA) was developed [Lin et al., 2006]. This antibody can hence be 
bound via streptavidin to radiolabelled DOTA-biotin for the treatment of leukaemia. In 
a human xenograft model, using an α-emitting radionuclide, this approach 
demonstrated highly specific tumour targeting and minimal toxicity to normal tissue 
[Pagel et al., 2011]. The same scFv, derived from a murine anti-CD45 antibody (clone 
BC8) that recognises all human CD45 isoforms, was used in the present study. 
2.3 Therapeutic Antibodies in Cancer Therapy 
Antibodies are part of the adaptive immune system. These proteins are produced by 
B cells in a vast range of antigen specificity. Their main function is to specifically bind 
pathogens and to recruit immune cells or molecules to destroy the pathogen. The fact 
that antibodies bind to their antigen with a high affinity and selectivity makes them 
a promising tool for targeted therapy. Monoclonal antibodies, deriving from one B cell, 
have long been eyed as a potential new class of therapeutics targeting cancer and 
other diseases [Booy et al., 2006]. Monoclonal antibodies have become an established 
and clinically well tolerated therapeutic option for a number of diseases [Reichert, 
2011; Nelson et al., 2010]. In cancer therapy, most of them target tumour-associated 
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antigens. Their anti-tumour effects derive from the ability to elicit effector mechanisms 
of the immune system mediated by the Fc region, such as antibody-dependent cellular 
cytotoxicity (ADCC), complement-mediated cytotoxicity (CMC), and phagocytosis. 
However, antibodies are only able to recruit effector cells bearing the respective Fc 
receptors, such as macrophages, granulocytes, monocytes, and NK cells. In contrast, 
the most potent effector cells, namely the cytotoxic T lymphocytes, lack Fc receptors 
and thus cannot be recruited and activated. Another limitation of monoclonal antibodies 
is that they can only target a single antigen. Due to the often multifactorial nature of 
cancer, dual-targeting approaches which target two molecules with one antibody, a so-
called bispecific antibody, ought to be therapeutically more effective [Kontermann, 
2012]. In addition, bispecific antibodies are able to redirect an immune response to the 
tumour site, circumventing the (sometimes disadvantageous) Fc-mediated or MHC-
restricted activation of effector cells [Müller and Kontermann, 2007]. 
2.3.1 The Concept of Bispecific Antibodies 
The principle of bispecific molecules for immunotherapy is based on the selective 
retargeting of effector cells to tumour cells. Bispecific antibodies carry one specificity 
for a trigger molecule on an effector cell and another one for a tumour antigen on the 
target cell. Hence, they are able to recruit an effector mechanism to a target. The 
effector cells can be recruited by different trigger molecules: for example, CD3 on 
T cells, FcγRIII (CD16) on NK cells, FcγRI (CD64) or FcαRI (CD89) on monocytes and 
granulocytes [Peipp and Valerius, 2002; van Spriel et al., 2000]. 
2.3.2 Recombinant Bispecific Antibody Formats 
Recombinant bispecific antibodies offer several advantages over conventionally 
produced antibodies. Initially, bispecific antibodies were generated by chemical cross-
linking of two different monoclonal antibodies or by fusion of two hybridoma clones. 
Since the first generation of therapeutic antibodies were mainly of mouse origin, their 
repeated application resulted in a rapid elimination by the immune system induced by 
the production of neutralising antibodies against the mouse bispecific antibodies 
(HAMA, human anti-mouse antibodies) [Klee, 2010]. The next antibodies were 
constructed as chimeric antibodies, with human constant antibody domains (~ 70 %) 
and only antigen-binding domains being of mouse origin, leading to a greatly reduced 
immunogenicity [Morrison et al., 1984; Galizia et al., 2007]. Further improved properties 
were achieved with humanised antibodies. In those, only the complementarity-
determining regions (CDR) that determine the antigen specificity of an antibody were 
retained of mouse origin [Jones et al., 1986; Riechmann et al., 1988; Hudis, 2007]. The 
generation of entirely human antibodies was enabled by the phage display technology 
[Hoogenboom and Chames, 2000] or by using transgenic mice [Lonberg, 2005]. 
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Although humanised or human antibodies are less immunogenic and can therefore act 
longer due to a prolonged half-life in humans, a generation of human anti-human 
antibodies (HAHA) was found [Getts et al., 2010]. The HAHA response, in turn, can be 
further reduced by ‘deimmunisation’, i.e. by the removal of the responsible T-cell 
epitopes [Hellendoorn et al., 2004; Jones et al., 2004]. The large-scale production of 
human or humanised antibodies is performed by using prokaryotic, yeast, or 
mammalian expression systems. 
In order to reduce immunogenicity and to avoid Fc-mediated side effects such as 
cytokine-release syndrome, recombinant bispecific antibodies, which lack the Fc-region 
and retain only the antigen-binding variable domains of an antibody, can be achieved 
by proteolytic cleavage or genetic engineering. Various formats of such antibodies 
have been developed in recent years. The most widely used formats, such as tandem 
scFv (taFv), diabody (Db), and single-chain diabody (scDb), are based on two single-
chain variable fragments (scFv) specific for different antigens (Fig. 2.5 A – C). A scFv 
fragment is one of the smallest antigen-binding molecules. It consists of the variable 
domains of the heavy (VH) and the light chain (VL) of an antibody joined by a flexible 
linker of 15 – 20 residues, providing the suitable folding into a functional scFv fragment 
[Huston et al., 1988; Bird et al., 1988]. Bearing only one antigen-binding site, scFv 
fragments are monovalent and monospecific. The reduction of the linker length to 
about 5 – 10 amino acids sterically inhibits the assembly of the variable domains of one 
chain to a functional unit and therefore forces the two VH-VL chains to homodimerise 
crosswise, resulting in a diabody with two antigen-binding sites [Holliger et al., 1993]. 
Thus, diabodies are bivalent molecules, either monospecific or bispecific. Bispecific 
diabodies express two polypeptide chains for the VH-VL configuration within the same 
cell, VHA-VLB and VHB-VLA. In the further developed single-chain diabody (scDb) 
format, the two diabody-forming polypeptide chains are joined by an additional middle 
linker of 15 – 20 residues. A scDb assembles due to the different linker lengths into 
a bispecific and monomeric molecule, for example in the VHA-VLB-linker-VHB-VLA 
orientation [Brüsselbach et al., 1999]. Another possibility is the tandem scFv (taFv) 
achieved by the linkage of two scFv fragments, for example into a VHA-VLA-linker-VHB-
VLB configuration [Mallender and Voss, 1994; Mack et al., 1995]. Lastly, several other 
genetically engineered recombinant antibodies which lack any constant domains were 
established (Fig. 2.5 D), as reviewed by Müller and Kontermann [2011] and 
Kontermann [2012]. 
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Fig. 2.5:  Recombinant bispecific antibody formats. A) Structures of the recombinant bispecific 
antibody formats: diabody (Db), single-chain diabody (scDb), and tandem scFv (taFv) derived 
from single-chain variable fragments (scFv). All formats are based on the variable domains of 
the heavy chain (VH) and the light chain (VL) of an antibody joined by linkers of different 
lengths. B) Ribbon and surface structure of scFv. C) Domain and linker arrangements in scFv, 
Db, scDb, and taFv molecules. Linker lengths are indicated with the number of amino acids. 
Adapted from Müller and Kontermann [2011]. D) Further examples of recombinant bispecific 
antibody formats which lack constant domains. mAb, monoclonal antibody. Adapted from 
Kontermann [2011a]. 
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The construction of all these formats through genetic means allows further 
manipulation to add novel functions such as the fusion to toxins, costimulatory 
molecules, or polyethylene glycol (PEG) to improve pharmacokinetics [Chapman, 
2002; Kontermann, 2011b]. All these antibody fragments may be expressed in soluble 
form in the periplasm of E. coli or using a mammalian expression system. As the taFv 
fragments were often found to form insoluble aggregates in bacteria, mammalian 
expression systems are nowadays used with preference [Kontermann, 2005]. Although 
mammalian expression often provides higher yields, better purity, and essential 
posttranslational modification, it is considerably more expensive and time-consuming 
than prokaryotic expression. 
The small size of antibody fragments, such as the above-mentioned (scFv ~ 25 kDa; 
Db, scDb, and taFv ~ 50 – 60 kDa in comparison to IgG ~ 150 kDa), allows for good 
penetration into the tumour tissue in therapeutical applications, but also gives rise to 
a rapid elimination from the circulation via renal clearance [Kipriyanov et al., 1999; 
Tryggvason and Wartiovaara, 2005]. In addition, the recycling processes mediated by 
the neonatal Fc receptor, which prolong the half-life of IgGs, have no effect, as these 
small fragments lack the Fc region. On account of their short serum half-lives, small 
fragments may not circulate long enough to induce therapeutic effects. Currently, 
different approaches are pursued in order to improve pharmacokinetics: 
i) N-glycosylation, ii) the fusion of PEG, iii) the fusion to Fc or an IgG-binding domain, 
iv) the fusion to human serum albumin, and v) the fusion of an albumin-binding domain 
from streptococcal protein G [Kontermann, 2011b; Müller et al., 2007; Stork et al., 
2007; Stork et al., 2008]. 
2.4 Bispecific Antibodies for Targeting Immune Effector Cells  
As mentioned above, bispecific antibodies are able to recruit effector cells of the 
immune system towards the tumour, which provides a promising approach to 
circumvent immune evasion mechanisms of the tumour [Dunn et al., 2004; Garcia-Lora 
et al., 2003]. Cytotoxic T cells have been chosen as potential tools in most retargeting 
approaches in cellular immunotherapy, as they rank among the most potent effector 
cells of the immune system. The following section describes the molecular 
mechanisms of T-cell activation in general and subsequently outlines a range of 
bispecific antibodies targeting tumour-associated antigens, which were developed for 
this purpose in recent years.  
2.4.1 Activation of Naive T Cells 
In the course of an adaptive immune response, naive T cells differentiate upon 
activation into armed effector T cells such as cytotoxic T cells. An efficient T-cell 
activation requires two independent signals delivered by the same antigen-presenting 
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cell (APC), namely a dendritic cell, macrophage, or B cell. The primary signal is 
received through the T-cell receptor complex. The second, or costimulatory, signal is 
provided by the interaction between costimulatory molecules, such as CD28 on the 
T cell and B7 molecules on the APC. Antigen binding to the T-cell receptor in the 
absence of costimulation may induce programmed cell death (apoptosis) as well as 
anergy, a state of unresponsiveness to subsequent antigen presentation [Chappert and 
Schwartz, 2010]. In contrast, the costimulatory signal alone has no effect on the T cell 
(Fig. 2.6). The expression of costimulatory molecules on APCs is generally induced by 
a range of microbial components that are recognised by receptors of the innate 
immune system to prevent immune responses to self antigens. 
 
Fig. 2.6:  T-cell fate under different conditions of TCR engagement. Simultaneous recognition of 
a specific major histocompatibility complex (MHC)-peptide complex by the T-cell receptor 
(TCR) and of B7.1 (CD80) or B7.2 (CD86) by the costimulatory receptor CD28 results in T-cell 
activation, cytokine production, proliferation, and differentiation. In the absence of CD28 
ligation, T cells undergo apoptosis or become anergic, whereas the costimulatory signal alone 
has no apparent effect. APC, antigen-presenting cell. Adapted from Alegre et al. [2001]. 
Clonal expansion and differentiation into armed effector cells upon T-cell activation is 
mainly driven by the cytokine interleukin-2 (IL-2), which is produced by the activated 
T cell itself. IL-2 induces T-cell proliferation and serves as a survival factor for these 
cells. Interestingly, for the synthesis and secretion of IL-2, the costimulatory signal is 
necessary. Armed effector cytotoxic T cells release lytic granules upon recognition of 
antigen on target cells. These granules contain the cytotoxic proteins perforin, 
granzymes, and granulysin. Perforin forms pores into the membrane of the target cell 
through which the granzymes can enter and induce apoptosis. Furthermore, cytotoxic 
T cells perform their killing function by activating apoptosis through the CD95 (Fas) 
ligand they express [Janeway et al., 2005]. 
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2.4.2 Primary Signal for T-Cell Activation 
The primary signal, which is antigen-specific, is triggered through the T-cell receptor 
engaging with an MHC-peptide complex, and its coreceptor, CD4 or CD8. In tumour 
defence, cytotoxic T cells bearing the coreceptor CD8 play an important role. TCRs 
recognise peptides presented by MHC molecules on an APC following protein 
processing. TCRs are heterodimers which are composed of two membrane-spanning 
chains, α and β, and only responsible for antigen recognition. The juxtaposition of both 
chains forms the antigen-binding site, thus accounting for the peptide-binding 
specificity of the TCR. The TCR is effective only in conjunction with the individual’s own 
MHC molecules. This dual recognition is called MHC restriction and was first 
discovered by Zinkernagel and Doherty in 1974. In contrast, the actual signalling as 
such is transmitted by the invariant accessory chains, namely the intracellular ζ-chains 
(homodimer) and the CD3 complex comprising a heterodimer of an ε-chain associated 
with either a δ-chain or a γ-chain (Fig. 2.7). These chains have ITAMs enabling them to 
signal upon antigen ligation. ITAMs are phosphorylated by activated tyrosine kinases of 
the Src-family (Lck and Fyn), followed by the activation of ZAP-70 (ζ-chain associated 
protein), a further tyrosine kinase propagating the signal onward. Ultimately, three 
important signalling pathways are initiated, culminating in the activation of the 
transcription factors NFκB, NFAT, and AP-1 in the nucleus. The activation of new gene 
transcription finally results in the differentiation, proliferation, and effector functions of 
T cells [Janeway et al., 2005]. 
 
Fig. 2.7:  Primary T-cell activation through the T-cell receptor (TCR). An antigen (Ag) bound to an 
MHC class I molecule on an antigen-presenting cell (APC) is recognised by the TCR complex 
of a T cell bearing the coreceptor CD8. Signalling is transmitted by the invariant accessory 
chains, the CD3 complex and ζ-chains, bearing immunoreceptor tyrosine-based activation 
motifs (ITAMs). 
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Antibodies targeting the CD3 ε-chain, the constant molecule of the TCR complex, 
circumvent both MHC restriction, i.e. antigen recognition by the TCR only in 
conjunction with self-MHC molecules, and the clonotypic antigen specificity of T cells. 
They are able to activate T cells in an MHC- and costimulation-independent manner by 
cross-linking CD3. However, they induce an even stronger, polyclonal T-cell response 
in the presence of appropriate costimulation. Examples of such antibodies are TR66 
[Lanzavecchia and Scheidegger, 1987; Traunecker et al., 1991] and UCHT-1 [Beverley 
and Callard, 1981]. The CD3-specific moiety of all bi- and trispecific constructs that are 
used for T-cell activation in the present study derives from diL2K [Brischwein et al., 
2006], a deimmunised variant of the human CD3ε-specific mouse mAb L2K [Dreier 
et al., 2002], which, in turn, is identical with TR66. Several bispecific antibodies have 
been developed for effector cell retargeting directed against CD3 and a tumour antigen 
(Table 2.1, p. 22). These are outlined in the following. 
2.4.3 Bispecific Antibodies for the Retargeting of T Cells 
A broad range of recombinant bispecific antibodies for T-cell activation, targeting 
tumour-associated antigens and CD3, have been developed and tested for anti-tumour 
activity in vitro and in vivo over the last years (Table 2.1, p. 22). A few of them are 
currently being tested in clinical trials [Müller and Kontermann, 2007; Kontermann, 
2011a]. For the construction of such bispecific antibodies, several different targets were 
chosen that are overexpressed by tumour cells, such as CD19, CD20, EpCAM 
(epithelial cell adhesion molecule), EGFR (epidermal growth factor receptor), HER2 
(human epidermal growth factor receptor 2), and CEA (carcinoembryonic antigen). 
Interestingly, CD3-specific antibodies of the BiTE (bispecific T-cell engager) format are 
able to induce T-cell activation in an MHC- and costimulation-independent manner. 
Several of such bispecific antibodies deriving from the monoclonal antibody TR66 were 
developed. BiTEs are tandem scFv molecules. Their second specificity was designed 
against different tumour antigens, including CD19 [Löffler et al., 2000; Dreier et al., 
2002; 2003], EpCAM [Schlereth et al., 2005; Brischwein et al., 2006], tyrosine kinase 
EphA2 [Hammond et al., 2007], CEA [Lutterbuese et al., 2009], EGFR [Lutterbuese 
et al., 2010], or the large melanoma-associated proteoglycan MCSP [Bluemel et al., 
2010]. In vitro studies revealed a high efficiency in tumour cell lysis at low 
concentrations and low effector-to-target cell ratios [Baeuerle et al., 2009; Hammond 
et al., 2007; Hoffmann et al., 2005]. The BiTE directed against the B-cell antigen CD19 
was characterised in great detail. It was described to inhibit the tumour growth very 
efficaciously in mice bearing human B cell lymphoma xenografts [Dreier et al., 2003] 
and to induce T-cell activation and B-cell depletion in chimpanzees [Schlereth et al., 
2006]. This BiTE, called blinatumomab or MT103, is currently being investigated in 
clinical trials. In a phase I dose-escalating study, partial or, in some cases, even 
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complete tumour regression was observed at very low doses in patients with non-
Hodgkin’s lymphoma (NHL) [Bargou et al., 2008]. In addition, clinical phase I and II 
trials are ongoing for the treatment of acute lymphoblastic leukaemia (ALL). For 
a completed phase II study, promising results have been reported [Topp et al., 2011]; 
another one is underway. A second BiTE antibody named MT110, targeting the pan-
carcinoma antigen EpCAM, was shown to eradicate established subcutaneous tumours 
in immunodeficient mice with human tumour xenografts [Schlereth et al., 2005; 
Brischwein et al., 2006]. MT110 is currently being tested in a dose-escalating phase I 
study for the treatment of solid tumours, including gastrointestinal, lung, breast, 
ovarian, and prostate cancer. Both BiTEs were the first (recombinant) bispecific 
antibodies of the second generation to enter the clinic. The outstanding potency and 
costimulation independence of BiTEs is assumed to be accounted for by a highly 
effective T-cell activation, which is achieved by inducing the formation of cytolytic 
synapses with high frequency [Wolf et al., 2005; Offner et al., 2006] and by supporting 
serial target cell lysis [Hoffmann et al., 2005]. On the other hand, dosage variation 
appears to be the only way to regulate the application of BiTEs, which may lead to 
unwanted and uncontrolled T-cell activation owing to their high and MHC-independent 
reactivity. 
Alternatively to anti-CD3 antibodies, superagonistic anti-CD28 bispecific antibodies 
were developed that induce effective tumour cell-restricted T-cell activation without 
concurrent primary signal through the TCR complex [Grosse-Hovest et al., 2003; 2005; 
Otz et al., 2009]. One of them, named rM28, is specific for a melanoma-associated 
proteoglycan and was tested in clinical phase I/II trials for local treatment of metastatic 
melanoma (ClinicalTrials.gov; identifier NCT00204594); the results are not available 
yet. However, the usage of superagonists bears a potentially high risk to generate 
a systemic T-cell activation and an excessive immune response by circumventing 
physiological control mechanisms as was revealed for another superagonistic but 
monoclonal anti-CD28 antibody (TGN1412) that caused unforeseen disastrous side 
effects in a phase I clinical trial [Beyersdorf et al., 2006; Suntharalingam et al., 2006]. 
Another anti-CD28 antibody was used for the construction of a trispecific CEA × CD3 × 
CD28 antibody by fusing the VH domain of a CD28-specific antibody to a bispecific 
CEA × CD3 tandem scFv molecule [Wang et al., 2004]. This antibody fusion protein, 
providing both signals required for T-cell activation in one molecule, was able to 
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Table 2.1:  Recombinant bispecific antibodies for cancer therapy targeting CD3 on 
T cells. Adapted from Müller and Kontermann [2007; 2011]. 
Target 
CD3 × … 
Type  Efficacy Potential indication Reference 
BCL-1 Db in vitro B-cell tumours [Holliger et al., 1996] 
CD19 taFv (BiTE) in vitro / in vivo B-cell tumours [Dreier et al., 2003; 
Bargou et al., 2008; 
Topp et al., 2011] 
CD19 Db in vitro / in vivo B-cell tumours [Kipriyanov et al., 1998; 
2002; Cochlovius et al., 
2000a] 
CD19 TandAb in vitro / in vivo B-cell tumours [Kipriyanov et al., 1999; 
Cochlovius et al., 2000b; 
Reusch et al., 2004; 
Le Gall et al., 2004] 
CD20 Db in vitro / in vivo B-cell tumours [Xiong et al., 2002; 
Liu et al., 2010] 
CD105 scDb in vitro Solid tumours [Korn et al., 2004] 
CEA Db in vitro / in vivo Various carcinomas [Holliger et al., 1999, 
Blanco et al., 2003, 
Compte et al., 2007; 
2009; 2010] 
CEA scDb in vitro Various carcinomas [Müller et al., 2007] 
EGFR Db in vitro / in vivo Various carcinomas [Hayashi et al., 2004] 
EpCAM taFv (BiTE) in vitro / in vivo Various carcinomas [Schlereth et al., 2005; 
Brischwein et al., 2006] 
EpCAM Db in vitro Various carcinomas [Helfrich et al., 1998] 
EpCAM taFv in vitro / in vivo Various carcinomas [Ren-Heidenreich et al., 
2004] 
EphA2 taFv (BiTE) in vitro / in vivo Various carcinomas, 
metastatic melanoma 
[Hammond et al., 2007] 
FAP taFv (BiTE) in vitro Various carcinomas [Wüest et al., 2001] 
HER2 Db in vitro Ovarian and breast 
cancer 
[Zhu et al., 1996] 
HER2 taFv (BiTE) in vitro Ovarian and breast 
cancer 
[Maletz et al., 2001] 
Lewis Y taFv (BiTE) in vitro Various carcinomas [Maletz et al., 2001] 
MUC1 Db in vitro Various carcinomas [Takemura et al., 2000] 
Pgp Db in vitro / in vivo Drug-resistant 
cancers 
[Gao et al., 2004; 
Guo et al., 2008] 
Pgp dsDb in vitro / in vivo Drug-resistant 
cancers 
[Liu et al., 2009] 
PSMA Db in vitro / in vivo Prostate cancer [Bühler et al., 2008; 
2009] 
Wue-1 taFv (BiTE) in vitro Multiple myeloma [Hönemann et al., 2004] 
BCL-1, surface idiotype of the mouse lymphoma line BCL-1; BiTE, bispecific T-cell engager; CEA, carcinoembryonic 
antigen; Db, diabody; dsDb, disulfide-stabilised diabody; EGFR, epithelial growth factor receptor; EpCAM, epithelial cell 
adhesion molecule; EphA2, ephrin A2 receptor; FAP, fibroblast activation protein; HER2, human epidermal growth 
factor receptor 2; MUC1, mucin-1; Pgp, P-glycoprotein; PSMA, prostate-specific membrane antigen; scDb, single-chain 
diabody; taFv, tandem scFv; TandAb, tandem single-chain diabody; Wue-1, an antigen on human plasma cells. 
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2.5 Dual Targeting with Bispecific Antibodies  
In the past years, various dual targeting bispecific antibodies were developed and were 
recently reviewed in great detail by Kontermann [2012]. Most of them target 
pathological factors such as receptors, ligands, or a combination of both. This appears 
beneficial, since complex diseases are often multifactorial. Besides cancer, they were 
developed for the treatment of inflammatory and infectious diseases and may act in an 
activating or inhibiting manner on the target molecule.  
An example for dual-targeting bispecific antibodies of small format is a bs-scFv 
(conforms taFv) directed against ErbB2 and ErbB3 (HER2 and HER3), which was 
shown to inhibit the growth of tumour cells in vitro [Robinson et al., 2008]. In addition, 
a bispecific immunotoxin called DT2219 was generated by fusing a truncated 
diphtheria toxin (DT) N-terminally to a taFv targeting CD22 and CD19, both found on B 
cells [Vallera et al., 2005; 2009]. In proliferation assays, this immunotoxin 
demonstrated a greater anti-tumour activity against double-positive tumour cells than 
its monospecific counterparts DT2222 and DT1919. Furthermore, in a mouse xenograft 
model of B-cell malignancy, DT2219 effectively inhibited the growth of established 
primary tumours, and it also prolonged survival in a model of systemic leukaemia-like 
malignancy. However, the functionality of this agent is not dependent on the 
simultaneous presence of both antigens. Thus, it may also eliminate single-positive 
cells. Nevertheless, the applicability of such an immunotoxin was suggested to lie in 
the treatment of all B-cell malignancies. This is why a clinical phase I trial for the 
treatment of B-cell leukaemia and lymphoma was initiated for an optimised version of 
this agent, called DT2219ARL.  
Other bispecific antibodies use dual targeting for retargeting effector molecules or 
effector cells. Trispecific antibodies, called single-chain Fv triple bodies (sctb), which 
were created simply by extending the taFv format by a third scFv appear to be an 
advantageous approach [Kellner et al., 2008; Kügler et al., 2010; Schubert et al., 2011; 
2012]. Triple bodies were developed for dual retargeting of effector cells. One of those 
triple bodies targets two antigens associated with AML (CD33 and CD123) and the low 
affinity FcγRIII (CD16), a trigger molecule on NK cells, neutrophils, and macrophages. 
The centrally located scFv against CD16 comprises a disulfide bond for more 
stabilisation. This trispecific CD123 × CD16 × CD33 triple body was shown to bind to 
both tumour antigens at the same time and to mediate ADCC of AML cells in vitro with 
high potency [Kügler et al., 2010]. The same group generated also another triple body 
of CD33 × CD16 × CD19 specificity [Schubert et al., 2011]. Here, in addition to the 
CD16-specific scFv, the C-terminal scFv against the B-cell antigen CD19 also 
contained a stabilising disulfide bond. This triple body mediated strong redirected lysis 
of tumour cells expressing both tumour antigens, CD33 and CD19. In addition, it 
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revealed a higher binding avidity to double-positive tumour cells than its respective 
bispecific counterparts (CD33 × CD16 and CD19 × CD16), which served as controls 
and are capable of monovalent targeting only. For a third triple body of HLA-DR × 
CD16 × CD19 specificity, lysis of double-positive cells was shown to occur with 
preference over single-positive cells [Schubert et al., 2012]. However, dual targeting 
with such a trispecific one-molecule strategy seems not to be able to strictly 
discriminate between double-positive tumour cells and single-positive healthy cells. 
Nevertheless, dual retargeting of effector cells appears to be a promising tool to 
increase efficacy and selectivity. 
In conclusion, such dual-targeting strategies require the existence and knowledge of 
two appropriate and specific (tumour) targets. In contrast, up to now no studies have 
been reported on a combinatorial dual-targeting approach, which exploits two 
conventional antigens in combination for specific tumour targeting and whose 
functionality strictly depends on the presence of and binding to both antigens at the 
same time. 
2.6 Thesis Aims and the Concept of a Dual Antigen-Restricted 
Trispecific Antibody 
In recent years preclinical and clinical studies revealed the great potential of 
recombinant bispecific antibodies for the retargeting of T cells as the most potent 
effector cells in cancer immunotherapy. BiTE antibodies emerged as the most 
successful recombinant bispecific molecules and are well characterised. In order to live 
up to the success of the BiTE antibody technology, one aim of the present study was 
the generation and functional characterisation of a bispecific tandem scFv (taFv) 
antibody against AChRγ and CD3 for the treatment of aggressive rhabdomyosarcoma 
(Fig. 2.8 on the next page). Through the simultaneous binding of this antibody to both 
antigens, T cells are supposed to be activated, thus leading to tumour-specific cell 
lysis. 
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Fig. 2.8:  Bispecific Antibody against Rhabdomyosarcoma. One molecule strategy for T-cell 
activation and the retargeting of T cells to tumour cells (here rhabdomyosarcoma) provided by 
a bispecific T-cell engager (BiTE) molecule directed against CD3 and fetal acetylcholine 
receptor (fAChR). 
As the second and major aim of this study, a similar but dual antigen-restricted 
trispecific concept was to be realised for the treatment of blood cancer in the context of 
haematopoietic stem cell transplantation (HSCT). For an HLA-mismatched setting 
where the patient is HLA-A2-positive, but the donor is not, it was aimed to exploit the 
HLA disparity for targeted immunotherapy by using a complementing trispecific 
antibody. This trispecific antibody should target CD3 and a combination of two other 
antigens, HLA-A2 and CD45. It should further be formed upon binding to the latter two 
antigens, which were chosen, because HLA-A2 is one of the most common HLA 
alleles, and because CD45 is a highly specific haematopoietic marker. This trispecific 
HLA-A2 × CD3 × CD45 antibody should assemble from two parts in such a way that 
the third specificity against CD3 is only created upon the prior binding of the two other 
antigens at the same cell. A high tumour specificity should be reached by this antibody 
due to the combination of two non-tumour-specific antigens, HLA-A2 and CD45, their 
coexpression on the recipient’s malignant haematopoietic cells, and the single 
expression of CD45 on the graft and HLA-A2 on the recipient’s non-haematopoietic 
cells, respectively. Thus, single positive cells should remain unaffected (Fig. 2.9). 
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Fig. 2.9:  Concept of a dual antigen-restricted trispecific antibody against leukaemia. A) Two parts 
of a trispecific antibody bind to a double positive leukaemic cell (HLA-A2+ CD45+) and 
assemble. B) The complemented trispecific antibody now can activate T cells via CD3. 
C) + D) The presence of a single antigen does not suffice for binding to CD3 and for T cell 
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3 Materials and Methods 
The descriptions of method details in this section are partly adapted from my diploma 
thesis at the University of Stuttgart [2008]. 
3.1 Materials 
3.1.1 Instruments 
Balances Basic BA 2100 [Sartorius, Göttingen, DE] 
Blotter PerfectBlue™ Semi-Dry Electroblotter SEDEC M [Peqlab, Erlangen, DE] 
Centrifuges Eppendorf 5417C [Eppendorf, Hamburg, DE],                                         
J2-HS with rotors JA14 and JA20 [Beckman Coulter, Krefeld, DE], 
Heraeus Megafuge 1.OR (cell culture), Varifuge 3.OR (cell culture),    
and Pico 17 Microcentrifuge [Thermo Scientific, Langenselbold, DE] 
CO2 Incubator Steri-Cycle with Class 100 HEPA [Thermo Scientific, Langenselbold, DE] 
Electrophoresis Systems Mini-PROTEAN® Tetra cell [Bio-Rad, Munich, DE],                        
PerfectBlue™ Gel System Mini S [Peqlab, Erlangen, DE],         
Electrophoresis Power Supply E834 [Consort, Turnhout, BE], 
Electrophoresis Power Supply EPS 301 [GE Healthcare, Freiburg, DE] 
ELISA Plate Reader Lucy 2 [Anthos Labtec, Krefeld, DE] 
Flow Cytometry System BD FACSCalibur [BD BioScience, Heidelberg, DE] 
Gel Imager Gel iX Imager Windows Version with UV-Transilluminator                 
[INTAS Science Imaging Instruments, Göttingen, DE] 
Heating Block Labtherm [Gebr. Liebisch, Bielefeld, DE] 
Infrared Imaging System Odyssey® 3.0 with Software [Li-Cor Biosciences, Bad Homburg, DE] 
Laminar Flow Cabinets Heraeus HB 2448 [Thermo Scientific, Langenselbold, DE],  
BDK [BDK Luft- und Reinraumtechnik, Sonnenbühl-Genkingen, DE] 
Magnetic Stirrer MR 2002 [Heidolph Instruments, Schwabach, DE] 
Microscope Digital Inverted Fluorescence Microscope, Evos® fl, Cell Imaging System 
[Advanced Microscopy Group, Bothell, US] 
PCR Cycler Primus 96 Plus Thermal Cycler [MWG Biotech, Ebersberg, DE] 
Shaking Incubators Stuart Orbital Incubators SI50 and SI500 [Stuart Scientific, Redhill, UK]  
Spectrophotometer GeneQuant pro RNA / DNA Calculator [Pharmacia Biotech, Uppsala, SE] 
Vortex Mixer 7-2020 [neoLab, Heidelberg, DE] 
X-ray film processor Cawomat 2000 IR [Cawo, Schrobenhausen, DE] 
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3.1.2 Special Implements 
Centrifuge Bottles Nalgene® wide-mouth with sealing caps, 250 ml, style 3141, # Z353736             
[Sigma-Aldrich, Steinheim, DE] 
CD14 MicroBeads Anti-human CD14 conjugated magnetic beads                                     
[Miltenyi Biotec, Bergisch Gladbach, DE] 
Chromatography Columns Poly-Prep # 731-1550 with Cap # 731-1555 [Bio-Rad, Munich, DE] 
Dialysis Membrane Visking MWCO 14,000; 34 mm, # 1784.1 [Roth, Karlsruhe, DE] 
ELISA Microplates MICROLON® 600, 96 well [Greiner Bio-One, Frickenhausen, DE] 
Filter Paper FN 100, 0.35 mm, 195g/m2 [Munktell & Filtrak, Bärenstein, DE] 
Folded Filter Rotilabo®, Type 600P [Roth, Karlsruhe, DE] 
IMAC Affinity Matrix Ni-NTA-Agarose, 25 ml, # 30210 [Qiagen, Hilden, DE] 
Nitrocellulose Membrane Whatman™ Protran™ BA83, 0.2 µm pore size                                      
[GE Healthcare, Freiburg, DE] 
Sterile Filter Acrodisc® Syringe Filters, 0.2 µm [Pall Life Sciences, Dreieich, DE] 
Tissue Culture Flasks/Dishes CellStar® [Greiner Bio-One, Frickenhausen, DE] 
UV-Cuvettes Semi-micro cuvette, # 67.742 [Sarstedt, Nümbrecht, DE],                  
Micro, center height 15 mm, 70 µl, # 7592 20 [Brand, Wertheim, DE] 
X-Ray Films Amersham Hyperfilms™ ECL [GE Healthcare, Freiburg, DE] 
3.1.3 Chemicals, Solutions, and Media 
Chemicals 
Chemicals were purchased with the highest purity grade available from AppliChem [Darmstadt, DE], 
Roche [Mannheim, DE], Roth [Karlsruhe, DE], and Sigma-Aldrich [Steinheim, DE] unless otherwise 
indicated. 
Buffers and Solutions 
Blocking Buffer 1 % BSA, 0.05 % NaN3 in sterile PBS 
Blotting Buffer 1 × 20 % methanol, 192 mM glycine, 25 mM Tris base, pH 8.3 
Bradford Solution 5 × Bio-Rad Protein Assay [Bio-Rad, Krefeld, DE] 
Destaining Solution 45 % methanol, 10 % glacial acetic acid in H2O 
DNA Loading Dye 6 × 10 mM Tris-HCl (pH 7.6), 0.03 % bromophenol blue, 0.03 % xylene 
cyanol FF, 60 % glycerol and 60 mM EDTA, supplied with GeneRuler™ 
DNA Ladder Mix [Fermentas, St. Leon-Rot, DE] 
ECL substrate solution 4 ml of solution A (0.1 M Tris-HCl, 1.4 mM luminal, pH 8.6) + 400 µl 
solution B (6.7 mM p-coumaric acid in DMSO) + 1.2 µl 30 % H2O2) 
FastAP™ Buffer 10 × supplied with FastAP™ Thermosensitive Alkaline Phosphatase 
FastDigest® (Green) Buffer 
10 × 
supplied with FastDigest® restriction enzymes 
MgCl2 25 mM, supplied with Taq DNA Polymerase 
(NH4)2SO4 Taq Buffer 10 × supplied with Taq DNA Polymerase [Fermentas, St. Leon-Rot, DE] 
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PBA 2 % FCS, 0.02 % NaN3 in sterile PBS 
PBS 1 × 140.1 mM NaCl, 18.8 mM Na2HPO4, 2.3 mM NaH2PO4 • H2O or         
PBS powder without Ca2+, Mg2+ (instamed Dulbecco) for dialysis,             
# L 182-50 [Biochrom, Berlin, DE] 
Periplasmic Preparation Buffer 30 mM Tris-HCl pH 8.0, 1 mM EDTA pH 8.0, 20 % (w/v) sucrose in H2O 
Reagent Diluent 0.1 % BSA, 0.05 % Tween 20, 20 mM Tris base, 150 mM NaCl in H2O, 
pH 7.2 – 7.4, sterile filtrated 
SDS-PAGE Loading Buffer 5 × 25 % β-mercaptoethanol (only for reducing loading buffer), 25 % glycerol, 
10 % (w/v) SDS, 0.05 % bromophenol blue, 313 mM Tris-HCl pH 6.8 
SDS-PAGE Running Buffer   
10 × 
1.92 M glycine, 250 mM Tris base, 1 % (w/v) SDS, pH 8.3 
Sodium Phosphate Buffer 5 × 250 mM sodium phosphate (36.2 g Na2HPO4 • 2 H2O + 6.4 g NaH2PO4 • 
2 H2O), 1.25 M NaCl, pH 7.5, ad 1 l H2O 
Staining Solution 0.25 % Coomassie Blue R 250 in destaining solution 
TAE Buffer 50 × 2 M Tris base, 1 M glacial acetic acid, 50 mM EDTA, pH 8.3, ad 1 l H2O 
TMB Substrate Solution 100 µg/ml TMB in 66,7 % DMSO, 0.006 % H2O2, 100 mM sodium 
acetate buffer pH 6.0 
Bacterial Culture 
Ampicillin Stock solution 100 mg/ml in H2O, # K029.1 [Roth, Karlsruhe, DE] 
Kanamycin Stock solution 100 mg/ml in H2O K 4000 [Sigma-Aldrich, Steinheim, DE]  
IPTG Isopropyl β-D-thiogalactopyranoside, stock solution 1 M in H2O,              
# CN08.2 [Roth, Karlsruhe, DE] 
LBamp/kan, glc Agar Plates LB medium, 1.5 % agar autoclaved, 100 µg/ml ampicillin/kanamycin, 1 % 
glucose added after cooling-down 
LB Medium 1 × LB medium (Lennox), 20 g/l in H2O (including 21 % tryptone, 0.5 % yeast 
extract, 0.5 % NaCl), # X964.2 [Roth, Karlsruhe, DE] 
TY Medium 2 × 2 × YT medium, 31 g/l in H2O (including 1.6 % tryptone, 1 % yeast 
extract, 0.5 % NaCl, # X966.2 [Roth, Karlsruhe, DE] 
Cell Culture 
Fetal Calf Serum (FCS) Fetal Bovine Serum, Standard Quality, EU approved, A15-101          
[PAA Laboratories, Cölbe, DE], heat inactivated at 56°C for 30 min 
Ficoll Lymphocyte Separation Medium LSM 1077, based on Ficoll 400 and 
sodium diatrizoate [PAA Laboratories, Cölbe, DE] 
Lipofectamine™ 2000 Transfection reagent, # 11668-027 [Gibco® Invitrogen, Karlsruhe, DE] 
Opti-MEM® I 1 × Reduced Serum Medium, liquid, # 31958-054                                            
[Gibco® Invitrogen, Karlsruhe, DE] 
Penicillin-Streptomycin-
Glutamine (Pen-Strep) 100 × 
liquid, 104 U/ml of penicillin, 10 mg/ml of streptomycin, # P11-010         
[PAA Laboratories, Cölbe, DE] 
PBS (Dulbecco’s) 1 × Without Ca and Mg, # H15-002 [PAA Laboratories, Cölbe, DE] 
Puromycin Selective reagent, liquid, 10 mg/ml, diluted to 1 mg/ml in sterile H2O  
[InvivoGen, San Diego, US] 
RPMI 1640 Medium 1 × liquid, with L-glutamine, # E15-840 [PAA Laboratories, Cölbe, DE] 
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DMEM Medium 1 × liquid, high glucose (4.5 g/l), with L-glutamine, # E15-810                   
[PAA Laboratories, Cölbe, DE] 
Trypan Blue 0.4 % trypan blue, liquid and sterile-filtered, T 8154                          
[Sigma-Aldrich, Steinheim, DE] 
Trypsin-EDTA 10 × liquid, 0.5 % Trypsin, 0.2 % EDTA, # L11-003                                     
[PAA Laboratories, Cölbe, DE] diluted to 1 × in sterile PBS  
3.1.4 Antibodies and their Working Dilution 
anti-AChRγ unconjugated, mouse IgG1, clone C9                                  
[MCA1330, AbD Serotec, Düsseldorf, DE] 
1 : 1 Flow cytometry 
anti-FLAG® tag FITC conjugate, mouse IgG1, clone M2                              
[F 4049, Sigma-Aldrich, Steinheim, DE] 
1 : 100 Flow cytometry 
anti-His6 tag unconjugated, mouse IgG1, clone H-3                               
[sc-8036, Santa Cruz Biotechnology, Heidelberg, DE] 
1 : 1,000 Western blot 
anti-His6 tag FITC conjugate, mouse IgG1κ, clone 13/45/31-2             
[DIA 920, Dianova, Hamburg, DE]  
1 : 50 – 1 : 200 Flow cytometry 
anti-His6 tag HRP conjugate, mouse IgG1, clone H-3                           
[sc-8036 HRP, Santa Cruz Biotechnology, Heidelberg, DE] 
1 : 1,000 Western blot 
anti-human CD3ε unconjugated, mouse IgG1κ, clone UCHT-1                
[# 21620030, ImmunoTools, Friesoythe, DE] 
5 µg/ml  Flow cytometry 
anti-human CD3ε FITC conjugate, mouse IgG1κ, clone UCHT-1              
[# 21620033, ImmunoTools, Friesoythe, DE] 
1 : 20 Flow cytometry 
anti-human CD45 FITC conjugate, mouse IgG1, clone 2D-1               
[sc-1187, Santa Cruz Biotechnology, Heidelberg, DE] 
1 : 44 Flow cytometry 
anti-human HLA-A2 PE conjugate, mouse IgG2bκ, clone BB7.2                             
[# 558570, BD Pharmingen™, BD Biosciences, Heidelberg, DE] 
1 : 10 Flow cytometry 
anti-mouse IgG (H+L) IRDye® 800CW conjugate, goat polyclonal                 
[# 926-32210, Li-Cor, Bad Homburg, DE] 
1 : 15,000 Western blot 
anti-mouse IgG (whole molecule) PE conjugate, goat polyclonal         
[P 9670, Sigma-Aldrich, Steinheim, DE]  
1 : 100 Flow cytometry 
mouse IgG1κ unconjugated, isotype control, clone MOPC-21                               
[M 5284, Sigma-Aldrich, Steinheim, DE] 
1 : 1 or 5 µg/ml Flow cytometry 
mouse IgG1 FITC conjugate, isotype control, clone MOPC-21                         
[# 555748, BD Pharmingen™, BD Biosciences, Heidelberg, DE] 
1 : 20 or 1 : 44 Flow cytometry 
mouse IgG2bκ PE conjugate, isotype control, clone 27-35                         
[# 555743, BD Pharmingen™, BD Biosciences, Heidelberg, DE] 
1 : 10 Flow cytometry 
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3.1.5 Antigens, Enzymes, Kits, and Markers 
Antigens, Nucleotides, Cytokines, Lectins, and Fluorescent Dyes 
BSA Bovine Serum Albumin, A 3059, (A 7030, A 4503)                              
[Sigma-Aldrich, Steinheim, DE] 
dNTP Mix 2 mM each deoxynucleotide, molecular biology grade, # R0241 
[Fermentas, St. Leon-Rot, DE] 
IL-2 Recombinant Human Interleukin-2, # 11340023                          
[ImmunoTools, Friesoythe, DE] 
PHA-L Phytohemagglutinin-L, # 11 249 738 001                                          
[Roche Diagnostics, Mannheim, DE] 
7-AAD 7-AAD (7-aminoactinomycin D) Viability Staining Solution, # 420404                        
[BIOZOL, Eching, DE] 
CFSE (CFDA SE) see Kits 
Enzymes 
Alkaline Phosphatase 1 U/µl, FastAP™ Thermosensitive Alkaline Phosphatase, # EF0654           
[Fermentas, St. Leon-Rot, DE] 
Lysozyme Muramidase; N-acetylmuramide glycanohydrolase from hen egg white, 
10 g,  # 10 837 059 001 [Roche Diagnostics, Mannheim, DE] 
Restriction Enzymes PvuI (10 U/µl) and FastDigest® enzymes AgeI, BamHI, EcoRI, HindIII, 
NcoI, NotI, PstI, SacI, SfiI, SpeI (1 FDU/µl)                                    
[Fermentas, St. Leon-Rot, DE] 
T4 DNA Ligase 5 U/µl, # EL0014 [Fermentas, St. Leon-Rot, DE] 
Taq DNA Polymerase 1 U/µl, recombinant, # EP 0403 [Fermentas, St. Leon-Rot, DE] 
Kits 
GeneJET™ Plasmid Miniprep Kit                [Fermentas, St. Leon-Rot, DE] 
Human IL-2 DuoSet ELISA Development Kit, DY202             [R&D Systems, Wiesbaden-Nordenstadt, DE] 
PureYield™ Plasmid Midiprep System                  [Promega, Mannheim, DE] 
REDTaq® ReadyMix™ PCR Reaction Mix (0.06 U/µl)             [Sigma-Aldrich, Steinheim, DE] 
Venor® GeM Mycoplasma Detection Kit              [Minerva Biolabs, Berlin, DE] 
Vybrant® CFDA SE Cell Tracer Kit               [Invitrogen, Karlsruhe, DE] 
Wizard® SV Gel and PCR Clean-Up System              [Promega, Mannheim, DE] 
Markers 
GeneRuler™ DNA Ladder Mix, # SM0333              [Fermentas, St. Leon-Rot, DE] 
PageRuler™ Prestained Protein Ladder Plus, # SM1811       [Fermentas, St. Leon-Rot, DE] 
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3.1.6 Oligonucleotides 
Primers for Cloning 
Numbered primers were purchased from Metabion [Martinsried, DE]. 
1_SfiI-NcoI-mut-His-back (32 bp) 
      
…
          SfiI          . 
5’-AG CCG G CC ATG GCA AGC AGC CAT CAC CAT CAT-3’ 
                                     NcoI                                             His6 tag 
3_scFvCD45-stop-EcoRI-for (40 bp) 
5’-CCG GAA TTC TTA TTA GCT CAC GGT CAC GCT GGT GCC CTG G-3’ 
                     EcoRI           stop                                    scFvCD45 
6_LMB4 (18 bp) 
5’-GCA AGG CGA TTA AGT TGG-3’ 
8_VHHLA-A2-BamHI-back (44 bp) 
5'-TAT GGA TCC GGT GGA GGA GGT TCA CAG GTG CAG CTG GTG CAG TC-3' 
                    BamHI                                                                             VHHLA-A2 
10_VLCD3-NcoI-back (34 bp) 
5'-CAT GCC ATG GCC GAC ATT GTA CTG ACC CAG TCT C-3' 
                         NcoI                                       VLCD3 
12_VHCD45-NcoI-SpeI-back (42 bp) 
5'-CAT ACC ATG GCC ACT AGT ACT GGT CAG GTG CAG CTG GTG GAA-3' 
                         NcoI                  SpeI                                                 VHCD45  
13_VHCD45-AgeI-for (83 bp) 
5'-ATA ACC GGT ACC TCC TCC TGA ACC ACC TCC TCC TGA ACC TCC TCC ACC… 
                      AgeI 
  …GCT CAC GGT CAC GCT GGT GCC CTG GCC CCA ATA A-3' 
            VHCD45 
15_VLCD45-NotI-for (48 bp) 
5'-A TAG TTG TGC GGC CGC TTT AAT TTC CAG TTT GGT GCC GCT GCC AAA GG-3' 
                                           NotI                           VLCD45 
16_VHCD3-HindIII-back (31 bp) 
5'-CCT AAG CTT GAC GTC CAA CTG GTG CAG TCA G-3' 
                    HindIII                     VHCD3 
17_VLCD3-SfiI-for (48 bp) 
5'-T TAT GGC CGG CTG GGC CGA TTT GAT CTC CAC CTT GGT CCC GCC ACC GA-3' 
                                       SfiI                                                VLCD3 
18_VLAChR-BamHI-back (43 bp) 
5'-TAT GGA TCC GGT GGA GGT TCA GTG ATG ACC CAG TCT CCA TCC T-3' 
                    BamHI                       VLAChR 
19_VHAChR-NotI-SacI-for (20 bp) 
5'-GCT CAG CCT AAT CAT CTA GC-3' 
          multi stop 
20_VHCD3-NotI-back (47 bp) 
5'-TA TTA TTA GCG GCC GCA GGT GGT TCA GAC GTC CAA CTG GTG CAG TCA-3' 
            NotI              VHCD3 
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21_VLCD3-stop-SacI-for (44 bp) 
5'-GGC GAG CTC TTA TTA TTT GAT CTC CAC CTT GGT CCC GCC ACC GA-3' 
                     SacI             stop                                           VLCD3 
23_VHCD3-SacI-back (33 bp) 
5'-TT GAG CTC GGT GAC GTC CAA CTG GTG CAG TCA G-3' 
                    SacI                           VHCD3 
24_VLAChR-SfiI-back (40 bp) 
5'-TAA TAG GCC CAG CCG GCC ATG GCC GTG ATG ACC CAG TCT C-3' 
                                       SfiI                                               VLAChR 
25_VHCD3-BamHI-for (37 bp) 
5'-T ATG GAT CC T GAG GAG ACG GTG ACC GTG GTG CCT TGG-3' 
     BamHI                                            VHCD3 
26_VLHLA-A2-SacI-for (37 bp) 
5'-CTT GAG CTC TCC GCC ACC ACG TTT GAT ATC CAC TTT G-3' 
      SacI             VLHLA-A2 
27_LMB3 (18 bp) 
5’-CAG GAA ACA GCT ATG ACC-3’ 
Primers for Screening or Sequencing 
Primers were available in-house or at GATC [Konstanz, DE]. 
pBM1.1:  T-7  (forward, 20 bp)  5’–TAA TAC GAC TCA CTA TAG GG–3’ 
pET-24a (reverse, 23 bp)  5'-GGG TTA TGC TAG TTA TTG CTC AG-3' 
alternative:  
19_VHAChR-NotI-SacI-for  (reverse, 20 bp)  sequence as stated above 
pIRES: CMV-F (forward, 21 bp)  5’–CGC AAA TGG GCG GTA GGC GTG–3’ 
pIRES-RP (reverse, 19 bp)  5'-TAT AGA CAA ACG CAC ACC G-3' 
pUC119: 27_LMB3 (forward, 18 bp)  5’–CAG GAA ACA GCT ATG ACC–3’ 
6_LMB4 (reverse, 18 bp)  5’–GCA AGG CGA TTA AGT TGG–3’ 
alternative:  
LMB2 (reverse, 18 bp)  5’–TGT AAA ACG ACG GCC AGT–3’ 
1_SfiI-NcoI-mut-His-back  (forward, 32 bp)   sequence as stated above 
3_scFvCD45-stop-EcoRI-for  (reverse, 40 bp)   sequence as stated above 
8_VHHLA-A2-BamHI-back  (forward, 44 bp)  sequence as stated above 
16_VHCD3-HindIII-back  (forward, 31 bp)   sequence as stated above  
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3.1.7 Vectors 
pUC119mycHis: Vector for Periplasmic Protein Expression in E. coli TG1 
The vector backbone used, pUC119mycHis (derived from the pUC119 plasmid), comprises a pelB leader 
sequence for periplasmic secretion, a myc tag and a hexahistidine tag for purification. Furthermore, this 
vector contains the lacI repressor gene, the lacZ promoter, the intergenic region of M13 bacteriophage 
(M13 IG), the ColE1 origin of replication, and a multiple cloning site (MCS). It also expresses the bla gene 





Fig. 3.1:  A) Schematic representation of the expression vector pUC119mycHis. PLac, lacZ promoter; 
pelB, leader sequence; MCS, multiple cloning site; myc and His6 tag; M13 IG, intergenic region; 
bla, encoding β-lactamase (ampicillin resistance gene); ColE1, origin of replication.  
B) Extract of pUC119mycHis sequence. The positions of primers LMB2, LMB3, and LMB4, 




                                        HindIII                  RBS  S 
...........caggaaacagctatgaccatgattacgccaagcttgcatgcaaattctatttcaaggagacagtcata 
                  LMB3 
                                                                     SfiI      .  
atg aaa tac cta ttg cct acg gca gcc gct gga ttg tta tta ctc gcg gcc cag ccg gcc  
_M   K   Y   L   L   P   T   A   A   A   G   L   L   L   L   A   A   Q   P   A_  
 pelB leader sequence 
 
                 PstI    SalI    XhoI  ,                    NotI   .   
atg gcc cag gtg cag ctg cag gtc gac ctc gag atc aaa cgg gcg gcc gca gaa caa aaa  
 M   A_  Q   V   Q   L   Q   V   D   L   E   I   K   R   A   A   A  _E   Q   K_ 
                                                                     myc tag… 
 
ctc atc tca gaa gag gat ctg aat ggg gcc gca cat cac cat cat cac cat taa taa  
_L   I   S   E   E   D   L   N_  G   A   A  _H   H   H   H   H   H   *   *   
…myc tag                                     His tag 
 
EcoRI        
gaattcactggccgtcgttttacaacgtcgtgactgggaaaaccctggcgttacccaacttaatcgccttgc.... 
            LMB2                                             LMB4 
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pET-BM1.1: Vector for Periplasmic Protein Expression in E. coli BL21 (DE3) 
The other vector backbone used, pBM1.1, was cloned from the pET-27b(+) plasmid from Novagen by 
Matthey et al. [1999]. The pET-27b(+) plasmid comprises a pelB leader sequence for periplasmic 
secretion, a HSV tag and a hexahistidine tag for purification. Furthermore, this vector contains the T-7 
promoter, the lacI coding sequence, the ColE1 and f1 origin of replication, and a multiple cloning site 






Fig. 3.2:  A) Schematic representation of the expression vector pET-27b(+). PT7, T7 promoter; pelB, 
leader sequence; MCS, multiple cloning site; HSV and His6 tag; KanR, encoding kanamycin 
resistance gene; ColE1 and f1, origin of replication; LacI, lacI repressor. B) Extract of pET-
27b(+) sequence. The positions of primers T7 and pET-24a, ribosomal binding site (RBS), 
pelB leader sequence, MCS, HSV and His6 tag are indicated.  
 
                                               ............taatacgactcactataggg 
                                                                   T7  




atg aaa tac ctg ctg ccg acc gct gct gct ggt ctg ctg ctc ctc gct gcc cag ccg gcg   
_M   K   Y   L   L   P   T   A   A   A   G   L   L   L   L   A   A   Q   P   A_  
 pelB leader sequence 
                                           EcoRI  .   
       NcoI                        BamHI            SacI     SalI   HindIII NotI… 
atg gcc atg gat atc gga att aat tcg gat ccg aat tcg agc tcc gtc gac aag ctt gcg   
_M   A_  M   D   I   G   I   N   S   D   P   N   S   S   S   V   D   K   L   A   
 
…NotI    XhoI  . 
gcc gca ctc gag atc aaa cgg gct agc cag cca gaa ctc gcc ccg gaa gac ccc gag gat   
 A   A   L   E   I   K   R   A  _S   Q   P   E   L   A   P   E   D   P   E   D_  
                                 HSV tag 
 
gtc gag cac cac cac cac cac cac tga gatccggctgctaacaaagcccgaaaggaagctgagttggctg 
 V   E  _H   H   H   H   H   H   * 
         His tag 
 
         CelII . 
ctgccaccgctgagcaataactagcataaccc.... 
                  pET-24a 
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pIRESpuro2 HLA-A2: Vector for Eukaryotic Protein Expression in HEK-293T Cells 
The cDNA of HLA-A2 based on genomic DNA, thus including promoter and introns of the human HLA-
A0201, was kindly provided by Dr. Grosse-Hovest, Department of Immunology, University of Tübingen, in 
the vector pIRESpuro2 [Clontech, Heidelberg, DE]. This vector comprises the human cytomegalovirus 
(CMV) immediate early enhancer and promoter, a synthetic intron (IVS), an internal ribosome entry site 
(IRES), a gene coffering puromycin resistance needed for eukaryotic selection, and the bovine growth 
hormone (BGH) poly-A signal. Additionally, ColE1, bla, and an MCS are present (Fig. 3.3).  
A 
 
Fig. 3.3:  A) Schematic representation of the expression vector pIRESpuro2 HLA-A2. PCMV, human 
cytomegalovirus immediate early promoter; IVS, synthetic intron; IRES, internal ribosome entry 
site; BGH, bovine growth hormone poly-A signal; PuroR, encoding puromycin resistance gene; 
ColE1, origin of replication; bla, encoding β-lactamase (ampicillin resistance gene). 
3.1.8 E. coli Strains 
BL21 Star™ (DE3): F- ompT hsdSB (rB-mB-) gal dcm rne131(DE3) 
[Invitrogen by Life Technologies GmbH, Darmstadt, DE] 
NEB 5-alpha: fhuA2 ∆(argF-lacZ)U169 phoA glnV44 Φ80∆ (lacZ)M15 gyrA96 recA1 relA1 
endA1 thi-1 hsdR17 
[New England Biolabs GmbH, Frankfurt, DE] 
TG1:   ∆(lac-pro), supE, thi, hsdD5 [F' traD36, proAB, lacIq, lacZ∆M15] 
[DSMZ, Braunschweig, DE] 
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3.1.9 Mammalian Cell Lines 
Table 3.1:  Mammalian cell lines and corresponding culture conditions. 
Cell Line Cell Type Medium 
A-204 human rhabdomyosarcoma; fAChR- RPMI 1640 + 10 % FCS 





highly transfectable derivative of the human embryonal 
kidney cell line HEK-293 carrying a plasmid containing 
the temperature sensitive mutant of SV-40 large T 
antigen; HLA-A2- 






HEK-293T cells stably transfected with the human MHC 
class I molecule HLA-A201 




human T-cell leukaemia (acute lymphoblastic) cells; 
CD3+, CD45+, HLA-A2- 
RPMI 1640 + 10 % FCS 
 
KMS-12-BM human multiple myeloma (B cell); CD45-, HLA-A2- RPMI 1640 + 10 % FCS 
L-363 
 
human plasma cell leukaemia related to multiple 
myeloma (B cell); CD45-, HLA-A2+ 
RPMI 1640 + 10 % FCS 
 





peripheral blood mononuclear cells of human origin, 
isolated from blood donor buffy coat by Ficoll density 
gradient centrifugation; largely monocyte-depleted; 
CD3+, CD45+, HLA-A2+/- 




Raji human Burkitt's lymphoma (B cell); CD45+, HLA-A2- RPMI 1640 + 10 % FCS 
RD human embryonal rhabdomyosarcoma; fAChR+ DMEM + 10 % FCS 
TE-671 
 
human embryonal rhabdomyosarcoma; fAChR+, 
a derivative of the RD cell line 
DMEM + 10 % FCS 
 
U266 human multiple myeloma (B cell); CD45+, HLA-A2+ RPMI 1640 + 10 % FCS 
Cells were cultured at 37°C in a humidified (60 % rel. humidity) incubator with a 5 % CO2 atmosphere and 
were tested for the presence of mycoplasma by using the Venor® GeM Mycoplasma Detection Kit from 
Minerva Biolabs according to the manufacturer’s instructions. 
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3.2 Strategies for Cloning of Recombinant Antibody Constructs 
3.2.1 Construction of Recombinant Bispecific AChRγ × CD3 taFvs  
The cDNA of the human scFv against AChRγ with an N-terminal His10 cluster was 
kindly provided by Prof. S. Gattenlöhner, Institute of Pathology, University of Würzburg. 
This scFv originates from a human Fab-fragment (Fab35) that was isolated from 
a thymic combinatorial cDNA library from a myasthenia gravis patient with high levels 
of AChRγ-specific autoantibodies [Matthews et al., 2002]. The conversion of Fab35 into 
the scFv format is detailed in Gattenlöhner et al. [2010] [see Section 8.1]. 
The deimmunised mouse scFv fragment diL2K [Brischwein et al., 2006] was chosen as 
the CD3-specific antibody fragment. It derives from the human CD3ε-specific mouse 
mAb L2K [Dreier et al., 2002], which is identical with the mAb TR66 [Lanzavecchia and 
Scheidegger, 1987, Traunecker et al., 1991]. The cDNA sequence of the scFv diL2K 
was obtained from a patent specification accessible online [Kinch et al., 2007] and was 
commercially synthesised [GenScript, Piscataway, US] after the addition of 
a C-terminal FlagHis6 tag and several desired restriction sites. 
scFvAChR had been available in the prokaryotic expression vector pBM1.1 [Matthey 
et al., 1999] with a flexible (G4S)2-G-(GS)2-linker between VL and VH, which allows the 
suitable folding into a functional scFv. 
scFvCD3 was cloned from the provided cloning vector pUC57 from GenScript into the 
prokaryotic expression vector pUC119 scFvHLA-A2 [see Section 8.5] via NcoI and 
EcoRI, generating pUC119 scFvCD3 [see Section 8.2]. Here, VH and VL were joined by 
a flexible GEGTST-(GSG)3-GAD-linker. 
For the cloning of His-taFvCD3-AChR, the coding sequence of scFvCD3 was amplified 
by PCR with the primers 16_VHCD3-HindIII-back and 17_VLCD3-SfiI-for, with plasmid 
pUC57 scFvCD3 as a template to introduce a HindIII restriction site at the N-terminus 
and an SAQPA-linker/SfiI restriction site at the C-terminus of scFvCD3. Then scFvCD3 
was inserted N-terminal to scFvAChR into pBM1.1 scFvAChR by digestion with HindIII 
and SfiI, resulting in pBM1.1 His-taFvCD3-AChR.  
For the construction of taFvCD3-AChR-FlagHis, the cDNA of scFvAChR was amplified 
from pBM1.1 scFvAChR by using the primers 18_VLAChR-BamHI-back and 
19_VHAChR-NotI-SacI-for to introduce a BamHI/GSG3S-encoding linker sequence at 
the N-terminus of scFvAChR. scFvAChR was then digested with BamHI/NotI. scFvCD3 
was cut from pUC57 scFvCD3 by SfiI/BamHI. Both inserts, scFvCD3 (SfiI/BamHI) and 
scFvAChR (BamHI/NotI), were introduced into pUC119 VHCD3-scFvCD45(VL-VH) [for 
cloning, see Section 3.2.2] via SfiI/NotI, generating pUC119 taFvCD3-AChR-FlagHis. 
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Amplification of the scFvCD3 coding sequence from pUC57 scFvCD3 with the primers 
20_VHCD3-NotI-back and 21_VLCD3-stop-SacI-for introduced NotI/A3G2S-linker at the 
N-terminus and stop/SacI at the C-terminus. Hence, scFvCD3 could be inserted 
C-terminally to scFvAChR into pBM1.1 scFvAChR via NotI/SacI, resulting in pBM1.1 
His-taFvAChRCD3.  
For the construction of taFvAChR-CD3-FlagHis, the cDNA of scFvCD3 was amplified 
from pUC57 scFvCD3 by using the primers 23_VHCD3-SacI-back and 06_LMB4 to 
introduce SacI N-terminal to scFvCD3. In addition, the cDNA of scFvAChR was 
amplified from pBM1.1 scFvAChR by using the primers 24_VLAChR-SfiI-back and 
19_VHAChR-NotI-SacI-for to introduce SfiI at the N-terminus of scFvAChR. Then 
scFvAChR and scFvCD3 were digested with SfiI/SacI and SacI/NotI, respectively. Both 
inserts, scFvAChR (SfiI/SacI) and scFvCD3 (SacI/NotI), were introduced into pUC119 
VHCD3-scFvCD45(VL-VH) via SfiI/NotI, generating pUC119 taFvAChR-CD3-FlagHis with 
an A3ELG-linker between the two scFvs. 
3.2.2 Construction of a Two-Part Trispecific HLA-A2 × CD3 × CD45 
Antibody 
The cDNA of the HLA-A2-specific scFv (clone 3PF12) with a C-terminal mycHis6 tag 
was kindly provided by Dr. Nicholas A. Watkins, Department of Haematology, 
University of Cambridge. scFvHLA-A2 was isolated from an alloimmunised patient and 
selected by V gene phage display technology [Watkins et al., 2000] [see Section 8.5]. 
The selected CD45-specific scFv is derived from human CD45-specific mouse mAb 
BC8 (hybridoma), which is reactive with all CD45 isoforms [Lin et al., 2006]. The cDNA 
sequence of scFvCD45 was obtained from the given publication and commercially 
synthesised [GenScript, Piscataway, US] in the VL-VH orientation after the addition of 
a His6Flag tag and a TCS at the N-terminus, GFP11 at the C-terminus, as well as 
several desired restriction sites. 
scFvHLA-A2 was available in the prokaryotic expression vector pUC119mycHis with 
a flexible (G4S)3-linker between VH and VL, which allows the suitable folding into 
a functional scFv. 
The situation with scFvCD45 was different, as the cDNA of scFvCD45 was achieved 
from a sequence of scFvCD45(VL-VH)-GFP11, which had already been acquired by 
purchase. First, the cDNA of scFvCD45(VL-VH)-GFP11 was amplified by PCR from the 
provided cloning vector pUC57 scFvCD45(VL-VH)-GFP11 by using the primers 01_SfiI-
NcoI-mut-His-back and 27_LMB3. On this occasion, the last amino acid in the pelB 
leader in the incorrectly ordered sequence was amended. Then scFvCD45(VL-VH)-
GFP11 was introduced into pUC119 scFvHLA-A2 via NcoI/EcoRI, generating pUC119 
scFvCD45(VL-VH)-GFP11 with the corrected pelB leader sequence. PCR amplification of 
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the scFvCD45(VL-VH) coding sequence from pUC119 scFvCD45(VL-VH)-GFP11 with the 
primers 01_SfiI-NcoI-mut-His-back and 03_scFvCD45-stop-EcoRI-for introduced 
stop/EcoRI C-terminal to scFvCD45(VL-VH). Thus, scFvCD45(VL-VH) could be inserted 
into the prokaryotic expression vector pUC119 scFvHLA-A2 via NcoI/EcoRI, resulting 
in pUC119 scFvCD45(VL-VH). Here, VL and VH were joined by a flexible KIS-(G4S)3-S-
linker. 
Due to suboptimal features of scFvCD45(VL-VH), which emerged in flow cytometry [see 
Fig. 4.17 in Section 4.4.4], scFvCD45(VH-VL) was additionally constructed. For this 
purpose, the cDNA of VHCD45 and VLCD45 was amplified from pUC119 
scFvCD45(VL-VH) by using the primer pair 12_VHCD45-NcoI-SpeI-back/13_VHCD45-
AgeI-for and 27_LMB3/15_VLCD45-NotI-for, respectively. In doing so, NcoI/SpeI was 
introduced N-terminal to VHCD45, (G4S)2-G3TG-linker/AgeI C-terminal to VHCD45, AgeI 
N-terminal to VLCD45, and NotI C-terminal to VLCD45. Then VHCD45 and VLCD45 
were digested with NcoI/AgeI and AgeI/NotI, respectively. Both inserts, VHCD45 
(NcoI/AgeI) and VLCD45 (AgeI/NotI), were introduced into pUC119 VHCD3-
scFvCD45(VL-VH) [for cloning, see below in this section] via NcoI/NotI, generating 
pUC119 scFvCD45(VH-VL) with a (G4S)2-G3TG-linker between VH and VL. 
For the construction of VLCD3-scFvHLA-A2, the cDNA of VLCD3 was amplified from 
pUC57 scFvCD3 by using the primers 10_VLCD3-NcoI-back and 06_LMB4, thus 
introducing NcoI at the N-terminus of VLCD3. The cDNA of scFvHLA-A2 was amplified 
from pUC119 scFvHLA-A2 by using the primers 08_VHHLA-A2-BamHI-back and 
06_LMB4, thus introducing BamHI/GS-(G4S)-linker at the N-terminus of scFvHLA-A2. 
Then VLCD3 and scFvHLA-A2 were digested with NcoI/BamHI and BamHI/NotI, 
respectively. Both inserts, VLCD3 (NcoI/BamHI) and scFvHLA-A2 (BamHI/NotI), were 
introduced into pUC119 scFvHLA-A2 via NcoI/NotI, generating pUC119 VLCD3-
scFvHLA-A2 with a GS-(G4S)-linker between VLCD3 and scFvHLA-A2. 
For the cloning of VHCD3-scFvCD45(VL-VH), the cDNA of VHCD3 was cut from pUC57 
scFvCD3 by NcoI/AgeI and inserted into pUC119 scFvCD45(VL-VH)-GFP11 via 
NcoI/AgeI, generating pUC119 VHCD3-scFvCD45(VL-VH)-GFP11 as an intermediate 
product. Then the coding sequence of a FlagHis6 tag was cloned from pUC57 
scFvCD3 into pUC119 VHCD3-scFvCD45(VL-VH)-GFP11 via NotI/EcoRI, resulting in 
pUC119 VHCD3-scFvCD45(VL-VH) with a GEGTSTG-linker between VHCD3 and 
scFvCD45(VL-VH). 
pUC119 VHCD3-scFvCD45(VH-VL) with the same GEGTSTG-linker between VHCD3 and 
scFvCD45(VH-VL) was obtained by cloning the cDNA of pelB-VHCD3 from pUC119 
VHCD3-scFvCD45(VL-VH)-GFP11 into pUC119 scFvCD45(VH-VL) via HindIII/SpeI. 
For the construction of VHCD3-scFvHLA-A2-mycHis, the cDNA of VHCD3 was amplified 
from pUC119 scFvCD3 by using the primers 27_LMB3 and 25_VHCD3-BamHI-for, thus 
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introducing BamHI at the C-terminus of VHCD3. Then VHCD3 was inserted into 
pUC119 VLCD3-scFvHLA-A2 via NcoI/BamHI, generating pUC119 VHCD3-scFvHLA-
A2-mycHis with a GS-(G4S)-linker between VHCD3 and scFvHLA-A2. 
Thereof VHCD3-scFvHLA-A2 was subsequently cloned into pUC119 scFvCD45(VH-VL) 
via NcoI/NotI, resulting in pUC119 VHCD3-scFvHLA-A2-FlagHis. 
3.2.3 Construction of Bispecific HLA-A2 × CD3 taFvs 
For cloning taFvCD3-HLA-A2-mycHis, the cDNA of scFvCD3 was cut from pUC119 
taFvCD3AChR-FlagHis by NcoI/BamHI. Then scFvCD3 was inserted into pUC119 
VLCD3-scFvHLA-A2 via NcoI/BamHI, generating pUC119 taFvCD3-HLA-A2-mycHis 
with a GS-(G4S)-linker between scFvCD3 and scFvHLA-A2. 
Thereof taFvCD3-HLA-A2 was then cloned into pUC119 VHCD3-scFvCD45(VL-VH) via 
SfiI/NotI, resulting in pUC119 taFvCD3-HLA-A2-FlagHis. 
For construction of taFvHLA-A2-CD3-mycHis, the cDNA of scFvHLA-A2 was amplified 
from pUC119 scFvHLA-A2 by using the primers 27_LMB3 and 26_VLHLA-A2-SacI-for, 
thus introducing G3EL-linker/SacI at the C-terminus of scFvHLA-A2. Then scFvHLA-A2 
was introduced into pUC119 taFvAChR-CD3-FlagHis [see Section 8.7] via SfiI/SacI, 
generating pUC119 taFvHLA-A2-CD3-mycHis with a G3ELG-linker between the two 
scFvs. 
The subsequent cloning of taFvHLA-A2-CD3 into pUC119 scFvHLA-A2 via NcoI/NotI 
resulted in pUC119 taFvCD3-HLA-A2-mycHis. 
3.3 Cloning of Recombinant Antibody Constructs 
3.3.1 Polymerase Chain Reaction (PCR) 
PCR enables selective amplification of specific regions of DNA. The following PCR 
master mix was prepared to amplify the chosen DNA fragments from corresponding 
vectors: 
Volume Compound (concentration) Final conc. 
10 µl DNA template  (1 ng/µl) 10 ng 
5 µl (NH4)2SO4 buffer  10 × 1 × 
4 µl MgCl2  (25 mM) 2 mM 
1 µl forward primer  (10 pmol/µl) 0.2 µM 
1 µl reverse primer  (10 pmol/µl) 0.2 µM 
1.25 µl dNTP set  (4 × 2 mM) 4 × 50 µM 
1.25 µl Taq DNA-Polymerase  (1 U/µl)  
ad 50 µl H2O  
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For amplification of DNA fragments, the same PCR programme was used, but with 
adapted annealing temperature: 
3 min 94°C initial denaturation   
30 sec 94°C denaturation  
30 sec 51 – 62°C annealing 30 × 
1 min 72°C extension  
5 min 72°C final extension  
Agarose gel electrophoresis was performed with a 1 % agarose gel in order to confirm 
that the amplification succeeded and to verify the size of the amplified DNA fragments. 
Following separation, PCR fragments were extracted from the gel by using the Wizard® 
SV Gel and PCR Clean-Up System from Promega (see Section 3.3.3) according to the 
manufacturer’s instructions. 
3.3.2 Restriction Digestion 
For restriction digestion, 2 (– 10) µg of vector DNA, 1 (– 5) µg of insert DNA, or the 
entire amount of PCR product DNA extracted from an agarose gel (see Section 3.3.1) 
were digested in a total volume of 20 (– 50) µl. In each digestion sample, 0.5 – 3 µl of 
the respective restriction enzyme were used in the corresponding buffer. Digestion 
occurred for 5 – 30 min under appropriate temperature conditions according to the 
manufacturer’s instructions. 
Finally, 1 µl of alkaline phosphatase was added to digested vector DNA and incubated 
for at least 10 min at 37°C. This enzyme enhances the efficiency of the following 
ligation by dephosphorylation of the 5’ end and thus preventing the DNA from self-
ligation. 
3.3.3 Agarose Gel Electrophoresis and DNA Gel Extraction 
Horizontal agarose gel electrophoresis was performed in order to analyse PCR 
products, to estimate the size of DNA molecules following restriction enzyme digestion, 
and to purify digested DNA. For this purpose, DNA samples were mixed with DNA 
loading dye and separated on a 0.8 – 1.5 % agarose gel containing 0.05 µg/ml 
ethidium bromide in TBE buffer. For size estimation, 3 or 5 µl of GeneRuler™ DNA 
Ladder Mix from Fermentas were loaded on each gel as well. After a gel was run for 
1 h at 100 V, relevant DNA bands were excised under ultraviolet light, and the DNA 
fragments were extracted from the gel by using the Wizard® SV Gel and PCR Clean-
Up System from Promega according to the manufacturer’s instructions. Finally, DNA 
was eluted from the column into 35 µl H2O.  
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3.3.4 Ligation 
For covalent binding of a linearised, dephosphorylated vector and an insert, T4 DNA 
ligase was used. Ligation was performed with 2.5 U of T4 DNA ligase in ligation buffer 
in a total volume of 20 µl, containing vector and insert at a ratio of 1 : 3 up to 1 : 16.5. 
For ligations of two fragments into one vector, ratios of 1 : 3 : 3 up to 1 : 10 : 10 
(V : I1 : I2) were prepared. As a negative control solely the vector was used. After 
ligation occurred for at least 1 h at room temperature (RT), 10 µl of each ligation 
sample were transformed into chemically competent cells (see Section 3.3.6). 
3.3.5 Preparation of Chemically Competent Cells 
Making bacterial cells chemically competent enables them to take up plasmid DNA, 
which is needed for the expression of recombinant proteins. In this case, cells of the 
E. coli strain TG1 and BL21 Star™ (DE3) were made chemically competent using 
CaCl2 as follows: 
100 ml of LB medium, including 1 % glucose, were inoculated with 1 ml of an overnight 
culture of bacterial cells and grown to exponential phase (OD600 0.4 – 0.8) at 37°C. 
Then the bacterial suspension was chilled on ice for 15 min, and cells were harvested 
by centrifugation for 10 min at 2,000 × g and 4°C. Following gentle resuspension in 
2 × 30 ml of 100 mM ice cold CaCl2, bacterial cells were centrifuged as stated above. 
Finally, in order to be suitable for storage, chemically competent cells were gently 
resuspended in 2 × 2.5 ml of 50 mM ice cold CaCl2 containing 20 % glycerol and then 
frozen in aliquots at -80°C. 
In order to determine the transformation efficiency of the chemically competent cells, 
100 µl of cells were transformed with 10 ng of pUC119 scFvHLA-A2 plasmid DNA, 
20 pg of pUC119 control plasmid DNA, or H2O as a negative control (3.3.6). The 
transformation efficiency is defined as the number of transformed cells generated by 
1 µg of plasmid DNA in a transformation reaction (indicated as ‘colony-forming units’ 
per µg). The resulting transformation efficiency usually amounted to 105 – 106 cfu/µg. 
3.3.6 Transformation of Chemically Competent Cells 
For transformation, 100 µl of chemically competent cells were thawed on ice and 
added to 10 µl of ligated DNA, then mixed up gently and incubated on ice for 15 min. 
Next, cells were subjected to a heat shock at 42°C for exactly 1.5 min in a water bath 
and subsequently cooled down on ice for 1 min. Since the plasmids used in this study 
carry ampicillin- or kanamycin-resistance genes, successfully transformed cells could 
be selected by ampicillin or kanamycin, respectively. Thus, 1 ml of LB medium was 
added and the cells were incubated for 45 min at 37°C with shaking to allow the 
expression of the resistance protein. Cells were then centrifuged for 1 min at 
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17,900 × g. Finally, after the supernatant was discarded, cells were resuspended in the 
backflow, plated on LBamp/glc or LBkan/glc agar plates and incubated overnight at 37°C. 
3.3.7 Screening of Positive Transformants by PCR 
In order to screen positively transformed cells, the REDTaq® ReadyMix™ PCR 
Reaction Mix from Sigma-Aldrich was used. Single colonies grown overnight were 
picked and analysed by PCR to check for incorporation of the insert. Simultaneously, 
the same colonies were streaked on a master plate and incubated overnight at 37°C. 
A PCR sample contained 10 µl of the REDTaq® ReadyMix™, including 0.6 U of Taq 
DNA polymerase, 1 µM of each primer, and H2O from the kit in a total volume of 20 µl. 
In order to achieve an unambiguous screening result, appropriate primers were chosen 
to amplify the DNA fragment inserted into the vector. The following PCR programme 
was used: 
5 min 94°C initial denaturation   
1 min 94°C denaturation  
1 min 50°C annealing 30 × 
2 min 72°C extension  
5 min 72°C final extension  
Finally, PCR fragments were separated by agarose gel electrophoresis, and positive 
clones were identified by the size of the bands. One of the positive clones was then 
used for plasmid DNA isolation. 
3.3.8 Plasmid DNA Isolation (Mini and Midi Preparation) 
For the isolation of plasmid DNA, overnight cultures were prepared in LB medium 
containing 1 % glucose and 100 µg/ml ampicillin or kanamycin. 4 ml of overnight 
culture were prepared for mini preparation, and 100 ml for midi preparation. Each 
overnight culture was inoculated with a single positively screened clone from the 
master plate. The next day, a glycerol stock (26 % glycerol) was prepared from an 
aliquot of the bacterial suspension for long-term storage of the clone, and the 
remaining cells were harvested by centrifugation for 2 min at 7,000 × g (mini) or 15 min 
at 6,000 × g (midi) and 4°C. The plasmid DNA isolation was performed by using the 
GeneJET™ Plasmid Miniprep Kit from Fermentas or the PureYield™ Plasmid Midiprep 
System from Promega following the manufacturers’ instructions. The eluted DNA was 
finally stored at –20°C. The DNA concentration was measured photometrically at OD260 
using the spectrophotometer GeneQuant pro from Pharmacia. 
In order to confirm the identity of the isolated plasmid DNA, a control digestion with 
appropriate restriction enzymes and / or sequence analysis was performed. 
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3.3.9 Sequence Analysis 
For sequence analysis, plasmid DNA at 28 – 87 ng/µl and the appropriate primers at 
10 pmol/µl were sent to GATC Biotech [Konstanz, DE] in H2O in a total volume of 30 µl. 
Sequence alignment was performed using the Blast algorithm [Tatusova and Madden 
1999], and the sequence was analysed by aid of Clone Manager 7 [Scientific & 
Educational Software, Cary, US]. 
3.4 Expression and Purification of Recombinant Antibodies 
3.4.1 Periplasmic Protein Expression 
All antibody fragments were expressed in the periplasm of the E. coli strains TG1 or 
BL21 Star™ (DE3), using the prokaryotic expression vector pUC119 and pBM1.1, 
respectively. For each antibody fragment, two litres of 2 × TY medium, including 0.1 % 
glucose and 100 µg/ml ampicillin or kanamycin, were inoculated with 20 ml of an 
overnight culture of transformed bacterial cells and grown to exponential phase 
(OD600 0.8 – 0.9) at 37°C. Since the antibody fragments are under control of the lactose 
promoter, protein expression was induced by addition of 1 mM IPTG, followed by 
incubation at RT with shaking for additional 3 h. Cells were harvested by centrifugation 
for 15 min at 1,700 × g and 4°C and resuspended in 100 ml periplasmic preparation 
buffer. Cell lysis was performed by adding 50 µg/ml freshly dissolved lysozyme [Roche 
Diagnostics] and incubating for 25 min on ice. Following, 10 mM MgSO4 were added to 
stabilise spheroblasts, and cells were centrifuged for 10 min at 6,000 × g and 4°C. 
Finally, the obtained supernatant, containing the periplasmic protein, was dialysed 
against PBS overnight at 4°C and was then centrifuged again for 15 min as stated 
above. Afterwards, recombinant proteins were purified by Ni-NTA-IMAC as described 
in the following section. 
3.4.2 Immobilised-Metal Affinity Chromatography (IMAC) 
For purification of recombinant proteins owning a His6 tag or a His10 cluster, an IMAC 
was performed by means of immobilised nickel-nitrilotriacetic acid (NTA) agarose 
beads [Qiagen]. First, a column of 1 ml Ni-NTA agarose needed to be equilibrated with 
approximately 10 ml of sterile 1 × sodium phosphate buffer with 20 mM imidazole. 
Then, crude protein, dialysed from periplasmic expression, was gradually applied to the 
column. After washing the column with about 20 ml of an appropriate IMAC wash buffer 
(1 × sodium phosphate buffer with 30 – 35 mM imidazole) until no more protein was 
detectable in the flow, bound protein was eluted from the column in 500 µl fractions 
with 1 × sodium phosphate buffer including 200 mM imidazole. All solutions were kept 
ice-cold throughout the entire purification. 
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All collected wash and elution fractions were tested for presence of protein by 
a qualitative Bradford assay by adding 10 µl of each sample to 90 µl of 1 × Bradford 
solution. Verification of the purification process was performed by an SDS-PAGE 
analysis. For this purpose, eluted fractions were run in parallel with crude protein, flow, 
and wash fraction under reducing conditions. Finally, positive fractions determined by 
the colorimetric reaction were pooled into peak and minor fractions and dialysed 
against PBS overnight at 4°C. For usage in stimulation assays, 0.01 % sodium azide 
was added to purified proteins as an alternative to lossy sterile filtration, and their 
concentration was determined. In addition, after protein quantification, (0.5 –) 2 µg of 
all purified proteins were also analysed by Western blotting under reducing conditions. 
3.4.3 Determination of Protein Concentration 
Protein concentration was determined by photometric measurement at OD280 
[GeneQuant pro], using the calculated molecular weight and ε value of each protein. 
3.5 Biochemical Characterisation 
3.5.1 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
In order to characterise the purified proteins with regard to molecular weight, purity, 
and potential degradation, an SDS-PAGE was performed. For this purpose, SDS gels 
with 12 % of polyacrylamide were prepared as follows: 
 12 % Resolving Gel 5 % Stacking Gel 
 2 gels 4 gels 2 gels 4 gels 
H2O 3.3 ml 6.6 ml 2.1 ml 5.5 ml 
30 % polyacrylamide 4 ml 8 ml 500 µl 1.3 ml 
1.0 M Tris-HCl pH 6.8 – – 380 µl 1 ml 
1.5 M Tris-HCl pH 8.8 2.5 ml 5 ml – – 
10 % SDS 100 µl 200 µl 30 µl 80 µl 
10 % APS 100 µl 200 µl 30 µl 80 µl 
TEMED 4 µl 8 µl 3 µl 8 µl 
Each sample was mixed up with reducing SDS-PAGE loading buffer, heated for        
5 – 10 min at 95°C and loaded on the gel. A prestained protein standard was used to 
estimate protein size. Then, gels were run for approximately 1.5 h at 150 V (stacking 
gel 80 V) and stained for 1 h with shaking, using staining solution containing 
Coomassie Blue R 250. The gels were first destained with destaining solution until 
single separated protein bands were discernible and then additionally destained with 
H2O overnight. The next day, a digital image was taken by a conventional scanner or 
the infrared imaging scanner Odyssey®. 
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3.5.2 Western Blot Analysis 
Purified recombinant proteins were further verified by Western blotting in order to 
confirm their identity. To this end, they were separated on 12 % SDS-PAGE gels and 
transferred onto nitrocellulose membranes by semi-dry blotting (Fig. 3.4) for 45 min 
(1 gel) – 90 min (4 gels) at 47 mA per gel up to 10 V. Further proceeding differed 
depending on the detection system. 
 
Fig. 3.4:  Western blot set-up. 
Fluorescent Imaging System 
After the blocking of remaining binding sites on the membrane with 5 % skimmed milk 
in PBS for 1 h at RT with shaking, the membrane was washed 3 × with PBS containing 
0.05 % Tween 20 and once with PBS alone for 5 min each. Next, bound proteins (His-
tagged antibody constructs) were sequentially detected by incubation with 
unconjugated mouse anti-His6 tag IgG1 antibody 1 : 1,000 diluted in PBS, 0.02 % NaN3 
overnight at 4°C. After renewed washing (4 × with PBS containing 0.05 % Tween 20), 
bound antibody was detected by polyclonal goat anti-mouse IgG antibody conjugated 
with IRDye® 800CW, 1 : 15,000 diluted in blocking solution containing 0.1 % Tween 20, 
for 1 h at RT protected from light with shaking. Finally, the blot was washed again (last 
wash with PBS) and scanned at 800 nm by using the infrared imaging system 
Odyssey®. 
ECL (Enhanced Chemiluminescence) System 
Here, remaining binding sites were blocked with 5 % skimmed milk in PBS containing 
0.1 % Tween 20, and the membrane was washed 3 × with PBS containing 0.05 % 
Tween 20. For protein detection, the membrane was incubated with an HRP-
conjugated mouse anti-His6 tag IgG1 antibody 1 : 1,000 diluted in blocking solution (see 
above) overnight at 4°C. After renewed washing (last washing with PBS devoid of 
Tween 20), bound antibody was developed by the ECL system. For this purpose, the 
membrane was incubated with the ECL substrate solution for 1 – 2 min and was 
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subsequently exposed to an X-ray film for a few seconds. The film was then 
automatically developed in an X-ray film processor. 
3.6 Cell Culture Techniques 
3.6.1 Cell Cultivation 
Mammalian cells were cultivated in T75 tissue culture flasks in 20 ml of the appropriate 
culture medium (see Section 3.1.9) in a humidified (60 % rel. humidity) incubator at 
37°C with 5 % CO2 atmosphere. Cells were split every 2 – 3 days. Adherent cells first 
needed to be detached with 1 × trypsin-EDTA. Cells were counted using the vital stain 
trypan blue. For storage, cells of 60 – 80 % confluence were harvested by 
centrifugation for 4 min at 1200 × g, resuspended in FCS with 10 % DMSO, aliquoted 
in cryovials, and gradually frozen to a temperature of -80°C in a cryobox containing 
isopropanol. Cells were thawed quickly at 37°C in a water bath and cautiously added to 
5 ml medium. In order to remove DMSO, cells were centrifuged again, resuspended in 
fresh medium and transferred into a tissue culture flask. 
3.6.2 Stable Transfection 
Since only a relatively low amount of the DNA that is introduced into the cell during the 
transfection process is inserted into the nuclear genome, the foreign DNA is usually 
lost rather quickly in the absence of selection pressure. In order to enable stable 
expression of HLA-A2 on HEK-293T cells, a gene conferring puromycin resistance was 
transfected in the same plasmid allowing stable transfectants to proliferate under 
puromycin selection pressure, while other cells die. In order to facilitate stable 
transfection, the HLA-A2-encoding plasmid DNA was linearised overnight with the 
restriction enzyme PvuI.  
For stable transfection, HEK-293T cells (tested negative for HLA-A2 and CD45) were 
seeded in a 6-well plate at a density of 106 cells per well in 2 ml of culture medium and 
incubated overnight at 37°C and 5 % CO2. Then, 166 µl Opti-MEM® I medium were 
incubated for 5 min with 6.7 µl of the transfection reagent Lipofectamine™ 2000. In 
parallel, additional 166 µl Opti-MEM® I medium were mixed with 2.66 µg of linearised 
plasmid DNA to be transfected. Both solutions were combined, gently mixed, and 
incubated for 20 min at RT. Meanwhile, the FCS containing medium on the cells was 
replaced by 1.33 ml Opti-MEM® I medium. Then, the DNA-Lipofectamine™ 2000 
complexes were cautiously added to the cells and incubated overnight. Medium was 
exchanged by Opti-MEM® I medium containing Pen-Strep after at least 6 h to remove 
remaining Lipofectamine™ 2000. 24 h after transfection, the cells were transferred into 
a ø 10 cm tissue culture plate in 8 ml RPMI 1640 medium containing 15 % FCS. After 
another 24 h, 3 µg/ml puromycin were added for selection of stable transfectants. This 
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selection medium was changed every 3 – 4 days until those cells that had the DNA 
inserted into their genome (resistant colonies) proliferated. This occurred approximately 
after 5 weeks. Finally, the selective reagent was decreased to 1 µg/ml, and the HLA-A2 
expression was tested by flow cytometry (see Section 3.7.1). 
Stocks of stably transfected cells cultured at each puromycin concentration were stored 
at -80°C. 
3.6.3 Preparation of Peripheral Blood Mononuclear Cells (PBMC) 
PBMC, comprising lymphocytes and monocytes, had been isolated from the buffy coat 
(leukapheresis) of a healthy human donor by density-gradient centrifugation using the 
Ficoll-based lymphocyte separation solution LSM 1077 (PAA, Cölbe, DE) according to 
the manufacturer's instructions. Furthermore, monocytes were depleted by magnetic-
activated cell sorting using anti-CD14 conjugated MicroBeads (Miltenyi Biotec, 
Bergisch Gladbach, DE) according to the manufacturer's instructions. Remaining 
PBMC, essentially including lymphocytes, were available in-house and were tested in 
flow cytometry for the expression of HLA-A2. Finally, they were frozen in aliquots for 
usage in T-cell activation assays, PBMC stimulation (see Section 3.7.2) and 
cytotoxicity assays (see Section 3.7.4). PBMC from a handful of different donors were 
used, but the HLA-A2-negative PBMC that were used for PBMC stimulation assays 
derived from one and the same donor. 
3.7 Functional Studies 
3.7.1 Flow Cytometry 
Binding studies with all antibody constructs and antigen surface expressions were 
tested by flow cytometry. 
In order to prove the surface expression of AChRγ, 5 × 105 rhabdomyosarcoma cells 
were incubated with a mouse anti-AChRγ antibody or an appropriate isotype control at 
4°C for 2 h. After threefold washing with 150 µl of PBA, cells were incubated with PE-
conjugated goat anti-mouse antibody at RT for 30 min and then washed again twice. 
For gating, of each cell type one sample of unstained cells was additionally prepared. 
Finally, cells were resuspended in 500 µl of PBA, transferred into FACS tubes, and 
analysed by flow cytometry using BD FACSCalibur. Received data were analysed with 
the aid of WinMDI 2.8 software. 
The surface expression of the molecules HLA-A2, CD3, and CD45 was examined by 
incubating 5 × 105 cells with directly FITC- or PE-labelled antibodies against those 
surface molecules or the appropriate isotype control at RT for 30 min. The following 
washing and analysis was performed as described above. 
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In order to provide evidence that the original scFvCD3 is indeed specific for CD3ɛ, 
a blocking assay was performed. 5 × 105 Jurkat cells were preincubated with 10 µg/ml 
of anti-human CD3ε or an isotype control in 50 µl of PBA at RT for 30 min, followed by 
the addition of 2 µg/ml of scFvCD3 in 50 µl of PBA and further incubation at 4°C for 
2 h. The resulting final concentrations were 5 µg/ml IgG and 1 µg/ml scFvCD3, 
respectively. After threefold washing as stated above, cells were incubated with FITC-
conjugated anti-His6 tag antibody at RT for 30 min, followed by washing and analysis 
as described above. 
The epitope binding specificity of taFvCD3-HLA-A2-FlagHis was assayed on HLA-A2-
expressing HEK-293T A2+ cells in a similar blocking assay. 5 × 105 cells were 
preincubated with 4 µM of scFvHLA-A2-mycHis, followed by the addition of 40 nM of 
taFvCD3-HLA-A2-FlagHis, resulting in final concentrations of 2 µM and 20 nM, 
respectively. After washing, bound taFvCD3-HLA-A2-FlagHis was detected by FITC-
conjugated anti-Flag antibody, again followed by washing and analysis as described 
above. 
Specific binding of the single antibody constructs to different antigen-presenting cells 
was also tested by flow cytometry. For this purpose, 5 × 105 cells were incubated with 
10 µg/ml of antibody construct in 100 µl of PBA per well on a 96-well V-shaped plate at 
4°C for 2 h. After threefold washing as stated above, cells were incubated with FITC-
conjugated anti-His6 tag antibody at RT for 30 min. Subsequent procedure was 
conducted as described above. 
Both the antibodies used and their appropriate dilutions are listed in Section 3.1.4.  
3.7.2 PBMC Stimulation Assay 
The stimulatory activity of recombinant antibodies was tested in a cell-based 
stimulation assay. Therein, T-cell activation mediated by bi- or trispecific antibody 
constructs in vitro was assessed by quantifying the induced interleukin-2 (IL-2) release. 
Stimulatory Activity of Bispecific AChRγ × CD3 taFv Fragments 
Adherent antigen-expressing tumour target cells (RD and HEK-293T A2+) were seeded 
in a flat-bottomed 96-well cell culture plate at a density of 105 cells per well in 100 µl of 
culture medium and incubated overnight at 37°C and 5 % CO2 to allow the cells to 
adhere. The next day, after removing the supernatant from the cells, (titrated) 
stimulatory antibodies (taFv or scFv as control) were added in 100 µl medium per well 
and preincubated for 1 h at 37°C and 5 % CO2 to ensure binding to AChRγ. 
Unstimulated monocyte-depleted PBMC (HLA-A2+) (see Section 3.6.3) had been 
thawed the day before and cultured in a ø 10 cm tissue culture plate overnight, allowing 
the adherence of potentially remaining monocytes to the plate. Those PBMC that 
remained in solution were harvested and then added to the target cells at a density of 
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2 × 105 per well in 100 µl medium and incubated for 24 h at 37°C and 5 % CO2. Finally, 
plates were centrifuged for 4 min at 1,200 × g to harvest 150 µl cell-free supernatants 
for IL-2 quantification in ELISA (see Section 3.7.3). 
Stimulatory Activity of Bispecific HLA-A2 × CD3 taFv Fragments 
Adherent antigen-expressing tumour target cells (HEK-293T A2+ and RD) were 
stimulated with bispecific HLA-A2 × CD3 taFv fragments in the presence or absence of 
unstimulated HLA-A2-positive PBMC as described above. 
Suspension antigen-expressing tumour target cells (U266) were seeded in a U-shaped 
96-well cell culture plate at a density of 105 cells per well in 50 µl of culture medium and 
incubated at 37°C and 5 % CO2 until antibody dilutions were prepared. Then titrated 
stimulatory taFv fragments were added in 100 µl medium per well and preincubated for 
1 h at 37°C and 5 % CO2 to ensure binding to HLA-A2. Unstimulated monocyte-
depleted HLA-A2-negative PBMC (see Section 3.6.3) were freshly thawed and then 
added to the target cells at a density of 2 × 105 per well in 50 µl medium and incubated 
for 24 h at 37°C and 5 % CO2. Finally, cell-free supernatants were achieved for IL-2 
quantification in ELISA as described above. 
Stimulatory Activity of Two-Part HLA-A2 × CD3 × HLA-A2 Trispecific Antibody 
Here, the assay was performed with adherent target cells (HEK-293T A2+), basically 
according to the description for bispecific AChRγ × CD3 taFv fragments above, but with 
the following exception. First, the antibody constructs for complementation (VLCD3-
scFvHLA-A2 and VHCD3-scFvHLA-A2) were mixed (55 µl of each). Then the antibody 
combination was added in 100 µl medium per well to the target cells. The assay was 
further performed as stated above. 
Stimulatory Activity of Two-Part HLA-A2 × CD3 × CD45 Trispecific Antibody 
All antigen-expressing tumour target cells (adherent and suspension) were seeded in 
a U-shaped 96-well cell culture plate at a density of 105 cells per well in 50 µl of culture 
medium and incubated at 37°C and 5 % CO2 until antibody dilutions were prepared. 
The antibody constructs for complementation (VLCD3-scFvHLA-A2 and VHCD3-
scFvCD45) were first mixed (55 µl of each) and subsequently titrated if applicable. In 
the following, the (titrated) antibody combination was added in 100 µl medium per well 
to the target cells (U266, Raji, KMS-12-BM, L-363, and MCF-7). Then 50 µl of 
unstimulated monocyte-depleted HLA-A2-negative PBMC were added to the target 
cells as stated above. Thus, all compounds amounted to a final volume of 200 µl as in 
the other experiments above. After 24 h of incubation at 37°C and 5 % CO2, finally, 
cell-free supernatants were harvested for IL-2 ELISA. 
In order to prove the dual-antigen dependence of the trispecific antibody, the following 
blocking experiment was performed. HLA-A2+ CD45+ target cells (U266) were first 
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incubated with 80 µl of scFvHLA-A2 or scFvCD45(VH-VL) in 100 × molar excess 
(2.7 µM final concentration) at RT for 30 min, followed by the addition of 10 µl of 
VLCD3-scFvHLA-A2 and VHCD3-scFvCD45(VH-VL) (27 nM final concentration), 
respectively. Apart from that, samples were treated as stated above. 
All experiments were performed in duplicates and repeated twice. 
3.7.3 IL-2 Sandwich ELISA (Enzyme-Linked Immunosorbent Assay) 
As an indicator for the stimulatory activity, T-cell activation induced by bi- or trispecific 
antibodies was measured in terms of the IL-2 release. Upon PBMC stimulation, the 
concentration of secreted IL-2 in the supernatant was quantified in an IL-2 sandwich 
ELISA by using the Human IL-2 DuoSet ELISA development kit from R&D Systems. 
First, a 96-well ELISA plate was coated with 400 ng / 100 µl per well of mouse anti-
human IL-2 antibody overnight at RT, followed by the saturation of nonspecific binding 
sites with blocking buffer for at least 1 h at RT. In the meantime, serial 1 : 2 dilutions of 
an IL-2 standard were prepared in duplicate in reagent diluent, starting with a maximum 
IL-2 concentration of 1,000 pg/ml. Then, supernatants containing IL-2 were 
appropriately diluted in RPMI 1640 medium containing 10 % FCS and Pen-Strep. Both 
diluted supernatants and standards were transferred into the ELISA plate and 
incubated for 2 h at RT. Subsequently, IL-2 was detected by incubation with 
25 ng / 100 µl per well of biotinylated goat anti-human IL-2 antibody for 2 h at RT. 
Finally, 100 µl of HRP-conjugated streptavidin, 1 : 200 diluted in reagent diluent, was 
added per well and incubated for 20 min at RT while protected from light. HRP 
catalyses a colorimetric reaction by using TMB as a substrate. Thus, 100 µl of freshly 
prepared TMB substrate solution was added per well and incubated until sufficient blue 
colour appeared. After stopping the reaction with 50 µl of 1 M H2SO4, the absorbance 
was measured in an ELISA plate reader at 450 nm. In order to achieve a background 
signal, at least 2 wells on each plate were incubated with either reagent diluent or 
medium only and the detecting antibody plus TMB. Between each incubation step, the 
plate was washed three times with PBS containing 0.05 % Tween 20 and once with 
PBS only. 
A seven point standard curve was created by plotting the absorbance signals of each 
standard sample against the IL-2 concentration. Thus, the amount of IL-2 of each 
supernatant could be determined by interpolation of the standard curve fitted with the 
nonlinear regression equation for one phase exponential association using the software 
GraphPad Prism®. 
3.7.4 7-AAD/CFSE Cell-Mediated Cytotoxicity Assay 
Cell-mediated cytotoxicity represents the cytolysis of target cells by effector cells such 
as T cells or NK cells. Here, cell-mediated cytotoxicity has been assessed using 
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a fluorescent assay, which consequently is free of radioactivity. In this method, the 
target cells are labelled with the green fluorescent CFSE (CFDA SE, 5-(6)-
carboxyfluorescein diacetate, succinimidyl ester) and a red fluorescent compound, 
namely 7-AAD (7-aminoactinomycin D). The highly cell permeable CFDA SE passively 
diffuses into cells. It is colourless and nonfluorescent until intracellular esterases 
remove its acetate groups and convert the molecule to the highly fluorescent 
carboxyfluorescein succinimidyl ester (CFSE). CFSE is retained within cells for a long 
time. It is inherited by daughter cells and therefore diluted with time. The fluorescent 
intercalator 7-AAD penetrates only dead or damaged cells and undergoes a spectral 
shift upon association with double stranded DNA. The combination of both allows the 
identification of four different cell populations by multicolour flow cytometry: double 
positive dead target cells (CFSE+ 7-AAD+), live target cells (CFSE+ 7-AAD-), and live 
(CFSE- 7-AAD-) or dead effector cells (CFSE- 7-AAD+). 
In order to examine whether the bi- and trispecific antibodies are able to mediate 
cytotoxicity by inducing the formation of a lytic synapse, the redirected lysis was 
measured in a cytotoxicity assay using 7-AAD and CFSE. 
Cytotoxicity of Bispecific AChRγ × CD3 taFv 
For this purpose, pelleted target cells were incubated with 100 µl of 1.5 µM CFSE in 
PBS per 2 × 106 cells for 10 min at RT while protected from light. In the following, cells 
were washed with 2 ml of FCS and allowed to stand for 1 min at RT for saturation of 
nonspecific binding sites. The cells were then washed twice with the appropriate 
medium containing 1 % FCS. Subsequently, 2.5 × 105 CFSE-labelled target cells were 
incubated with 27 nM of antibody constructs in the presence or absence of 2.5 × 106 
unstimulated PBMC (E : T ratio of 10 : 1) in 1 ml medium containing 10 % FCS per well 
on a 48-well plate at 37°C for 24 h. As control for spontaneous cell death, CFSE-
labelled target cells were incubated either alone or with PBMC only, i.e. in the absence 
of any antibody constructs. Maximum cell death was determined by incubating target 
cells with 0.1 % Triton X-100 only. After 0 h, 4 h, and 24 h, respectively, 250 µl of cell 
suspension was obtained and stained with 5 µl of 7-AAD per 106 cells for 10 min at RT 
while protected from light. Finally, cells were analysed by multicolour flow cytometry 
using BD FACSCalibur (BD BioScience, Heidelberg, DE). Since PBMC alone also led 
to some target cell death, the specific cell death was calculated as follows: 
% ‘Ab+PBMC’ − % ‘PBMC’
100 − % ‘PBMC’
 × 100 % 
Ab: antibody construct 
Cytotoxicity of Two-Part Trispecific HLA-A2 × CD3 × CD45 Antibody 
The cytotoxicity assay with U266 as target cells was performed as described above 
with the following exceptions. 5 ml of FCS were used for washing and blocking. 5 × 105 
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CFSE-labelled target cells were incubated with 27 nM of antibody constructs in the 
presence or absence of unstimulated HLA-A2-negative PBMC in 2 ml per well on 
a 24-well plate for 72 h. After 0 h, 24 h, 48 h, and 72 h, respectively, 330 µl of cell 
suspension was obtained and stained with 7-AAD. Finally, cells were analysed by 
multicolour flow cytometry and the specific cell death was calculated as described 
above. Cell death was determined after 24 h and 48 h only, since no effect was visible 
after 0 h and too low cell counts were measured after 72 h. 
For a second experiment, 2.5 × 105 CFSE-labelled target cells were incubated with 
titrated antibody constructs in the presence or absence of unstimulated HLA-A2-
negative PBMC in 1 ml per well on a 48-well plate for 24 h. After 0 h and 24 h, 
respectively, 250 µl of cell suspension was obtained and stained with 7-AAD. Data 
from multicolour flow cytometry were normalised to the lowest value using GraphPad 
Prism® (24 h data only). 
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4 Results 
In the following, the generation and functional characterisation of antibody constructs of 
two concepts will be described: first, bispecific antibodies of the taFv format against 
CD3 and AChRγ for the treatment of aggressive rhabdomyosarcoma, and second, 
construct pairs for complementation of a trispecific HLA-A2 × CD3 × CD45 antibody for 
the treatment of leukaemia and other haematological malignancies in the context of 
haematopoietic stem cell transplantation. 
4.1 Bispecific AChRγ × CD3 Antibodies of taFv Format 
4.1.1 Construction of Recombinant Bispecific AChRγ × CD3 taFvs  
In order to live up to the success of the BiTE antibody technology, one aim of the 
present study was to generate an effector-cell retargeting bispecific antibody against 
AChRγ and CD3. For this purpose, the taFv format was chosen, the same that was 
used for the BiTE antibodies [Baeuerle et al., 2009]. This format is achieved by the 
linkage of two different scFv fragments in tandem. Thus, scFv fragments against 
AChRγ and CD3 were required as a basis for the construction of the taFv constructs 
but also as positive or negative controls depending on the experimental assay. The 
antibody fragment specific for the γ subunit of the fAChR used in the present study for 
the generation of the bispecific AChRγ × CD3 taFvs originates from “scFv35” 
(analogous to Fab35) and is referred to as scFvAChR in the following. The cDNA of the 
human scFvAChR was kindly provided by Prof. S. Gattenlöhner. For targeting T cells, 
the human CD3ε-specific mouse scFv diL2K (deimmunised L2K) was used (see also 
details in Section 3.2.1). 
Both scFvCD3 and scFvAChR were equipped with a 15 – 18 aa long flexible linker 
between the variable domains, which allows the suitable folding into a functional scFv 
(Fig. 4.1 A). For detection and purification, scFvAChR includes an N-terminal His10 
cluster, and scFvCD3 includes a C-terminal FlagHis6 tag. 
Four taFv variants were created in order to identify a construct showing favourable 
expression, binding properties, and activity in functional assays. The four variants 
evaluated differ in the orientation of the two scFvs, in the location of the tags for 
detection and purification, and in the expression vector used (Fig. 4.1 B). They contain 
either a FlagHis6 tag at the C-terminus in the pUC119 vector or a His10 cluster and an 
ECS at the N-terminus in the pBM1.1 vector. All four variants target T cells via CD3, on 
the one hand, and AChRγ-expressing tumour cells, on the other hand, so they 
represent bispecific molecules. 
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All four taFv constructs were equipped with short middle linkers (5 – 6 aa), which allow 
folding of the two scFv fragments into a functional taFv. They include either an 
N-terminal His10 cluster or a C-terminal FlagHis6 tag for detection and purification, as 
do scFvAChR and scFvCD3, respectively. All sequences are provided in the appendix. 
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Fig. 4.1:  Schematic illustration of the structure of the scFv and the bispecific taFv constructs 
targeting AChRγ and CD3. A) scFv fragments specific for AChRγ and CD3, respectively. The 
variable domains of the heavy (VH) and light chain (VL) of antibodies specific for AChRγ or 
CD3ɛ were joined by a flexible linker into the scFv format. B) Bispecific taFv constructs 
targeting AChRγ and CD3 evaluated in this study. Two scFv fragments, scFvAChR and 
scFvCD3, were joined by a 5 – 6 aa linker into the taFv format. The figure shows also the 
variable antibody domains, pelB leader sequences, important restriction sites, linkers and their 
lengths, His and Flag tags, ECS, and stop codons. 
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4.1.2 Expression of Bispecific AChRγ × CD3 taFvs 
The two scFvs, used as controls, and the four bispecific AChRγ × CD3 taFvs were 
periplasmically expressed in E. coli TG1 or BL21(DE3) using the following prokaryotic 
expression vectors: pUC119mycHis for scFvCD3, taFvCD3-AChR-FlagHis, and 
taFvAChR-CD3-FlagHis, and pBM1.1 for scFvAChR, His-taFvCD3-AChR, and His-
taFvAChRCD3. Subsequently, all proteins were purified by IMAC (see Sections 3.4.1 
and 3.4.2). In order to verify the purification process and to determine the degree of 
purity, protein samples of all fractions were subjected to SDS-PAGE, followed by 
Coomassie Blue staining for visualisation of proteins. For each recombinant protein, 
a major band appeared on the gel in fractions containing the eluates. As an example, 
the purifications of the scFvs and taFvCD3-AChR-FlagHis are depicted in Fig. 4.2 A - C 
on the next page. Aliquots of all purified proteins were separated by SDS-PAGE under 
reducing conditions and analysed by Western blot (Fig. 4.2 D, p. 58) as described in 
Section 3.5.2. This revealed proteins migrating with apparent molecular weights that 
reasonably correspond to the calculated molecular weights deduced from the amino 
acid sequence of the constructs (Table 4.1). 
Table 4.1:  Overview of molecular weights (MW) and yields of the recombinant antibody 
constructs. The most important constructs of this study are highlighted in bold. 




[mg/l] E. coli strain 
His-scFvAChR 31 31 0.5 BL21(DE3) 
scFvCD3-FlagHis 35 28 1.0 TG1 
His-taFvAChR-CD3 71 57 0.2 BL21(DE3) 
His-taFvCD3-AChR 68 57 0.2 BL21(DE3) 
taFvCD3-AChR-FlagHis 63 55 0.2 TG1 
taFvAChR-CD3-FlagHis 63 55 0.1 BL21(DE3) 
The Western blot analysis revealed a single protein band for scFvAChR, scFvCD3, and 
taFvAChR-CD3-FlagHis, whereas for His-taFvAChR-CD3, His-taFvCD3-AChR, and 
taFvCD3-AChR-FlagHis minor bands appeared at a lower molecular weight in addition 
to a predominant band. These minor bands presumably derived from some His-
containing cleavage products, corresponding to one, two, or three residual variable 
domains. By periplasmic expression, the highest yields were obtained for scFvs with 
0.5 – 1.0 mg/l, as listed in Table 4.1. The yields obtained for taFvs amounted to only 
0.1 – 0.2 mg/l.  




Fig. 4.2:  SDS-PAGE and Western blot 
Purification process
following protein fractions were 
visualised by Coomassie Blue staining
4, protein marker; 
lane were separated by 12 % SDS





analysis of purified recombinant antibody constructs. 
 of A) scFvAChR, B) scFvCD3, and C) taFvCD3
separated by 12 % SDS-PAGE under reducing conditions
: lane 1, crude extract; 2, flow
5 – 10, eluates 1 – 6. D) 1 µg (scFv) or 2 µg (taFv) of purified protein per 
-PAGE under reducing conditions. Proteins were detected 
-His6 tag IgG1 antibody. Lane 1, scFvAChR; 
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-AChR; 9, taFvCD3-
 Results 
Agnes Banaszek 59 
4.1.3 Binding Studies with Bispecific AChRγ × CD3 taFvs by Flow 
Cytometry 
Expression of CD3 on the Surface of PBMC and Jurkat Cells 
In order to prove the functionality of the CD3-specific scFv domain of the bispecific taFv 
fragments, binding to PBMC and Jurkat cells was analysed. First, the anticipated 
expression of CD3 on these cells was verified with an anti-CD3 mAb by flow cytometry. 
For this purpose, human PBMC were isolated from the buffy coat of a healthy human 
donor by Ficoll-based density gradient centrifugation and monocytes were mostly 
depleted (see Section 3.6.3), so that the further used PBMC essentially consisted of 
lymphocytes. In the following, both PBMC and Jurkat cells were incubated with a FITC-
conjugated antibody specific for CD3ɛ or the corresponding isotype control and 
analysed by flow cytometry (Fig. 4.3). 
 
Fig. 4.3:  Expression of CD3ɛ on PBMC and Jurkat cells, analysed by flow cytometry. Detection 
was performed by incubating cells with FITC-conjugated antibody specific for CD3ɛ (clone 
UCHT-1) or mouse IgG1κ-FITC as an isotype control. Grey filled, unstained cells; green line, 
antibody against CD3ɛ molecule or isotype control. 
As expected, both the PBMC and the human T-cell leukaemia cell line Jurkat revealed 
high amounts of CD3 expression, on PMBC more than on the Jurkat cell line. 
Analysis of Specific Binding of scFvCD3 by Flow Cytometry 
In order to prove that the original scFvCD3, which was used for the construction of the 
bispecific AChRγ × CD3 taFv fragments, is indeed specific for CD3ɛ, a blocking assay 
was performed, as described in Section 3.7.1. Therein, CD3-expressing Jurkat cells 
were preincubated with a mouse mAb directed against human CD3ε (clone UCHT-1) 
before the addition of scFvCD3. As shown in Fig. 4.4, the binding of scFvCD3 to CD3ɛ 
was thereby entirely blocked. On the contrary, binding of scFvCD3 occurred in the 
presence of an isotype control instead. Consequently, scFvCD3 clearly recognises the 
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same or at least an overlapping epitope on CD3ɛ as the commercially available 
antibody of proven specificity for CD3ɛ. 
 
Fig. 4.4:  Binding specificity of scFvCD3 to CD3 expressed on Jurkat cells, analysed by flow 
cytometry. Blocking of binding of 1 µg/ml of scFvCD3 to CD3-expressing Jurkat cells by 
preceding incubation with 10 µg/ml anti-human CD3ε antibody (clone UCHT-1) or mouse 
IgG1κ as an isotype control (resulting in 5 µg/ml final concentration each). Binding was 
detected by FITC-conjugated anti-His6 tag antibody. Grey filled, unstained cells; black line, 
secondary antibody alone; coloured line, scFvCD3. 
Expression of AChRγ on the Surface of Rhabdomyosarcoma Cell Lines 
Initially, the rhabdomyosarcoma cell lines TE-671, RD, and AX-OH-1 were tested for 
AChRγ expression by flow cytometry; namely by incubating these cell lines with 
a mouse anti-AChRγ antibody and by subsequently detecting the binding with a PE-
conjugated goat anti-mouse antibody (Fig. 4.5). 
 
Fig. 4.5:  Expression of AChRγ on the rhabdomyosarcoma cell lines TE-671, RD, and AX-OH-1, 
analysed by flow cytometry. Cells were incubated with a mouse anti-AChRγ antibody. 
Binding to AChRγ was detected by PE-conjugated goat anti-mouse IgG antibody. Grey filled, 
secondary antibody alone; red line, detected mAb against AChRγ. 
As expected, all three rhabdomyosarcoma cell lines expressed AChRγ, but to 
a variable extent. AX-OH-1 cells showed the highest expression, whereas TE-671 
revealed the lowest expression. 
Binding Studies with scFvAChR by Flow Cytometry 
Specific binding of the supposedly AChRγ-specific scFv was tested by flow cytometry. 
For this purpose, the three AChRγ-expressing rhabdomyosarcoma cell lines described 
above were each incubated with scFvAChR, followed by incubation with a FITC-
conjugated anti-His6 tag antibody (Fig. 4.6 A, p. 62). scFvAChR exhibited the strongest 
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binding to TE-671, followed by AX-OH-1 and, lastly, RD cells. Unexpectedly, the results 
did not correlate well with the expression determined with the anti-AChRγ mAb (see 
Fig. 4.5). Here, AX-OH-1 cells showed the highest expression, whereas TE-671 
revealed the lowest expression. Since it remained unclear which cells are most suitable 
for further experiments, all three cell lines were used for binding studies by flow 
cytometry. 
Binding Studies with Bispecific AChRγ × CD3 taFvs by Flow Cytometry 
The binding abilities of the bispecific AChRγ × CD3 taFv fragments to antigen-
expressing cells were also tested by flow cytometry. The taFv fragments were tested 
for binding to CD3 by using PBMC and Jurkat cells. Additionally, binding to AChRγ was 
tested on TE-671, RD, and AX-OH-1 cells. For reasons of clarity, only the results for 
Jurkat and TE-671 cells are shown (Fig. 4.6 B, p. 62). 
Three of the four taFv fragments revealed specific binding to CD3-expressing cells as 
well as AChRγ-expressing TE-671 cells. Surprisingly, for one of them, namely His-
taFvAChR-CD3, no significant binding at all was detected to any of the tested cell lines. 
This finding occurred despite repeating the experiment on TE-671 and AX-OH-1 cells. 
A possible reason is assumed to be the high level of protein degradation indicated in 
Western blot analysis (see Fig. 4.2 D). His-taFvCD3-AChR revealed moderate binding 
properties to both CD3-expressing cells and AChRγ on TE-671. taFvAChR-CD3-
FlagHis showed the best binding to TE-671, which was even slightly better than that of 
scFvAChR, and a strong binding to CD3. taFvCD3-AChR-FlagHis showed best binding 
to CD3, which was even a little (PBMC, not shown) or significantly (Jurkat) better than 
scFvCD3, and moderate binding to TE-671. scFvAChR did not show any binding to 
(AChRγ-negative) PBMC (not shown). The results for AX-OH-1 complied well with 
those for TE-671, but with an overall lower binding for all constructs (not shown). 
However, surprisingly, poor or even non-significant binding was observed to RD cells 
(not shown), although they have previously displayed an even higher AChRγ 
expression than TE-671 (see Fig. 4.5 and discussion in Section 5.1). Despite showing 
the highest AChRγ expression, as detected by the commercial anti-AChRγ antibody in 
this study (see Fig. 4.5), AX-OH-1 cells were rather difficult to cultivate and therefore 
not suitable for functional assays. On that account, and since the AChRγ expression 
detected by using the commercial antibody was higher on RD than on TE-671 cells, RD 
cells were chosen for preliminary stimulation and cytotoxicity assays. 
In sum, taFvAChR-CD3-FlagHis and taFvCD3-AChR-FlagHis proved themselves able 
to strongly bind both CD3-expressing cells and AChRγ-expressing cells. 
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Fig. 4.6:  Binding of scFvAChR to AChRγ and of bispecific AChRγ × CD3 taFv fragments to CD3 
and AChRγ, analysed by flow cytometry. A) Rhabdomyosarcoma cell lines TE-671, RD, 
AX-OH-1 (all AChRγ+) were incubated with 10 µg/ml of His-scFvAChR. B) Binding of 10 µg/ml 
of each bispecific taFv fragment to Jurkat (CD3+) or TE-671 (AChRγ+) cells. Binding was 
detected by FITC-conjugated anti-His6 tag antibody. Grey filled, secondary antibody alone; 
green line, His-scFvAChR; black line, antibody fragment. 
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4.2 Stimulatory Activity of Bispecific AChRγ × CD3 taFvs 
Since CD3-specific antibodies of the BiTE (bispecific T-cell engager) format [Baeuerle 
et al., 2009] are able to induce T-cell activation in a costimulation-independent manner, 
their ability to activate T cells can easily be evaluated by using in vitro functional 
assays. As the recombinant bispecific taFv fragments generated in this study target the 
T-cell receptor complex molecule CD3 and the tumour antigen AChRγ, they should be 
able to activate T cells in the same way when simultaneously bound to the tumour 
target antigen. Thus, T cells are activated in a target cell-dependent manner. In order 
to assess the potential of the generated recombinant bispecific AChRγ × CD3 taFv 
fragments to activate T cells in vitro, a cell-based stimulation assay was performed as 
described in Section 3.7.2. Therein, PBMC were stimulated by bispecific antibodies 
that were previously bound to target cells. Representing an early T-cell activation 
marker, the T-cell growth factor IL-2 is secreted upon the activation of T cells. In this 
way, T-cell activation was then measured after 24 h in terms of the induced IL-2 
release. 
For the reasons stated in Section 4.1.3, p. 61, RD cells were chosen as AChRγ-
expressing target cells to examine the stimulatory potential of bispecific AChRγ × CD3 
taFv fragments. For this purpose, the four bispecific constructs were titrated from   
0.3 – 243 nM on RD cells, followed by the addition of unstimulated PBMC at an E : T 
ratio of 2 : 1 (Fig. 4.7 A). As a control, background signals of IL-2 were achieved by 
incubating PBMC with target cells only, i.e. in the absence of antibody constructs. 
Three of four constructs exhibited a stimulatory effect on PBMC in a concentration-
dependent manner. The most effective stimulation was achieved with taFvCD3-AChR-
FlagHis at 243 nM, resulting in a maximum IL-2 concentration of about 250 pg/ml and 
indicating an incipient saturation of AChRγ-binding sites on the target cells. At the 
same concentration, the resulting IL-2 release amounted to 56 pg/ml for His-taFvCD3-
AChR, 21 pg/ml for taFvAChR-CD3-FlagHis, and 3 pg/ml for His-taFvAChR-CD3, 
which corresponds to approximately 23 %, 9 %, and 1 % of the IL-2 release achieved 
by stimulation with taFvCD3-AChR-FlagHis. The background signal was at 4 pg/ml 
(2 % of taFvCD3-AChR-FlagHis). In contrast, all four constructs had a far lower 
stimulatory effect on PBMC when AChRγ-negative target cells (HEK-293T A2+) were 
used instead (Fig. 4.7 B). Here, the background signal was at 11 pg/ml. For three of 
four constructs, the IL-2 signal was up to twice as high as the background (below 
23 pg/ml IL-2), indicating some unspecific binding to HEK-293T A2+ cells. As expected, 
scFvCD3 and scFvAChR, used as negative controls, had no stimulatory effect on 
PBMC. Since soluble scFvCD3 is not able to crosslink CD3, T-cell activation is not 
induced. In conclusion, three of the four constructs do mediate T-cell activation, with 
taFvCD3-AChR-FlagHis being the most potent one by far. T-cell stimulation seems to 
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Fig. 4.7:  T-cell activation mediated by bispecific AChRγ × CD3 taFv fragments. A) AChRγ-
expressing target cells (RD) were incubated with titrated antibody constructs (0.3 – 243 nM) in 
duplicate. B) RD and HEK-293T A2+ (AChRγ-) cells, respectively, were incubated with 243 nM 
of the indicated antibody constructs in duplicate. In the following, unstimulated PBMC were 
added (E : T ratio of 2 : 1) and IL-2 release was measured in ELISA after 24 h. These results 
are representative of three independent experiments. 
4.3 Cytotoxicity of a Bispecific AChRγ × CD3 taFv 
Having shown that taFvCD3-AChR-FlagHis activates T cells in terms of the IL-2 
release induced, it was then examined whether it also induces the formation of a lytic 
synapse. For this purpose, the redirected lysis by cytotoxic T cells was measured in 
vitro in a flow cytometry-based cytotoxicity assay. Basically, PBMC were stimulated by 
bispecific antibodies that were previously bound to CFSE-labelled target cells. The 
fluorescent intercalator 7-AAD mainly penetrates cells without intact cell membranes, 
thus representing a marker for apoptosis. So after 0 h, 4 h, and 24 h, apoptosis was 
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then detected by staining with 7-AAD. Since dead target cells should be double positive 
(CFSE+ 7-AAD+), they can easily be identified by multicolour flow cytometry, 
i.e. distinguished from live target cells (CFSE+ 7-AAD-), and live (CFSE- 7-AAD-) or 
dead PBMC (CFSE- 7-AAD+). 
In order to examine the mediated cytotoxicity, CFSE-labelled AChRγ-expressing target 
cells (RD) were preincubated with 27 nM taFvCD3-AChR-FlagHis in the presence or 
absence of unstimulated PBMC at an E : T ratio of 10 : 1 (Fig. 4.8 A). As negative 
control, the AChRγ-negative rhabdomyosarcoma cell line A-204 [Gattenlöhner et al., 
2006] was additionally tested in parallel (Fig. 4.8 B). As control for spontaneous cell 
death, CFSE-labelled target cells were incubated either alone or with PBMC only, i.e. in 
the absence of taFv. Maximum cell death was determined by incubating target cells 
with 0.1 % Triton X-100 only. Each data set was normalised to the lowest value. 
A B 
 
Fig. 4.8:  Cytotoxicity mediated by taFvCD3-AChR-FlagHis. CFSE-labelled A) RD (AChRγ+) cells or 
B) A-204 (AChRγ-) cells were incubated with either 27 nM taFvCD3-AChR-FlagHis, 
unstimulated PBMC (E : T ratio of 10 : 1), or both. Samples were taken after 0 h, 4 h, and 24 h 
and stained with 7-AAD. Dead target cells (CFSE+ 7-AAD+) were identified by multicolour flow 
cytometry. 
Specific cytotoxic effects did not occur until after 24 h. After this time, taFvCD3-AChR-
FlagHis had no effect on the RD cells in the absence of PBMC, whereas 
a considerable cytotoxicity was observed in conjunction with PBMC (black bars). Since 
PBMC alone also led to some target cell death, the specific cell death was calculated 
as described in Section 3.7.4. For taFvCD3-AChR-FlagHis at 27 nM, the percentage of 
cytotoxic activity amounted to 60 % on RD cells versus 15 % on A-204 cells, indicating 
some unspecific binding to A-204. So the cytotoxic effect was much lower when the 
AChRγ-negative A-204 served as target cells. The spontaneous cell death amounted to 
1.2 %, 13.6 %, and 29.9 % of RD cells and 0.2 %, 3.2 %, and 2.6 % of A-204 cells after 
0 h, 4 h, and 24 h, respectively. In a similar second experiment without A-204 cells and 
the taFv alone sample, a comparable cytotoxic activity was achieved for taFvCD3-
AChR-FlagHis on RD cells, indicating that the findings were reproducible (data not 
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that further experiments are required for verification. Thus, it was shown that at 
nanomolar concentration, one of the four bispecific AChRγ × CD3 taFv fragments, 
namely taFvCD3-AChR-FlagHis, is not only able to specifically activate T cells to 
release IL-2, but also to induce cytotoxicity to AChRγ-expressing tumour cells. 
4.4 Two-Part Trispecific HLA-A2 × CD3 × CD45 Antibody 
After the successful generation of a functional bispecific AChRγ × CD3 antibody, the 
major aim of this study was to extend this approach to a dual antigen-restricted 
trispecific concept for targeted immunotherapy. More precisely, this study aimed to 
figure out, if it is possible to assemble a functional trispecific HLA-A2 × CD3 × CD45 
antibody from two parts in such a way that the third specificity against CD3 is only 
created upon the prior binding of the two other antigens at the same cell. This would 
allow approaches which require a dual-targeting strategy, such as the treatment of 
leukaemia and other haematological malignancies in the context of haematopoietic 
stem cell transplantation (HSCT). 
Patients with, for example, leukaemia or multiple myeloma often require HSCT (with 
preceding radiation or chemotherapy). Unfortunately, for one out of five patients, no 
matching donor can be found, because an HLA-identical donor is very rare. The 
probability of finding an HLA-compatible donor (with a 10/10 match in HLA-A, -B, -C, 
-DRB1, and -DQB1) varies between one in 20,000 and one in several million [DKMS]. If 
no matching donor can be identified, grafts with one mismatch are increasingly 
employed. However, initial therapy, including HSCT, sometimes fails to eliminate all 
cancer cells, leading to a subsequent relapse of the original malignancy. Many 
recipients of donor transplants relapse: among those receiving HLA-identical sibling 
transplants about 40 – 45 % relapse and among those receiving unrelated donor 
transplants about 35 % relapse. Thus, relapse remains the most frequent cause of 
treatment failure and mortality [Barrett and Battiwalla, 2010]. 
For an HLA-mismatched setting where the patient is HLA-A2-positive, but the donor is 
not, it was aimed to exploit the HLA disparity for targeted immunotherapy by using 
a complementing trispecific antibody. Besides CD3, this trispecific antibody should 
target HLA-A2, one of the most common HLA alleles, and CD45, a highly specific 
haematopoietic marker, at the same time. More precisely, this combinatorial approach 
was to be realised by the development of two self-assembling single-chain antibody 
constructs: a scFv specific for HLA-A2, and a scFv against CD45, each linked to the VL 
and the VH domain of a CD3ε-specific antibody, respectively. After the binding of each 
scFv to its respective target, HLA-A2 and CD45, coexpressed on the same cell, the 
unpaired variable domains should assemble to a functional scFv against CD3ε. This 
assembly should exclusively occur on the recipient’s malignant haematopoietic cells, 
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causing the complementation of the trispecific antibody, then able to activate T cells via 
CD3, and finally leading to T cell-mediated tumour-specific cell destruction. In the 
present dual-targeting approach both antigens, HLA-A2 and CD45, are tumour-specific 
only when combined, i.e. not by themselves. In this way, residual blood cancer cells of 
host origin could be specifically recognised and finally eliminated shortly after HSCT, 
thus preventing a relapse of disease. Furthermore, the preceding radiation or 
chemotherapy could be substantially reduced or – ideally – even omitted. 
Moreover, this study aimed to figure out if the affinity of VHCD3 and VLCD3 to each 
other would be sufficient for a self-assembly of both single-chain antibody constructs or 
if this approach would require further affinity enhancement through an incorporation of 
heterodimerising peptides, such as jun-fos leucine zippers [de Kruif and Logtenberg, 
1996; Kostelny et al., 1992; Pack and Plückthun, 1992; O’Shea et al., 1989; Arndt 
et al., 2001]. However, the affinity must not be too high to avoid binding to single-
positive target cells.  
4.4.1 Construction of a Two-Part Trispecific HLA-A2 × CD3 × CD45 
Antibody 
The constructs for complementation were achieved by the linkage of a complete scFv 
specific for HLA-A2 or CD45 to the VL and VH domain of a CD3-specific antibody, 
respectively. These constructs are referred to as VLCD3-scFvHLA-A2 and VHCD3-
scFvCD45 in the following. For a first proof of concept, antibody constructs which 
consist of a complete scFv of the same specificity, namely HLA-A2, and a split anti-
CD3 moiety were additionally constructed (VLCD3-scFvHLA-A2 and VHCD3-
scFvHLA-A2). Furthermore, scFv fragments against CD3, HLA-A2, and CD45 were 
required as basis for the construction of the above mentioned constructs and as 
positive or negative control, depending on the experimental assay. For the use as 
positive control in functional assays, bispecific HLA-A2 × CD3 taFv constructs were 
additionally created. 
The human HLA-A2-specific antibody fragment used in this study, 3PF12, was isolated 
from an alloimmunised patient by phage display with a nanomolar affinity for its target 
HLA-A2 and does not cross-react with HLA-A2-negative platelets [Watkins et al., 2000]. 
The trispecific HLA-A2 × CD3 × (CD45 / HLA-A2) and bispecific HLA-A2 × CD3 
antibody constructs used in the present study for effector-cell retargeting originate from 
3PF12. In the following, it is referred to as scFvHLA-A2. The cDNA of scFvHLA-A2 
(clone 3PF12) was kindly provided by Dr. Nicholas A. Watkins.  
The human CD45-specific scFv that was used in the present study for the construction 
of the trispecific HLA-A2 × CD3 × CD45 antibody derived from a mouse scFv (clone 
BC8) that recognises all human CD45 isoforms [Lin et al., 2006]. It was commercially 
synthesised according to the cDNA sequence specified by Lin et al. [2006] and is 
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referred to as scFvCD45 in the following. More details regarding the encoding 
sequences, their origin, and the cloning of scFvCD45 are given in Section 3.2.2. 
Both scFvHLA-A2 and scFvCD45 (in VL-VH and VH-VL orientation) were equipped with 
a 15 – 19 aa long flexible linker between the variable domains, which allows the 
suitable folding into a functional scFv (Fig. 4.9). 

















Fig. 4.9:  Schematic representation of the structure of the scFv fragments specific for HLA-A2 
and CD45, respectively. The variable domains of the heavy (VH) and light chain (VL) of 
antibodies specific for HLA-A2 or CD45 were joined by a flexible linker into the scFv format. 
Furthermore, pelB leader sequences, important restriction sites, linkers and their lengths, myc, 
His, and Flag tags, TCS, and stop codons are indicated. 
For the assembling VH and VL domains, the same CD3ε-specific scFv served as 
a template, as set out above in Section 4.1.1. With scFvCD3, scFvHLA-A2, 
scFvCD45(VL-VH), and scFvCD45(VH-VL) as a basis, five constructs were developed for 
the trispecific concept. VLCD3-scFvHLA-A2, VHCD3-scFvCD45(VL-VH), and VHCD3-
scFvCD45(VH-VL) were developed for complementation on cells expressing both 
HLA-A2 and CD45. For a first proof of concept on HLA-A2-expressing cells (i.e. for 
assembly with VLCD3-scFvHLA-A2), VHCD3-scFvHLA-A2-mycHis and VHCD3-
scFvHLA-A2-FlagHis were additionally constructed (Fig. 4.10). 
All five created constructs for complementation were equipped with short linkers (7 aa) 
between VH or VL and scFv to provide flexibility and prevent an incorrect folding of the 
constructs. They include either a myc or a Flag tag in addition to a His6 tag at the 
C-terminus for detection and purification, as do scFvHLA-A2 and scFvCD45(VH-VL), 
whereas scFvCD45(VL-VH) contains a His6Flag tag at the N-terminus. 
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Fig. 4.10:  Schematic illustration of the structure of the constructs for complementation on cells 
expressing either both HLA-A2 and CD45 or HLA-A2 only. The variable domains of the 
heavy (VH) and light chain (VL) of antibodies specific for HLA-A2, CD45, or CD3ɛ were joined 
by flexible linkers into the respective VH/LCD3-scFv format. The figure shows also pelB leader 
sequences, important restriction sites, linkers and their lengths, myc, His and Flag tags, and 
stop codons. 
The accurate cloning strategies of all constructs are detailed in Section 3.2 and all 
sequences are included in the appendix. 
4.4.2 Construction of Recombinant Bispecific HLA-A2 × CD3 taFvs 
For the use as a positive control, a bispecific taFv antibody against HLA-A2 and CD3 
was created. More precisely, four variants were created in order to be able to identify 
the construct showing the best features (Fig. 4.11). The four variants differ in the 
orientation of the two scFvs and the location of tags for detection and purification. All 
four variants target T cells via CD3 on the one hand and HLA-A2-expressing cells on 
the other hand, thus representing bispecific molecules.  
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Fig. 4.11:  Schematic representation of the structure of bispecific taFv constructs targeting HLA-
A2 and CD3. Two scFv fragments, scFvHLA-A2 and scFvCD3, were joined by a 6 – 7 aa 
linker into the taFv format. Furthermore, pelB leader sequences, important restriction sites, 
linkers and their lengths, myc, His, and Flag tags, and stop codons are indicated. 
All four created taFv constructs were equipped with short middle linkers (6 – 7 aa) to 
provide a suitable folding of the two scFv fragments into a functional taFv and include 
either a myc or a Flag tag in addition to a His6 tag at the C-terminus for detection and 
purification. 
4.4.3 Expression of Two-Part Trispecific HLA-A2 × CD3 × CD45 
Antibodies 
The five constructs for complementation were periplasmically expressed in E. coli TG1 
by using the prokaryotic expression vector pUC119mycHis. The four scFvs and the 
four bispecific HLA-A2 × CD3 taFvs were produced in the same way. Subsequently, all 
proteins were purified by IMAC (see Sections 3.4.1 and 3.4.2). 
The purification process was verified and the degree of purity was determined by SDS-
PAGE followed by Coomassie Blue staining to visualise all proteins. A major band 
appeared on the gel for each recombinant protein in the eluate fractions. As an 
example, the purifications of scFvHLA-A2, scFvCD45(VH-VL), VLCD3-scFvHLA-A2, 
VHCD3-scFvCD45(VH-VL), and taFvCD3-HLA-A2-mycHis are depicted in Fig. 4.12. The 
purification of scFvCD3 is shown above in Fig. 4.2, p. 58. 




Fig. 4.12:  SDS-PAGE analysis of the purification process of the recombinant antibody fragments. 
Purification of A) 
scFvCD45(VH-VL), and 
separated by 12 % SDS
staining: lane 1, crude extract; 
1 – 6. 
In order to identify the purified antibody constructs
to molecular weight and potential degradation, 
the exception of scFvCD45
separated by SDS-PAGE under reducing conditions and analysed by Western blot 
(Fig. 4.13). The identity of the recombinant proteins was confirmed 





scFvHLA-A2, B) scFvCD45(VH-VL), C) VLCD3-scFvHLA
E) taFvCD3-HLA-A2-mycHis. The following protein fractions were 
-PAGE under reducing conditions and visualised by Coomassie Blue 
2, flow-through; 3, wash; 4, protein marker; 
 and to characterise them 
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Fig. 4.13:  Western blot analysis of purified recombinant antibody constructs. 
protein per lane were separated 
case of scFvCD45
proteins were detected 






SDS-PAGE under reducing conditions and subsequent Western blot analysis revealed 
proteins migrating with apparent molecular weights that reasonably correspond to the 
calculated molecular weights deduced from the amino acid sequence of the constructs 
(Table 4.2). 
Western blot analysis revealed a major protein band for each antibody construct. For 
scFvCD45(VL-VH), scFvHLA
VLCD3-scFvHLA-A2, and taFvHLA
at a lower molecular weight. These minor bands presumably derived from some His
by 12 % SDS-PAGE under reducing conditions (0.5 µg in 
(VL-VH) and 1 µg of taFvCD3-A2-FlagHis). For Western blot analysis, 
A) by HRP-conjugated mouse anti-His6 tag IgG
1 antibody and IRDye 800 conjugated polyclonal goat anti
, scFvCD45(VL-VH); M, protein marker; 2, VHCD3-
-A2-mycHis; 4, taFvCD3-HLA-A2-FlagHis; 5, taFvHLA
-mycHis; 7, scFvHLA-A2; 8, scFvCD45(V
10, VHCD3-scFvCD45(VH-VL); 11, VLCD3-scFvHLA
-A2, VHCD3-scFvCD45(VL-VH), VHCD3
-A2-CD3-mycHis, additional minor bands appeared 
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containing cleavage products, corresponding to one, two or three residual variable 
domains. With the exception of taFvHLA-A2-CD3-mycHis, these bands are negligible.  
Table 4.2:  Overview of molecular weights (MW) and yields of the recombinant antibody 
constructs. The most important constructs of this study are highlighted in bold. 
Construct Apparent MW SDS-PAGE [kDa] 
Predicted MW 
Sequence [kDa] Yield [mg/l] 
scFvCD3-FlagHis 
  35* 28 1.0 
scFvHLA-A2-mycHis 27 29 1.5 
HisFlag-scFvCD45(VL-VH) 30 30 0.1 
scFvCD45(VH-VL)-FlagHis 31 29 1.0 
VLCD3-scFvHLA-A2-mycHis 47 41 0.8 
VHCD3-scFvCD45(VL-VH)-FlagHis 49 43 0.3 
VHCD3-scFvCD45(VH-VL)-FlagHis 49 42 0.4 
VHCD3-scFvHLA-A2-mycHis 50 42 0.2 
VHCD3-scFvHLA-A2-FlagHis 48 42 0.2 
taFvCD3-HLA-A2-mycHis 64 55 0.2 
taFvCD3-HLA-A2-FlagHis 64 55 0.2 
taFvHLA-A2-CD3-mycHis 67 55 0.2 
taFvHLA-A2-CD3-FlagHis 67 55 0.3 
* data from Western blot analysis shown above in Fig. 4.2 D in Section 4.1.2 
The highest yields from periplasmic expression in E. coli TG1 were obtained for scFvs 
with 1.0 – 1.5 mg/l, as listed in Table 4.2. The yield of scFvCD45(VL-VH) was 
exceptionally low with 0.1 mg/l. The yield obtained for VLCD3-scFvHLA-A2 amounted 
to 0.8 mg/l, whereas the yields of VH-scFvs (0.2 – 0.4 mg/l) were similar to those of 
taFvs (0.2 – 0.3 mg/l). 
4.4.4 Binding Studies with the Self-Assembling Constructs by Flow 
Cytometry 
Expression of CD3 and CD45 on Jurkat and HLA-A2 on HEK-293T A2+ cells 
In order to prove the binding properties of the five constructs for complementation, their 
binding to Jurkat cells (CD3+ CD45+) and to HEK-293T cells stably transfected with 
HLA-A2 (HEK-293T A2+) was analysed. First, the anticipated expression of CD3, 
CD45, and HLA-A2 on these cells was verified by flow cytometry. For this purpose, 
Jurkat and HEK-293T A2+ cells were incubated with a PE-conjugated antibody specific 
for HLA-A2, FITC-conjugated antibody specific for CD3ɛ or CD45, or the corresponding 
isotype control, mouse IgG2b-PE or mouse IgG1κ-FITC. Subsequently, the respective 
antigen expression was analysed by flow cytometry (Fig. 4.14). The CD3-expression 
on HEK-293T A2+ was not tested, as these cells should be CD3-negative, because of 
their non-haematopoietic origin.  
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Fig. 4.14:  Expression of HLA-A2, CD3, and CD45 on Jurkat cells and HEK-293T A2+ cells, analysed 
by flow cytometry. Detection was performed by incubating cells with anti-HLA-A2-PE, anti-
CD3-FITC, anti-CD45-FITC antibody, or the corresponding isotype control, mouse IgG2b-PE 
or mouse IgG1-FITC. Grey filled, unstained cells; coloured line, antibody against a cell-surface 
molecule or isotype control. 
As expected, the human T-cell leukaemia cell line Jurkat revealed high amounts of 
CD3 and CD45, and HEK-293T A2+ cells expressed high amounts of HLA-A2, but no 
CD45. More importantly, Jurkat cells appeared to be HLA-A2-negative. Thus, both cell 
lines proved to be appropriate for binding studies with the constructs for 
complementation. 
Binding Studies with Bispecific HLA-A2 × CD3 taFvs by Flow Cytometry 
The binding ability of the bispecific HLA-A2 × CD3 taFv fragments to antigen-
expressing cells was tested by flow cytometry. The taFv fragments were tested for 
binding to HEK-293T A2+ cells and to Jurkat cells expressing high levels of CD3 (Fig. 
4.15). 
All four taFv fragments revealed a strong binding to HEK-293T A2+ cells, as did their 
parental monospecific equivalent scFvHLA-A2. They also bound to CD3-expressing 
Jurkat cells, but to a variable extent. taFvHLA-A2-CD3-FlagHis revealed good binding 
to CD3, but it was exceeded by taFvCD3-HLA-A2-mycHis and taFvHLA-A2-CD3-
mycHis. taFvCD3-HLA-A2-FlagHis showed the best binding to CD3, which was even 
better than that shown by the monospecific equivalent scFvCD3. scFvHLA-A2, having 
been used as a negative control on Jurkat cells, did not show any binding to CD3. 
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Fig. 4.15:  Binding of bispecific HLA-A2 × CD3 taFv fragments to HLA-A2 and CD3, analysed by 
flow cytometry. Binding of 10 µg/ml of each bispecific taFv fragment to HEK-293T A2+ and 
Jurkat (CD3+) cells. Binding was detected by FITC-conjugated anti-His6 tag antibody. Grey 
filled, unstained cells; black line, secondary antibody alone; green line, antibody construct.  
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In order to rule out unspecific binding of the bispecific HLA-A2 × CD3 taFvs to HEK-
293T A2+ cells, a blocking assay was performed as described in section 3.7.1. Therein, 
HEK-293T A2+ cells were preincubated with scFvHLA-A2 before the addition of 
taFvCD3-HLA-A2-FlagHis as an example for the bispecific taFvs. Thus, the binding of 
taFvCD3-HLA-A2-FlagHis was entirely blocked. On the contrary, complete binding 
occurred in the absence of scFvHLA-A2 (Fig. 4.16). Consequently, the observed 
binding of taFvCD3-HLA-A2-FlagHis is clearly accomplished via HLA-A2 through its 
HLA-A2-specific antibody moiety. 
 
Fig. 4.16:  Binding specificity of taFvCD3-HLA-A2-mycHis to HLA-A2, analysed by flow cytometry. 
Binding of 20 nM taFvCD3-HLA-A2-FlagHis to HEK-293T A2+ cells in the presence or absence 
of preincubated scFvHLA-A2-mycHis at 4 µM (2 µM final concentration). Binding was detected 
by FITC-conjugated anti-Flag tag antibody. Grey filled, unstained cells; black line, secondary 
antibody alone; green line, taFvCD3-HLA-A2-FlagHis.  
In sum, all four taFv fragments proved themselves able to strongly bind to both HEK-
293T A2+ and CD3-expressing Jurkat cells according to their specificities. taFvCD3-
HLA-A2, with either FlagHis or mycHis tag, represents the best candidate for use as 
a positive control in subsequent functional assays with the constructs for 
complementation. 
Binding Studies with the Constructs for Complementation by Flow Cytometry 
The binding ability of the individual constructs for complementation to antigen-
expressing cells was tested by flow cytometry. The individual constructs were tested for 
binding to HEK-293T A2+ cells and Jurkat cells (Fig. 4.17). 
All five constructs for complementation individually bound to cells expressing the 
respective antigen according to the specificity of the complete scFv molecule they 
harbour. The three HLA-A2-specific ones, VLCD3-scFvHLA-A2, VHCD3-scFvHLA-A2-
mycHis, and VHCD3-scFvHLA-A2-FlagHis, revealed a binding to HEK-293T A2+ cells 
that was as strong as that of scFvHLA-A2. As expected, no binding of the HLA-A2-
specific constructs (including scFvHLA-A2) to Jurkat cells was observed, indicating that 
neither the VLCD3 domain nor the VHCD3 domain interacts with CD3 on Jurkat cells. 
The complete scFvCD3 construct, on the other hand, strongly bound to Jurkat, but not 
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Fig. 4.17:  Binding of the antibody constructs for complementation to HLA-A2, CD3, or CD45, 
analysed by flow cytometry. Binding of 10 µg/ml of each antibody construct to HEK-293T 
A2+ cells or to Jurkat cells (CD3+ CD45+). Binding was detected by a FITC-conjugated anti-
His6 tag antibody. Grey filled, unstained cells; black line, secondary antibody alone; green line, 
antibody construct.  
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The CD45-specific constructs bound to Jurkat cells to a variable extent. 
scFvCD45(VH-VL) showed the best binding to Jurkat cells, which was in fact better than 
that of scFvCD45(VL-VH). VHCD3-scFvCD45(VH-VL) and VHCD3-scFvCD45(VL-VH) 
revealed a slightly less strong binding than their respective scFv equivalent. As 
expected, no binding of scFvCD45(VL-VH) to HEK-293T A2+ cells was detected. 
4.5 Complementation of Two-Part Trispecific HLA-A2 × CD3 × 
CD45 Antibody 
As a first proof of the occurrence of the self-assembly of VLCD3-scFv and VHCD3-scFv 
on double-positive cells, the same in vitro functional assay that was described for the 
bispecific AChRγ × CD3 taFv fragments in Sections 4.2 and 3.7.2 was performed. This 
assay was used to investigate the potential of the generated two-part trispecific 
HLA-A2 × CD3 × CD45 antibodies and the bispecific HLA-A2 × CD3 taFv fragments to 
activate T cells in vitro. 
4.5.1 Expression of HLA-A2 and CD45 on Target Cells for PBMC 
Stimulation Assay 
In order to prove the stimulatory activity of the two-part trispecific HLA-A2 × CD3 × 
CD45 antibody variants, in addition to HLA-A2-negative PBMC, different target cells 
were required that express both HLA-A2 and CD45, either HLA-A2 or CD45, or neither 
of them. Since additional transfections of HEK-293T and HEK-293T A2+ cells with 
CD45 repeatedly led to a very low CD45-expression (not shown), other target cell lines 
expressing the respective antigens were searched. Therefore, the expression of 
HLA-A2 and CD45 was examined on different cell lines by flow cytometry. For this 
purpose, in addition to PBMC, also MCF-7, Raji, and ten different human multiple 
myeloma cell lines were incubated with a PE-conjugated antibody specific for HLA-A2, 
FITC-conjugated antibody specific for CD45, or the corresponding isotype control, 
mouse IgG2b-PE or mouse IgG1κ-FITC (Fig. 4.18). 
Of the tested human multiple myeloma cell lines solely U266 revealed high expressions 
of both HLA-A2 and CD45. L-363 expressed high amounts of HLA-A2, but no 
detectable CD45, whereas the human Burkitt’s lymphoma cell line Raji expressed 
CD45, but no detectable HLA-A2. On KMS-12-BM cells neither HLA-A2 nor CD45 was 
detected. The human breast cancer cell line MCF-7 appeared to be HLA-A2-positive. 
The PBMC were HLA-A2-negative. CD45-expression on MCF-7 and PBMC was not 
tested, as MCF-7 cells should be CD45-negative, because of their non-haematopoietic 
origin, whereas the PBMC are definitely CD45-positive due to their haematopoietic 
origin. Other PBMC were tested CD45-positive and were well bound by the CD45-
specific scFvs (data not shown). 
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Fig. 4.18:  Expression of HLA-A2 and CD45 on target cells and PBMC for stimulation assays, 
analysed by flow cytometry. Detection was performed by incubating cells with anti-HLA-A2-
PE, anti-CD45-FITC antibody, or the corresponding isotype control, mouse IgG2b-PE or 
mouse IgG1-FITC. Grey filled, unstained cells; coloured line, antibody against a cell-surface 
molecule or isotype control. 
4.5.2 Stimulatory Activity of Bispecific HLA-A2 × CD3 taFvs 
The stimulatory potential of bispecific HLA-A2 × CD3 taFv fragments was examined on 
HLA-A2-expressing target cells, namely HEK-293T A2+ (see Fig. 4.14, p. 74) or U266 
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0.3 – 243 nM on U266 cells, followed by the addition of unstimulated HLA-A2-negative 
PBMC at an E : T ratio of 2 : 1 (see Fig. 4.18 above). As a control, background signals 
of IL-2 were achieved by incubating PBMC with target cells only, i.e. in the absence of 








Fig. 4.19:  T-cell activation mediated by bispecific HLA-A2 × CD3 taFv fragments (positive control). 
A) HLA-A2-expressing target cells (U266) were incubated with titrated antibody constructs 
(0.3 – 243 nM) in duplicate, followed by addition of unstimulated HLA-A2-negative PBMC 
(E : T ratio of 2 : 1). B) HEK-293T A2+ and RD (HLA-A2-) cells were incubated with 27 nM of 
the indicated antibody constructs in triplicate, respectively, prior to an addition of unstimulated 
HLA-A2-positive PBMC (E : T ratio of 2 : 1). IL-2 secretion was measured in ELISA after 24 h. 
The results of A) are representative of three independent experiments. Please note that U266 
cells express much higher HLA-A2 levels than HEK-293T cells explaining the superior IL-2 
inducibility in the assays with U266 cells. 
All four taFv fragments exhibited a stimulatory effect on PBMC in a concentration-
dependent manner. The most effective stimulation was achieved with taFvCD3-HLA-
A2-FlagHis at 243 nM, resulting in a maximum IL-2 concentration of about 19 ng/ml. At 
the same concentration, the resulting IL-2 release amounted to 16 ng/ml for taFvCD3-
HLA-A2-mycHis and 6 ng/ml for taFvHLA-A2-CD3-FlagHis as well as taFvHLA-A2-
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CD3-mycHis. These IL-2 amounts correspond to approximately 82 % and 32 % of the 
IL-2 release achieved by the stimulation with taFvCD3-HLA-A2-FlagHis. An incipient 
saturation of HLA-A2-binding sites on the target cells is indicated for taFvCD3-HLA-A2-
mycHis. Interestingly, in a preliminary experiment, all four taFvs had also a stimulatory 
effect when HLA-A2-negative target cells (RD) and HLA-A2-positive PBMC (PBMC 
A2+) were used instead (Fig. 4.19 B). Here, the IL-2 release was a little lower but 
comparable to that reached with HEK-293T A2+ used in parallel with PBMC A2+. This 
indicates a mutual stimulation of the PBMC A2+ regardless of the target cells RD (see 
discussion, Section 5.2). On average, a 30 % loss in IL-2 release could be observed. 
As expected, scFvHLA-A2, used as negative control, had no stimulatory effect on 
PBMC. In conclusion, all four constructs mediate T-cell activation with the two 
taFvCD3-HLA-A2 variants being most potent. 
4.5.3 Stimulatory Activity of HLA-A2 × CD3 × HLA-A2 Specific 
Antibodies 
In order to facilitate the self-assembly of VLCD3 and VHCD3, as a first proof of concept, 
the self-assembly of VLCD3-scFvHLA-A2 and VHCD3-scFvHLA-A2 was tested on HLA-
A2-expressing cells. Here, both the VLCD3 and VHCD3 domain was linked to the same 
complete scFv specific for HLA-A2. Thus, differences in epitope localisation, size, or 
expression level of the two potentially targeted antigens should not have any impact on 
complementation. For the examination of the stimulatory activity, HEK-293T A2+ cells 
were preincubated with 27 nM VLCD3-scFvHLA-A2-mycHis, VHCD3-scFvHLA-A2-
mycHis, and VHCD3-scFvHLA-A2-FlagHis, either alone or in the combination VLCD3-
scFvHLA-A2 + VHCD3-scFvHLA-A2. Subsequently, unstimulated HLA-A2-negative 
PBMC were added at an E : T ratio of 2 : 1. The bispecific taFvCD3-HLA-A2-mycHis 
served as positive control. Subsequent measurement of IL-2 release after 24 h 
revealed the following IL-2 concentrations (Fig. 4.20). 
Stimulation with 27 nM taFvCD3-HLA-A2-mycHis led to an IL-2 secretion of 262 pg/ml. 
In comparison to that, the combination of VLCD3-scFvHLA-A2-mycHis with VHCD3-
scFvHLA-A2-mycHis (Combn A + B) amounted to 55 pg/ml and that of VLCD3-
scFvHLA-A2-mycHis with VHCD3-scFvHLA-A2-FlagHis (Combn A + C) to 71 pg/ml. In 
both cases, each VH/LCD3-scFv was used at 27 nM concentration, which corresponds 
to the same amount of the assembled CD3-specific moiety in taFv. In contrast, as 
expected, these constructs for complementation had no stimulatory effect on PBMC 
when applied individually. Neither had scFvCD3 nor scFvHLA-A2, which were used as 
negative controls. Regarding the stimulation with taFvCD3-HLA-A2, the IL-2 release 
achieved by stimulation with the combinations resulted in 21 % (A + B) and 27 % 
(A + C), respectively. These values are approximately 10 fold over the background 
achieved by incubating PBMC with target cells only (6 pg/ml). Evidently, 
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complementation of a functional scFvCD3 occurred in both cases. In conclusion, both 
combinations mediated an activation of T cells, with A + C tending to be slightly more 
potent than A + B. In addition, as expected, these constructs for complementation had 
no stimulatory effect when HLA-A2-negative target cells (RD) were used instead (data 
not shown). 
 
Fig. 4.20:  Complementation and stimulatory activity of two-part trispecific HLA-A2 × CD3 × HLA-
A2 constructs on HLA-A2+ cells. HLA-A2-expressing target cells (HEK-293T A2+) were 
incubated with 27 nM antibody constructs in duplicate, followed by addition of unstimulated 
HLA-A2-negative PBMC (E : T ratio of 2 : 1). IL-2 release was measured in ELISA after 24 h.  
4.5.4 Stimulatory Activity of Two-Part Trispecific HLA-A2 × CD3 × 
CD45 Antibodies 
In a second step, the strategy of the self-assembling trispecific antibody was 
transferred to a system that indeed depends on two different antigens, namely HLA-A2 
and CD45. The stimulatory properties of the two variants of trispecific HLA-A2 × CD3 × 
CD45 antibody were examined on U266 cells that express high levels of HLA-A2 as 
well as CD45 (see Fig. 4.18, p. 79). For this purpose, VLCD3-scFvHLA-A2, VHCD3-
scFvCD45(VL-VH), and VHCD3-scFvCD45(VH-VL), either alone or in the combination 
VLCD3-scFvHLA-A2 + VHCD3-scFvCD45, were titrated from 0.04 – 243 nM on U266 
cells. Subsequently, unstimulated HLA-A2-negative PBMC were added (E : T ratio of 
2 : 1) and the IL-2 release was measured after 24 h (Fig. 4.21). 
For both combinations where functional scFvCD3 complementation is possible [VLCD3-
scFvHLA-A2 + VHCD3-scFvCD45(VL-VH) (Combn A + D) and VLCD3-scFvHLA-A2 + 
VHCD3-scFvCD45(VH-VL) (Combn A + E)], a stimulatory effect on PBMC could be 
observed in a concentration-dependent manner. The most effective stimulation was 































































































Combn   A + B
Combn   A + C
VLCD3-scFvHLA-A2-mycHis    A
VHCD3-scFvHLA-A2-mycHis  B











Agnes Banaszek 83 
without reaching saturation. Individually applied VHCD3-scFvCD45(VL-VH) and VHCD3-
scFvCD45(VH-VL) had no stimulatory effect on PBMC. Only VLCD3-scFvHLA-A2 showed 
a marginal effect, leading to an IL-2 release of 712 pg/ml at 243 nM concentration. This 
corresponds to only approximately 5 % of the IL-2 release achieved by the stimulation 
with the assembled trispecific antibody at this concentration, but clearly exceeding the 
background, reached without any antibody (101 pg/ml), by a factor of seven. In 
conclusion, both combinations mediated the activation of T cells, indicating that it is 
possible to make the assembly of a functional scFvCD3 molecule dependent on the 
availability of two distinct cell surface antigens.  
 
Fig. 4.21:  Complementation and stimulatory activity of two-part trispecific HLA-A2 × CD3 × CD45 
constructs on HLA-A2+ CD45+ cells. Target cells expressing both HLA-A2 and CD45 (U266) 
were incubated with titrated antibody constructs (0.04 – 243 nM) in duplicate. In the following, 
unstimulated HLA-A2-negative PBMC (E : T ratio of 2 : 1) were added and IL-2 secretion was 
measured in ELISA after 24 h. Results are representative of four independent experiments.  
For better illustration and to compare the two-part trispecific antibody with the bispecific 
positive control, a similar experiment was performed (Fig. 4.22). Here, simultaneously 
with taFvCD3-HLA-A2-mycHis, the VLCD3-scFvHLA-A2 and VHCD3-scFvCD45(VH-VL) 
constructs, either alone or in combination, were titrated from 0.3 – 243 nM on U266 
cells, followed by the addition of unstimulated HLA-A2-negative PBMC (E : T ratio of 
2 : 1) and measurement of IL-2 release after 24 h. 
At lower concentrations (0.3 – 3 nM), a slightly higher stimulatory effect was observed 
for the two-part trispecific antibody. Here, on average, stimulation with the two-part 
trispecific antibody led to an IL-2 release that was 12 % higher than stimulation with the 
bispecific positive control. In contrast, at higher concentrations (9 – 243 nM), the 
bispecific positive control was considerably more potent. Here, stimulation with the two-
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positive control. In conclusion, the two-part trispecific HLA-A2 × CD3 × CD45 construct 
(Combn A + E) mediated activation of T cells tendentially less well than taFvCD3-
HLA-A2-mycHis used as bispecific positive control. 
 
Fig. 4.22:  Stimulatory activity of two-part trispecific HLA-A2 × CD3 × CD45 constructs compared 
to bispecific HLA-A2 × CD3 taFv on HLA-A2+ CD45+ cells. Target cells expressing both 
HLA-A2 and CD45 (U266) were incubated with titrated antibody constructs (0.3 – 243 nM) in 
duplicate, followed by addition of unstimulated HLA-A2-negative PBMC (E : T ratio of 2 : 1). 
IL-2 release was measured in ELISA after 24 h.  
4.5.5 Dual-Antigen Restriction of Trispecific HLA-A2 × CD3 × CD45 
Antibody 
Under the described experimental conditions, it has to be ruled out that a spontaneous 
and premature self-assembly of VLCD3-scFvHLA-A2 and VHCD3-scFvCD45(VH-VL) 
occurs in solution without contact to at least one antigen, HLA-A2 or CD45. According 
to this, the interaction of either VLCD3-scFvHLA-A2 with HLA-A2 or VHCD3-scFvCD45 
with CD45 on U266 cells was blocked by prior incubation with HLA-A2- and CD45-
specific scFv, respectively (Fig. 4.23). 
The stimulatory activity of both trispecific antibody pairs at 27 nM was blocked by 
preincubation with 2.7 µM scFv. The induced IL-2 secretion was reduced to 4.4 % by 
blocking with scFvHLA-A2 for the combination A + D and to 5.9 % for the combination 
A + E. In comparison, the stimulatory activity of the bispecific taFvCD3-HLA-A2-mycHis 
was only reduced to 26 % and not, as it was expected, to the same extent as the 
trispecific antibodies. The IL-2 release induced by the combinations was reduced to 
1.7 % (Combn A + D) and 1.4 % (Combn A + E), respectively, by blocking with 
scFvCD45(VH-VL) to the level achieved by each single construct for complementation on 
its own (last block of bars). In summary, the stimulatory activity of both trispecific 
antibodies was confirmed to be dual antigen-restricted, since the affinity of VHCD3-scFv 
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and VLCD3-scFv to each other is definitely insufficient for complementation in the 
absence of at least one antigen, HLA-A2 or CD45. 
 
Fig. 4.23:  Dual antigen-restricted complementation of two-part trispecific HLA-A2 × CD3 × CD45 
constructs on HLA-A2+ CD45+ cells. Target cells expressing both HLA-A2 and CD45 (U266) 
were preincubated with or without 5.4 µM scFvHLA-A2 or scFvCD45(VH-VL) (each 2.7 µM final 
concentration), followed by an incubation with 27 nM antibody constructs in duplicate. 
Unstimulated HLA-A2-negative PBMC were added (E : T ratio of 2 : 1) and IL-2 release was 
measured in ELISA after 24 h. These results are representative of two independent 
experiments. Combn A + D, VLCD3-scFvHLA-A2 + VHCD3-scFvCD45(VL-VH); Combn A + E, 
VLCD3-scFvHLA-A2 + VHCD3-scFvCD45(VH-VL).  
In order to prove the dual-antigen restriction of the trispecific construct in another way, 
the stimulatory activity of the two variants of trispecific HLA-A2 × CD3 × CD45 antibody 
was examined on target cells expressing high levels of only one antigen at a time, 
HLA-A2 or CD45, or neither of them (see Fig. 4.18, p. 79). Here, the respective target 
cells were preincubated with the trispecific combinations A + D and A + E, as described 
above for Fig. 4.21 in Section 4.5.4, but at 27 nM of A, D, and E each. In the following, 
unstimulated HLA-A2-negative PBMC were added (E : T ratio of 2 : 1) and IL-2 release 
was measured in ELISA after 24 h. The following IL-2 concentrations resulted with 
target cells expressing high levels of CD45, but no detectable HLA-A2 (Raji, Fig. 
4.24 A) or neither of these antigens (KMS-12-BM, Fig. 4.24 B). Here, the T-cell 
stimulant PHA-L served as positive control. 
Stimulation with 1 µg/ml PHA-L led to an IL-2 secretion of 34 ng/ml on Raji cells and of 
33 ng/ml on KMS-12-BM cells. As expected, both variants of the trispecific 
HLA-A2 × CD3 × CD45 antibody had no stimulatory effect on PBMC. Stimulation with 
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background signals which were achieved by incubating PBMC with target cells only 
(last bar in each diagram), approximately 500 pg/ml on Raji and 80 pg/ml on KMS-12-
BM cells. In conclusion, both variants of the trispecific HLA-A2 × CD3 × CD45 antibody 
were not able to active T cells in the presence of only CD45 or in the absence of both 
HLA-A2 and CD45. Consequently, it is ensured that the self-assembly of VLCD3-
scFvHLA-A2 and VHCD3-scFvCD45 only occurs when both antigens, HLA-A2 and 
CD45, are present. 
A B 
  
Fig. 4.24:  No complementation of two-part trispecific HLA-A2 × CD3 × CD45 constructs on HLA-
A2- CD45+ and HLA-A2- CD45- cells. Target cells expressing A) no HLA-A2 but CD45 (Raji) 
or B) neither HLA-A2 nor CD45 (KMS-12-BM) were incubated with 1 µg/ml PHA-L as positive 
control or 27 nM antibody constructs in duplicate, respectively. Unstimulated HLA-A2-negative 
PBMC (E : T ratio of 2 : 1) were added and IL-2 secretion was measured in ELISA after 24 h. 
Results are representative of A) four and B) three independent experiments. A, VLCD3-
scFvHLA-A2; D, VHCD3-scFvCD45(VL-VH); E, VHCD3-scFvCD45(VH-VL). 
Furthermore, target cells expressing HLA-A2, but no detectable CD45 (L-363 and 
MCF-7), were preincubated with 27 nM taFvCD3-HLA-A2-mycHis as a bispecific 
positive control and the trispecific combinations, A + D and A + E (Fig. 4.25). MCF-7 
cells were additionally preincubated with the constructs for complementation, 
A, D, and E, on their own. Apart from that, the assay was further performed as above. It 
should be noted that the MCF-7 cells are known to be homozygous for HLA-A2 
[Christensen et al., 2009].  
As expected, due to its ability to crosslink between HLA-A2 on target cells and CD3 on 
T cells, the bispecific taFvCD3-HLA-A2-mycHis had a stimulatory effect on PBMC, 
leading to an IL-2 secretion of 10 ng/ml at 27 nM on both L-363 and MCF-7 cells. 
Unfortunately, the combination of VLCD3-scFvHLA-A2 with VHCD3-scFvCD45 also led 
to a stimulation of PBMC. The stimulation with the trispecific combination led to an IL-2 
release of approximately 7 ng/ml on L-363 and 5 ng/ml on MCF-7 cells. It is worthy of 
note that each construct for complementation on its own had no stimulatory effect on 
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unknown reasons, both variants of the trispecific HLA-A2 × CD3 × CD45 antibody 
unspecifically mediated the activation of T cells, reaching 68 % and 48 % of the 
stimulatory activity of the bispecific positive control on L-363 and MCF-7 cells, 
respectively. 
A B 
Fig. 4.25:  Unspecific activity of two-part trispecific HLA-A2 × CD3 × CD45 constructs on HLA-A2+ 
CD45- cells. Target cells expressing HLA-A2, but no CD45, A) L-363 and B) MCF-7, were 
incubated with 27 nM antibody constructs in duplicate, followed by addition of unstimulated 
HLA-A2-negative PBMC (E : T ratio of 2 : 1). IL-2 release was measured in ELISA after 24 h. 
Results are representative of A) three and B) two independent experiments. A, VLCD3-
scFvHLA-A2; D, VHCD3-scFvCD45(VL-VH); E, VHCD3-scFvCD45(VH-VL). 
4.6 Cytotoxicity of Two-Part Trispecific HLA-A2 × CD3 × CD45 
Antibody 
So far, it was shown in this study that the complementation of the two-part trispecific 
HLA-A2 × CD3 × CD45 constructs is functional, dual antigen-restricted, and able to 
activate T cells by inducing IL-2 release in a costimulation-independent manner. For 
further evaluation, the trispecific constructs were investigated for the ability to recruit 
T cells for lysis of target cells expressing both HLA-A2 and CD45. In order to measure 
tumour cell lysis by cytotoxic T cells in vitro, the same flow cytometry-based cytotoxicity 
assay was performed as described for the bispecific AChRγ × CD3 taFv fragments in 
Section 4.3 (see method details in Section 3.7.4). 
CFSE-labelled target cells expressing both HLA-A2 and CD45 (U266) were 
preincubated with 27 nM VLCD3-scFvHLA-A2, VHCD3-scFvCD45(VL-VH), and VHCD3-
scFvCD45(VH-VL), either alone or in the combination VLCD3-scFvHLA-A2 + VHCD3-
scFvCD45 in the presence or absence of unstimulated PBMC at an E : T ratio of 10 : 1 
(Fig. 4.26). The bispecific taFvCD3-HLA-A2-mycHis served as positive control. Cell 
death was determined after 24 h and 48 h only, since after 0 h no effect was visible (as 
expected) and after 72 h too low cell counts were measured. As control for 
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PBMC only, i.e. in the absence of antibody constructs. Maximum cell death was 
achieved by incubating target cells with 0.1 % Triton X-100.  
 
Fig. 4.26:  Cytotoxicity mediated by trispecific HLA-A2 × CD3 × CD45 constructs. CFSE-labelled 
target cells expressing both HLA-A2 and CD45 (U266) were incubated with 27 nM antibody 
constructs in the presence or absence of unstimulated HLA-A2-negative PBMC (E : T ratio of 
10 : 1). After 24 h and 48 h, samples were taken and stained with 7-AAD. Dead target cells 
(CFSE+ 7-AAD+) were identified by multicolour flow cytometry. taFv, taFvCD3-HLA-A2-mycHis; 
A, VLCD3-scFvHLA-A2; D, VHCD3-scFvCD45(VL-VH); E, VHCD3-scFvCD45(VH-VL). 
As expected, in the absence of PBMC, neither of the antibody constructs had 
a cytotoxic effect on U266 – not even after 48 h. In contrast, in conjunction with PBMC, 
a considerable cytotoxic effect was observed when U266 were stimulated with the 
bispecific taFv or the trispecific antibody variants. Due to some target cell death 
induced by PBMC alone, the specific cell death was calculated as described in Section 
3.7.4. For the bispecific taFv and the trispecific combinations at 27 nM, the percentage 
of cytotoxic activity on U266 amounted to approximately 59 % (57 – 61) and  
60 % (59 – 62) after 24 h and 48 h, respectively. On the other hand, for individually 
applied VLCD3-scFvHLA-A2, VHCD3-scFvCD45(VL-VH), and VHCD3-scFvCD45(VH-VL), 
the percentage of cytotoxic activity only reached approximately 9 % (7 – 11) after 24 h. 
After 48 h, only VLCD3-scFvHLA-A2 had a higher cytotoxic effect than expected, 
leading to a specific cell death of 26 % versus 3 % for VHCD3-scFvCD45(VL-VH) and 8 % 
for VHCD3-scFvCD45(VH-VL). For both trispecific variants, the cytotoxic activity on U266 
was comparable to that of the bispecific taFvCD3-HLA-A2-mycHis. One should note 
that these data are preliminary, as they were performed only once, so that further 
experiments are required for detailed and quantitative verification.  
For a more precise evaluation of the cytotoxic activity of VLCD3-scFvHLA-A2 in 
combination with VHCD3-scFvCD45(VH-VL) (Combn A + E), both antibody constructs 
were titrated from 0.04 – 27 nM on CFSE-labelled U266 cells in the presence or 
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percentage of dead U266 cells (CFSE+ 7-AAD+) was determined after 24 h by 
multicolour flow cytometry (Fig. 4.27). As control for spontaneous cell death, CFSE-
labelled U266 were incubated with PBMC only. As negative control, individually applied 
VLCD3-scFvHLA-A2 and VHCD3-scFvCD45(VH-VL) were additionally tested at 27 nM in 
parallel. Data were normalised to the lowest value. 
 
Fig. 4.27:  Cytotoxicity mediated by two-part trispecific HLA-A2 × CD3 × CD45 construct. CFSE-
labelled target cells expressing HLA-A2 and CD45 (U266) were incubated with titrated 
antibody constructs (0.04 – 27 nM) in the presence of unstimulated HLA-A2-negative PBMC 
(E : T ratio of 10 : 1). After 24 h, samples were taken and stained with 7-AAD. Dead target 
cells (CFSE+ 7-AAD+) were identified by multicolour flow cytometry. A, VLCD3-scFvHLA-A2; 
E, VHCD3-scFvCD45(VH-VL). 
The complemented trispecific antibody exhibited a cytotoxic effect on U266 in 
a concentration-dependent manner. The most effective redirected cell lysis of U266 
was achieved at 9 nM, resulting in a maximum specific cell death of 72 %, and was not 
further increased by a higher concentration of antibody constructs. The determined 
EC50 value was 0.6 nM. As expected, the individual constructs for complementation did 
not reveal any cytotoxic activity on U266 cells at the highest tested concentration of 
27 nM. The spontaneous cell death amounted to 12.9 % and 35.7 % after 0 h and 24 h, 
respectively. These data were confirmed in a second experiment. 
Finally, it was shown that, at nanomolar concentration, the trispecific antibody 
assembled from VLCD3-scFvHLA-A2 and VHCD3-scFvCD45(VH-VL) is not only able to 
specifically activate T cells to release IL-2, but also to induce cytotoxicity to tumour 
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5 Discussion 
In order to overcome the side effects caused by the current conventional cancer 
treatments, new targeted therapies based on recombinant antibodies are gaining 
ground. This work introduces two such targeted therapies, one of which being of 
combinatorial and highly innovative nature. 
5.1 Bispecific AChRγ × CD3 Antibodies of taFv Format 
For the treatment of the aggressive rhabdomyosarcoma, which predominantly children 
suffer from and which is treatment-resistant after the occurrence of metastasis or 
relapse, a bispecific AChRγ × CD3 antibody of taFv format was developed by analogy 
with the BiTE antibody format [Baeuerle et al., 2009]. 
The AChRγ expression on the three rhabdomyosarcoma cell lines available for the 
present study was determined by means of incubation of a commercial anti-AChRγ 
antibody (clone C9) (see Fig. 4.5, p. 60). Unfortunately, binding of the scFvAChR used 
in this study did not correlate well with the AChRγ expression data obtained with the 
commercial antibody. This was unexpected, because a scFvAChR-related monovalent 
Fab was found to bind specifically to AChRγ by Matthews et al. [2002], as it efficiently 
blocked binding of two bivalent mAb specific for fetal AChR, one of which being C9. 
Also Gattenlöhner et al. [2010] described the same scFvAChR but fused to exotoxin A 
(scFv35-ETA), binding specifically and equally to RD and TE-671 cells in flow 
cytometry. In the present study, scFvAChR exhibited the strongest binding to TE-671, 
although these cells revealed the lowest expression, whereas AX-OH-1 cells with the 
highest expression were only moderately bound by scFvAChR. Possible reasons for 
this discrepancy, for instance, might be the unknown exact antigen specificity of 
scFvAChR, differential AChR isoform expression on these cells, or the trypsinisation of 
TE-671 and RD cells. For detachment, the very sensitive AX-OH-1 cells were treated 
with Accutase instead of trypsin, which is less damaging to cells. The mild treatment 
might have led to the highest apparent AChRγ expression. In contrast, as proteolysis of 
AChR with trypsin was reported by Neumann et al. [1986], a cleavage of AChR has to 
be taken into account on TE-671 and RD cells, especially because these cell lines are 
highly adherent and were needed to be treated with trypsin for several minutes to 
detach. Unfortunately, using a cell scraper did not lead to evaluable results in flow 
cytometry due to highly unspecific binding of the detecting anti-His-FITC antibody 
despite thorough washing (not shown). Thus, binding studies with scFvAChR and the 
bispecific AChRγ × CD3 taFv fragments need to be repeated under optimised 
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conditions, e.g. by dissociation with Accutase instead, or by using a different cell line 
expressing fetal AChR. 
Despite the confirmed high affinity of the Fab, from which scFvAChR is derived, the 
γ subunit specificity of scFvAChR can only be assumed [Matthews et al., 2002], 
because the fetal AChR is composed of five subunits (α2βγδ) [Unwin, 2000]. The two 
acetylcholine binding sites are located at the α/δ and either the α/γ or α/ε interfaces 
[Unwin, 2005]. The majority of mAb specific for AChR derived from patients with 
myasthenia gravis (autoimmune neuromuscular disease) are thought to target the main 
immunogenic region on the α subunit [Tzartos et al., 1998], whereas antibodies against 
the fetal AChR seem to bind a site at the α/γ interface [Riemersma et al., 1996] (see 
Fig. 2.1, p. 7). The α/γ interface is also bound by acetylcholine, so that it was 
suggested that antibodies binding this site inhibit the function of fetal AChR. It is very 
likely that scFvAChR belongs to this antibody group, as it derives from the same 
patient described. Thus, scFvAChR supposedly binds the γ subunit, but in combination 
with the α subunit. The expression of the α subunit on the three rhabdomyosarcoma 
cell lines used in the present study have not been tested, but it might be informative 
whether the expression differs. In order to figure out to which subunit exactly 
scFvAChR is binding, single subunits or a combination of α and γ of AChR could be 
expressed on cells and tested for specific binding by scFvAChR. However, it is 
questionable whether the AChR subunits are able to be individually expressed. 
However, two of the four constructed taFvs revealed good binding to CD3-expressing 
cells as well as AChRγ-expressing TE-671 cells, with taFvCD3-AChR-FlagHis binding 
better to CD3 and taFvAChR-CD3-FlagHis binding better to AChRγ (see Fig. 4.6, 
p. 62). Obviously, the location of the particular scFv on the polypeptide chain is 
decisive for its binding properties. The N-terminal location seems to be less hindering 
for the respective antigen-binding site and, thus, more advantageous. The taFv 
fragments with an N-terminal His10 cluster seem to be prone to degradation and to 
a reduced binding activity, although His-taFvCD3-AChR revealed moderate binding 
properties to both CD3 and AChRγ. 
Despite the fact that the results from the binding studies in flow cytometry still have 
room for improvement, one of the four taFvs, namely taFvCD3-AChR-FlagHis, showed 
some stimulatory and cytotoxic activity on AChRγ-expressing cells (see Figs. 4.7 and 
4.8, pp. 64 + 65). taFvCD3-AChR-FlagHis was able to mediate T-cell activation in 
a concentration-dependent manner at nanomolar concentrations of 81 nM, as 
measured by IL-2 release, and revealed 60 % cytotoxic activity at 27 nM to AChRγ-
expressing rhabdomyosarcoma versus 15 % to AChRγ-negative rhabdomyosarcoma. 
This might be advantageous since, for therapeutic application, an efficacy at low 
concentrations is wanted, which minimises side effects, production costs, and above 
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all, the amount of protein required to reach the tumour. Unfortunately, the relatively 
high spontaneous cell death of RD cells (30 % after 24 h versus 3 % for A-204 cells) 
reflects a suboptimal condition of the RD cells. This might be due to a too short period 
of time after thawing, again trypsinisation of the RD cells, or simply a suboptimal 
condition of the thawed batch of cells. Since these data are preliminary and only in 
parts fully convincing, further experiments are required for verification with cells that 
have not been treated with trypsin and display a higher AChRγ expression. They will 
certainly lead to a higher stimulatory and cytotoxic activity, confirming the potential of 
this bispecific antibody. Likewise, using purified T cells instead of PBMC for both 
stimulatory and cytotoxic assays would presumably reveal a higher activity for this 
bispecific antibody. 
A future aim for this approach is to reach results that are at least similar to those 
reported by Gattenlöhner et al. [2010] for an anti-fAChR immunotoxin (scFv35-ETA), 
which contains the same scFvAChR. This immunotoxin displayed a specific cytotoxic 
effect on fAChR-positive rhabdomyosarcoma cell lines in a dose-dependent manner 
and led to a delay in tumour development in a murine transplantation model. However, 
the application of the anti-fAChR immunotoxin was insufficient for a real cure of the 
tumour in mice, as tumours occurred shortly after the end of treatment. However, these 
results showed some activity in vitro and in vivo, thus, demonstrating fAChR to be 
a prominent target and the bispecific AChRγ × CD3 antibody to be a promising 
candidate for future preclinical studies. 
5.2 Two-Part Trispecific HLA-A2 × CD3 × CD45 Antibody 
Leukaemia and other blood cancers are mostly treated with chemotherapy or even 
radiation therapy. In certain cases, haematopoietic stem cell transplantation is 
performed. Sometimes initial therapy fails to eliminate all cancer cells, leading to 
a recurrence of the cancer and a subsequent relapse of disease. This study presents 
the development of a two-part trispecific HLA-A2 × CD3 × CD45 antibody for the 
treatment of leukaemia and other haematological malignancies in the context of 
haematopoietic stem cell transplantation. A future application is suggested for 
a treatment after haematopoietic stem cell transplantation in order to prevent disease 
recurrence. 
Dual-specific antibodies have already been reported. Recently Kontermann [2012] 
summarised a plethora of “Dual targeting strategies with bispecific antibodies”. In some 
cases, heterodimeric antibodies bearing two different antigen-binding sites were 
developed. These are IgG-like bispecific antibodies which aim to take advantage of the 
IgG-related long half-life and effector functions. Bispecific antibodies of smaller 
recombinant formats have also been developed. These strategies have shown that two 
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tumour-specific antigens are helpful for tumour targeting by increasing the binding 
avidity. Most molecules of these two types have a prefolded or fixed shape in common. 
Moreover, several techniques have been developed to achieve multivalent antibodies 
[Deyev and Lebedenko, 2008]. Some of them consist of two or more modules, which 
have to assemble first before application and are thus produced to act as an overall 
entity as well. Alternatively, in another approach, a small trispecific CEA × CD3 × CD28 
antibody construct was developed [Wang et al., 2004]. This trispecific antibody was 
shown to induce tumour-specific cell lysis following an efficient T-cell activation. 
However, the results of this study also demonstrated the risk of a target-independent 
T-cell activation and, thus, the risk of inducing severe side effects due to superagonistic 
properties of such a trispecific one-molecule strategy. Another trispecific antibody, 
namely a single-chain Fv triple body (sctb), was developed, which extended a taFv, like 
the one used for BiTE antibodies, by a third scFv [Kügler et al., 2010; Schubert et al., 
2011]. For this trispecific CD123 × CD16 × CD33 triple body, which targets two 
antigens associated with acute myeloid leukaemia (CD33 and CD123) and the low 
affinity FcγRIII (CD16), dual retargeting of NK cells to myeloid leukaemia was 
demonstrated [Kügler et al., 2010]. Another triple body of CD33 × CD16 × CD19 
specificity, which was generated by the same group [Schubert et al., 2011], mediated 
strong redirected lysis of tumour cells expressing both tumour antigens, CD33 and 
CD19 (B-cell antigen). Although showing high efficacy and selectivity due to an 
increased functional affinity for the tumour, the presence of both antigens is not an 
obligatory prerequisite for tumour targeting through these triple bodies. Theoretically, 
only one tumour antigen should be sufficient for tumour targeting. Furthermore, such 
approaches require even more, namely two, tumour-specific antigens. On this point, 
our strategy mainly differs from those mentioned above in ways that will be explained in 
the following. 
One of the major limitations of using highly cytotoxic approaches such as BiTE 
antibodies [Baeuerle et al., 2009] is the lack of tumour-specific antigens. On that 
account, the unique idea to condition the cytotoxic activity on the coincident presence 
of two antigens to enlarge the specificity for tumour tissue appears to be a promising 
tool for targeted therapy. Incidentally, the two antigens do not need to be tumour 
specific in itself as do HLA-A2 and CD45 in the present study, in which 
a complementing trispecific antibody for such a combinatorial approach was 
developed. 
An assembly of an effector molecule-targeting moiety by two antibody molecules has 
not yet been reported. The success of such an assembly approach might depend, to 
a great extent, on the particular antibody for assembly, on the spatial arrangement of 
all three antigen-binding sites, and on the distribution of target molecules on the cell 
surface. For that reason, the well-studied anti-CD3 antibody from the BiTE technology 
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was selected, and target antigens were chosen that are expressed in large amounts on 
the cell, namely HLA-A2 and CD45 [Matthews et al., 1991]. Additionally, differences in 
epitope localisation regarding the distance to the target cell membrane and the size of 
the two targeted antigens might have an impact on the complementation of the 
trispecific construct, as these parameters were described to determine the potency of 
T cell-mediated lysis by BiTE antibodies by Bluemel et al. [2010]. More precisely, it was 
postulated that the formation of a lytic synapse may be more efficient the closer the 
membranes of T cell and target cell can adhere to each other. The longitudinal 
dimension of HLA-A2 (HLA class I molecule) is about 7 nm [Bjorkman et al., 1987, 
Barclay et al., 1997]. The epitope recognized by the scFvHLA-A2 is assumed to be 
formed by the amino acid residues 142 and 145 (TTKH) located on the α2 domain of 
the heavy chain of the HLA class I molecule close to the peptide binding cleft [Watkins 
et al., 2000]. Since the parental monoclonal antibody of scFvCD45, BC8, is reactive 
with all CD45 isoforms, only the C-terminal part of the extracellular domain of CD45, 
which is identical in all isoforms, comes into question as the recognised epitope. This 
conserved part comprises a cysteine-rich domain and three fibronectin type III domains 
with an overall dimension of 28 nm [McCall et al., 1992]. The length of CD3ε is 
approximately 4 nm [Sun et al., 2001]. For comparison, the TCR-peptide-MHC complex 
spans approximately 14 nm [Garboczi et al., 1996; Garcia et al., 1998]. Thus, the size 
difference between the two antigens, HLA-A2 and CD45, might evoke difficulties to 
reach an optimal cell-to-cell distance for T-cell activation due to steric orientation. In 
order to provide enough flexibility to enable functionality of all three antigen-binding 
sites of the trispecific construct, linkers of 7 aa length were inserted between the 
variable domains of anti-CD3 and the respective scFv fragments. Furthermore, VHCD3 
and VLCD3 were N-terminally fused to the scFvs to avoid both restrictions caused by 
and affecting the C-terminal tags. 
First of all, this study shows that a self-assembly of VH and VL (in this case of an anti-
CD3 antibody) is feasible, when brought into close proximity of each other on the 
surface of a single cell. Secondly, such a complemented Fv is functional. The 
constructed two-part trispecific antibodies were shown to be able to activate T cells and 
to induce cytotoxic T cell responses in a concentration-dependent manner at 
nanomolar concentrations of 3 – 243 nM (Fig. 4.21, p. 83) and 9 nM (Fig. 4.27, p. 89), 
respectively. Again, this can be regarded as favourable since, for therapeutic 
application, an efficacy at low concentrations is preferable in order to minimise side 
effects, production costs, and, above all, the amount of protein needed to reach the 
tumour. Nevertheless, an efficacy at lower concentrations is probably sufficient for 
targeting blood cancer (e.g. leukaemia), since blood cancer is assumed to be more 
accessible for such targeting approaches than solid tumours, which require higher 
concentrations to be targeted effectively [Müller and Kontermann, 2010]. Over and 
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above this, the fact that blood cells express high amounts of costimulatory molecules 
might likewise be beneficial.  
In the first proof of concept experiment, the stimulatory activity of the two-part trispecific 
HLA-A2 × CD3 × HLA-A2 construct turned out to be diminished compared to the 
bispecific taFv (see Fig. 4.20, p. 82). However, it was still considerable in spite of the 
initial expectations that an insertion of heterodimerising peptides, such as jun-fos 
leucine zippers [de Kruif and Logtenberg, 1996; Kostelny et al., 1992; Pack and 
Plückthun, 1992; O’Shea et al., 1989; Arndt et al., 2001], would be required to improve 
the affinity of VH and VL for each other. The diminished stimulatory activity might be 
understood as a result of the lesser amount of HLA-A2 antigen that was available for 
binding due to competition between VLCD3-scFvHLA-A2 and VHCD3-scFvHLA-A2. 
Such competitive effects should not occur when complementation relies on two 
different antigens. In the comparative experiment with the actually intended trispecific 
HLA-A2 × CD3 × CD45 antibody, the bispecific control antibody again tended to be 
more potent (see Fig. 4.22, p. 84). BiTE antibodies have consistently been reported to 
mediate redirected tumour cell lysis at half-maximal effective concentrations in the pM 
to nM range [Baeuerle et al., 2009; Hoffmann et al., 2005; Bluemel et al., 2010; 
Lutterbuese et al., 2009], whereas the present trispecific concept indicates an efficacy 
in the nM range (see Figs. 4.20, 4.21, and 4.27, pp. 82 + 83, 89). In the comparative 
experiment mentioned above, it has to be considered that both the bispecific and the 
two-part combinatorial trispecific construct are of different designs and, thus, probably 
subjected to different binding kinetics. As a consequence, the reduced activity of the 
trispecific construct might simply be explained by the fact that its two halves first have 
to meet, and VH and VL of the anti-CD3 moiety need to assemble before being able to 
bind and stimulate T cells. It was assumed that the affinity of VHCD3 and VLCD3 is low, 
since the stability of the noncovalently-associated VH and VL in fact varies from 
antibody to antibody, but an isolated Fv fragment usually tends to dissociate rapidly 
due to the weak interface between VH and VL. For Fv fragments, dissociation constants 
have been reported ranging from 10-5 M to 10-8 M [Skerra and Plückthun, 1988; 
Glockshuber et al., 1990; Jäger and Plückthun, 1999; Mallender et al., 1996; Polymenis 
and Stollar, 1995]. Within the bispecific control antibody, however, VHCD3 and VLCD3 
are already available in a prefolded form (scFvCD3). Hence, the reduced activity of the 
trispecific antibodies is reasonable. 
At the same time, for the new approach presented here, a low affinity of VH and VL for 
each other might be beneficial, as high affinity involves the risk of premature 
complementation and, thus, of redirecting cytotoxic T cells to cells expressing only one 
of the two target antigens. Especially an attack on cells expressing only HLA-A2 would 
be devastating, as almost all nucleated cells in the body express HLA class I 
molecules. Driven by a much higher affinity of VLCD3 and VHCD3 for each other, 
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a premature self-assembly of VLCD3-scFvHLA-A2 and VHCD3-scFvCD45 would 
already occur in solution without contact to at least one antigen, HLA-A2 or CD45. Both 
molecules would then probably combine into a trispecific antibody in solution, thus 
being able to activate T cells in dependence of the presence of only one antigen. 
Therefore, a low to medium affinity of VLCD3 and VHCD3 is requested, i.e. an affinity 
high enough to enable self-assembly, but low enough to preclude premature 
complementation. Incidentally, even in the case of a soluble trispecific antibody, T-cell 
activation would probably not work in a target cell-independent fashion, since soluble 
scFvCD3 is not able to crosslink CD3 on T cells (see Figs. 4.7 and 4.20, pp. 64 + 82). 
Likewise, in the absence of target cells, neither the bispecific control antibody nor the 
constructs for complementation had a stimulatory effect on T cells (data not shown). 
However, this trispecific approach was shown to be dual antigen-restricted and to 
activate T cells in a target-cell dependent fashion. As shown in Fig. 4.24 (p. 86), 
HLA-A2-negative T cells were not activated by the trispecific HLA-A2 × CD3 × CD45 
antibody, when the target cells expressed neither HLA-A2 nor CD45 or CD45 only. 
Thus, a spontaneous premature complementation can definitely be excluded. 
Unfortunately, the trispecific antibody activated T cells when using HLA-A2-positive 
target cells (see Fig. 4.25, p. 87), reaching 48 % (MCF-7) to 68 % (L-363) of the 
stimulatory activity of the bispecific positive control. Three possible reasons that might 
explain this fact have to be taken into account. First, in case of L-363, some residual 
CD45 expression is conceivable, even though it was undetectable in flow cytometry 
(see Fig. 4.18, p. 79 and Colette et al., 2007). During maturation, this multiple myeloma 
cell line might have undergone an incomplete loss of CD45 [Kumar et al., 2005]. 
Secondly, in case of the breast cancer cell line MCF-7, some unspecific binding of the 
anti-CD45 moiety has to be considered. It cannot be ruled out that MCF-7 cells express 
molecules related to CD45, which is also known as PTPRC, protein tyrosine 
phosphatase, receptor type, C. For example, MCF-7 cells have been reported to 
express PTPγ, another member of the protein tyrosine phosphatase family [Liu et al., 
2004]. As the CD45-specific scFv used in this study is derived from an anti-CD45 
antibody, which was described to be reactive with all CD45 isoforms [Lin et al., 2006], 
its specificity might be directed against an epitope also expressed on other protein 
tyrosine phosphatases, including fibronectin type III domains. This problem might be 
solved by using different HLA-A2-expressing cells or by exchanging the anti-CD45 
moiety with a more specific anti-CD45 antibody. However, the results from Fig. 4.25 
(p. 87) suggest a higher specificity and selectivity of scFvHLA-A2 to HLA-A2 than of 
scFvCD45 to CD45. The third possible reason might be that CD45 is provided by a T 
cell that is different to the one targeted via CD3 and, thus, serves as a second target 
cell besides the intended HLA-A2-positive target cell. In such a case, the assembled 
trispecific antibody would have to stretch between CD45 on a T cell and HLA-A2 on the 
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intended target cell, while binding CD3 on a different T cell. Then, HLA-A2-positive 
target cells and HLA-A2-negative T cells alone would be sufficient for stimulation. 
Although sterically unfavourable, such a constellation remains to be verified. 
Nevertheless, the stimulatory activity of the trispecific antibodies was reaffirmed to be 
dual antigen-restricted (Fig. 4.23, p. 85). Here it was shown that, if just one of both 
target antigens is not available for binding, the binding affinity of VHCD3-scFvCD45 and 
VLCD3-scFvHLA-A2 for each other is not high enough for complementation of the 
trispecific antibody, thus leading to an almost completely prevented T-cell activation. 
Hence, the presence of both antigens is imperative for T-cell activation by the two-part 
trispecific HLA-A2 × CD3 × CD45 antibody. Only in case the third possibility proves 
true, the blocking experiment with scFvCD45 should be verified as well, since CD45 
might also be blocked on T cells. Furthermore, the trispecific antibody mediated 
cytotoxicity of HLA-A2- and CD45-expressing cells with a maximum specific cell death 
of 72 % at 9 nM and with a half-maximal effective concentration of 0.6 nM (see Fig. 
4.27, p. 89). Thus, despite the much larger magnitude of CD45 than HLA-A2, the 
trispecific concept succeeded. The formation of a lytic synapse or cross-linkage of T 
cells was obviously not impaired by the size of CD45. It bears mentioning that these 
results were obtained with unstimulated PBMC. 
Despite the promising results, this two-part trispecific concept also implicates some 
minor obstacles related to the future therapeutic application. For one thing, the 
immunogenicity of the trispecific antibody might lead to HAMA responses due to the 
anti-CD45 moiety of murine origin. Thus, adverse events or a decrease in the 
effectiveness of the treatment may be induced [Moldenhauer, 2011]. It is worth 
considering to circumvent such HAMA responses by humanisation [Jones et al., 1986; 
Riechmann et al., 1988; Hudis, 2007], deimmunisation [Hellendoorn et al., 2004; Jones 
et al., 2004], or, more simply, by exchanging this antibody moiety. 
For another thing, the uncombined VH and VL expose highly hydrophobic interfaces and 
have the propensity to aggregate when expressed individually, VH more so than VL. 
This might also lead to aggregation of the whole antibody construct including VH 
and VL. In fact, some aggregation was observed for more or less all constructs 
generated in this study, especially after thawing. Aggregates were visibly reduced after 
storage at 4°C and always discarded by centrifugation before functional assays were 
performed. Before therapeutic application, the aggregate formation of the components 
of the trispecific antibody described here should be studied in more detail, since 
aggregates may lead to reduced bioactivity and increase immunogenicity. Several 
methods have been developed in order to i) isolate non-aggregating VH domains from 
synthetic libraries [Jespers et al., 2004; Christ et al., 2007], ii) reduce the 
hydrophobicity of the former light chain interface in the course of the development of 
single domain antibodies [Davies and Riechmann, 1994; 1996], and iii) prevent 
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aggregation [Barthelemy et al., 2008; Dudgeon et al., 2012]. However, an application of 
these methods on the approach presented here would require a balancing act, since, in 
the end, changing residues in the interface would also affect the assembly of VH 
and VL. Another, more encouraging strategy was developed by Schaefer and 
Plückthun [2012], according to which negatively charged residues attached to the 
N-terminus of human IgG molecules confirmed a beneficial effect on aggregation 
resistance. These residues, which remained from the used Pichia secretion system, 
are hypothesised to increase the net negative charge of the antibody, while not 
affecting the antigen binding. 
Despite the free hydrophobic interfaces being prone to aggregation, this two-part 
trispecific antibody effectively activates T cells. However, for unknown reasons, some 
slight stimulatory and cytotoxic activity was also observed for VLCD3-scFvHLA-A2 at 
the highest tested concentration (see Figs. 4.21, 4.22, and 4.26, pp. 83 + 84, 88), even 
though no binding was detected to Jurkat cells (CD3+ HLA-A2-) by flow cytometry (see 
Fig. 4.17, p. 77). Indeed, one can argue that the stimulation and cytotoxic assays are 
more sensitive than the binding studies in flow cytometry. Although the effect seems 
negligible, it remains to be determined whether it is utterly out of the question that 
VLCD3-scFvHLA-A2 shows some activity, if only minor, due to specific antigen binding 
by itself. Even though uncombined VL often have reduced affinity and solubility, they 
can retain noticeable antigen-binding specificity [Colby et al., 2004; van den Beucken 
et al., 2001; Mei et al., 1991; Edelman et al., 1963; Roholt et al., 1964; Sun et al., 
1994]. A more precise answer to that question for the present concept might be 
provided by binding studies with the bioluminescent protein Gaussia luciferase (GLuc) 
[Tannous et al., 2005] in fusion with a dimeric single-chain CD3 molecule following the 
example set by Law et al. [2002], who constructed a single-chain CD3δε-Ig fusion 
protein. Unfortunately, preliminary GLuc (ELISA) assays with CD3δε-GLuc from 
mammalian expression did not prove to be suitable for binding by scFvCD3, although it 
was bound well by an anti-CD3ɛ antibody (clone UCHT-1) (data not shown). Since 
most anti-CD3 antibodies recognise an immunodominant conformational epitope on 
CD3ε, which is only expressed when CD3ε is bound either to CD3δ or to CD3γ 
[Salmerón et al., 1991], CD3γε-GLuc and CD3γε were additionally constructed, but 
have not yet been tested. However, it remains possible that scFvCD3 has a different 
affinity for CD3δε than for CD3γε heterodimer or that the conformational epitope even 
depends on the intact TCR complex, like it was assumed for the anti-CD3ɛ antibody 
OKT3 [Kjer-Nielsen et al., 2004]. Moreover, scFvCD3 derives from the anti-CD3ɛ 
antibody TR66 [Lanzavecchia and Scheidegger, 1987; Traunecker et al., 1991], which 
does not recognise isolated CD3ɛ, whereas UCHT-1 does [Tunnacliffe et al., 1989]. 
Thus, it remains unclear, whether CD3γε-GLuc or CD3γε would be more suitable for 
binding by scFvCD3 than CD3δε-GLuc was. 
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Remarkably, the bispecific HLA-A2 × CD3 taFv fragments also had a stimulatory effect 
on HLA-A2-positive PBMC, regardless of whether HLA-A2-positive or -negative target 
cells were being used (see Fig. 4.19 B, p. 80). Thus, HLA-A2-positive T cells (HLA-A2+ 
CD45+ CD3+) seem to kill each other in the manner of fratricide. Such a scenario is also 
conceivable for the trispecific HLA-A2 × CD3 × CD45 antibody. It might be worth 
considering to benefit from this approach by treating the recipient (e.g. leukaemia 
patient) directly prior to the haematopoietic stem cell transplantation, since graft 
rejection may occur due to some remaining T cells of host origin. In this way, 
a complete elimination of malignant cells as well as a prevention of graft rejection could 
be realised at the same time.  
Another limiting factor of the present approach is the small size of the self-assembling 
constructs. With around 40 kDa in size they might be cleared rapidly from the blood 
circulation due to the renal filter with a cut-off of 60 kDa. For instance, the small 
antibody molecules scFv (~ 25 kDa) and scDb (~ 55 kDa, like taFv) exhibit terminal 
half-lives of only 1 – 4 h and 5 – 6 h, while albumin (~ 67 kDa) and IgG (~ 150 kDa) 
have a long half-life of 19 days and 3 – 4 weeks in humans, respectively [Müller and 
Kontermann, 2010]. A range of different approaches have therefore been developed to 
extend the circulation time of these molecules to facilitate application and to improve 
efficacy [Kontermann, 2009; 2011b]. At large, they intend either to enlarge the 
molecular weight by increasing the hydrodynamic radius, for example through 
PEGylation, or to use recycling processes mediated by the neonatal Fc receptor 
(FcRn). There are a few possibilities to achieve the latter strategy: i) fusion of the 
therapeutic molecule to Fc or to human serum albumin, or ii) binding of the therapeutic 
molecule to human serum albumin or IgG. However, before making any effort on half-
life extension, the present approach should first prove successful in vivo. Studies with 
mice are ongoing and will show if the promising in vitro findings can be confirmed. 
5.3 Conclusions and Future Directions 
In conclusion, both the bispecific AChRγ × CD3 antibody against rhabdomyosarcoma 
and the trispecific HLA-A2 × CD3 × CD45 antibody against blood cancer seem to be 
promising approaches for the recruitment of T cells. The dual antigen-restricted 
trispecific antibody approach in particular achieved astonishing results. Thus, providing 
T-cell activation, VLCD3-scFvHLA-A2 in conjunction with VHCD3-scFvCD45 are worth 
being tested in further assays, such as cytotoxicity assays, proliferation assays, and 
subsequent in vivo animal studies to confirm these findings and to evaluate their whole 
therapeutic potential for targeted cancer immunotherapy. Such assays and functional 
studies in mice are in progress. 
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7 Abbreviations 
µ micro (10-6) 
7-AAD 7-aminoactinomycin D, red fluorescent dye 
aa amino acid 
AChRγ, fAChR acetylcholine receptor gamma, fetal AChR 
APC antigen-presenting cell 
APS ammonium peroxodisulfate 
B7.1/B7.2 (CD80/CD86) costimulatory molecules 
BE Belgium 
BiTE bispecific T-cell engager 
bp base pairs 
BSA bovine serum albumin 
CD cluster of differentiation 
CD3 part of T-cell receptor complex implicated in T-cell activation 
CEA carcinoembryonic antigen, tumour antigen 
CFSE, CFDA SE 5-(6)-carboxyfluorescein diacetate, succinimidyl ester, green fluorescent dye 
CO2 carbon dioxide 
Db diabody 
DE Germany 
DMSO dimethyl sulfoxide 
DNA or cDNA deoxyribonucleic acid, coding DNA 
dNTP deoxyribonucleoside triphosphate 
DT diphtheria toxin 
EC50 half maximal effective concentration 
ECL enhanced chemiluminescence 
ECS enterokinase cleavage site (DYKDDDDK) 
EDTA ethylenediaminetetraacetic acid 
ELISA enzyme-linked immunosorbent assay 
E : T effector cell to target cell ratio 
ETA Pseudomonas exotoxin A 
Fab fragment antigen binding, part of an antibody, cleaved with enzyme papain 
FACS fluorescence activated cell sorter 
Fc Fragment crystallisable, constant part of an antibody 
FCS fetal calf serum, FBS 
Fig Figure 
FITC fluorescein-5-isothiocyanate, green fluorescent dye 
Flag polypeptide protein tag (DYKDDDDK) 
g standard gravity of earth, 9.80665 m/s2 
GFP11 green fluorescent protein, the smaller GFP fragment of the split GFP assay 
GLuc Gaussia luciferase 
h hours 
Her2/Her3 human epidermal growth factor receptor 2/3 
His6/10 polyhistidine-tag or cluster (HHHHHH or HHHHHHHHHH) 
H2SO4 sulphuric acid 
HAHA human anti-human antibody 
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HAMA human anti-mouse antibody 
HRP horseradish peroxidise, enzyme used for TMB/H2O2 colour reaction in ELISA 
Ig immunoglobulin 
IL-2 interleukin-2, T-cell growth factor 
IMAC Immobilised-metal affinity chromatography 
ITAM immunoreceptor tyrosine-based activation motif 
kDa kilo Dalton = 103 Dalton, unified atomic mass unit, 1 g/mol 
m milli (10-3) or meter 
M molar mass 
mAb monoclonal antibody 
mol amount of chemical substance 
MCS multiple cloning site 
MHC major histocompatibility complex 
MW molecular weight 
MWCO molecular weight cut-off 
n nano (10-9) 
OD600 optical density at 600 nm 
p pico (10-12) 
PAGE polyacrylamide gel electrophoresis 
pBM1.1 prokaryotic expression vector  
PBMC peripheral blood mononuclear cells 
PBS phosphate-buffered saline 
PCR polymerase chain reaction 
PE phycoerythrin, red fluorescent dye 
PEG polyethylene glycol 
Pen/Strep penicillin/streptomycin 
PHA-L phytohemagglutinin L, T-cell stimulant 
pIRESpuro2 eukaryotic expression vector 
pUC119 prokaryotic expression vector  
RT room temperature 
scDb single-chain diabody, bispecific antibody format 
scFv single-chain variable-fragment, comprises a monovalent binding site for the 
antigen 
SDS sodium dodecyl sulphate 
SE Sweden 
TAA tumour-associated antigen 
taFv tandem single-chain variable fragment (scFv), bispecific antibody format 
TCS thrombin cleavage site (LVRGS) 
TCR T-cell receptor 
TEMED N,N,N,N-Tetramethylethylendiamin  
TMB 3,3’,5,5’-tetramethylbenzidine, colour substrate in ELISA 
Tris tris(hydroxymethyl)aminomethane 
Tween polyoxyethylene sorbitan monolaurate 
U unit 
UK United Kingdom 
US United States 
V Volt 













  1  atgaaatacc tgctgccgac cgctgctgct ggtctgctgc tcctcgctgc ccagccggcg atggccatgg   
       m  k  y   l  l  p   t  a  a  a   g  l  l   l  l  a   a  q  p  a   m  a  m   
                                 pelB leader 
 
                                                                           HindIII…  
 71  gccatcatca tcatcatcat catcatcatc acagcagcgg ccatatcgac gacgacgaca agcatatgaa   
      g  h  h   h  h  h  h   h  h  h   h  s  s   g  h  i  d   d  d  d   k  h  m   
                   His cluster                                 ECS 
 
         .      SfiI     .         
141  gcttatggcc cagccggccg tgatgaccca gtctccatcc tccctgtctg catctgtagg agacagagtc   
     k  l  m  a   q  p  a   v  m  t   q  s  p  s   s  l  s   a  s  v   g  d  r  v   
 
211  accatcgctt gccgggcaag tcagaccatt agcaactatt taaattggta tcagcagaaa ccagggaaag   
       t  i  a   c  r  a   s  q  t  i   s  n  y   l  n  w   y  q  q  k   p  g  k   
 
281  cccctaagct cctgatctat ggtgcatcca gtttgcaaag tggggtccca tcaaggttca gtggcagtgg   
      a  p  k   l  l  i  y   g  a  s   s  l  q   s  g  v  p   s  r  f   s  g  s   
 
351  atctgggaca gatttcactc tcaccatcag cagtctgcaa cctgaagatt ttgcaactta ctactgtcaa   
     g  s  g  t   d  f  t   l  t  i   s  s  l  q   p  e  d   f  a  t   y  y  c  q   
 
421  cagagttaca gtacccctcc gacgtacact tttggccagg ggaccaagct ggagatcaaa ggtggcggtg   
       q  s  y   s  t  p   p  t  y  t   f  g  q   g  t  k   l  e  i  k   g  g  g .   
 
 
491  gctcgggcgg tggtgggtcg ggtggcagcg gatcatcggg gggcgacttg gtccagccgg gggggtccct   
      g  s  g   g  g  g  s   g  g  s   g  s  s   g  g  d  l   v  q  p   g  g  s   
          …(G4S)2-G2S-GS-linker (15 aa) 
 
561  gagagtctcc tgtgtagcct ctggatttac atttaggacc tatgtgatga actgggtccg ccaggctcca   
     l  r  v  s   c  v  a   s  g  f   t  f  r  t   y  v  m   n  w  v   r  q  a  p   
 
631  ggaaaggggc tggagtgggt ggcccacata agtccagagg gaactgaaga atactatgcg gaccctgtga   
       g  k  g   l  e  w   v  a  h  i   s  p  e   g  t  e   e  y  y  a   d  p  v   
 
701  agggccgatt taccgtctcc agagacaacg cgaagaattc agtatttctg caaatgaata gtctgagagg   
      k  g  r   f  t  v  s   r  d  n   a  k  n   s  v  f  l   q  m  n   s  l  r   
 
771  cgaggacacg gctgtgtatt attgcgcgag agtccgacgc tatggtccct ctacgctcag tccgttcacc   
     g  e  d  t   a  v  y   y  c  a   r  v  r  r   y  g  p   s  t  l   s  p  f  t   
 
                                                                             NotI…. 
841  tggaaggaca atcactacgc catggacgtc tggggccaag ggacaacggt caccgtctct ccagcggccg   
       w  k  d   n  h  y   a  m  d  v   w  g  q   g  t  t   v  t  v  s   p  a  a   
 
        SacI .    
911  cagagctcta gatgattagc tagatgatta g 
      a  e  l   *            *   
                    *            *   
                        *            *   
                   stop in 3 frames 
 
 Sequences 




                                                                      NcoI .  
                                                             SfiI     .  
  1  atgaaatacc tattgcctac ggcagccgct ggattgttat tactcgcggc ccagccggcc atggccgacg   
       m  k  y   l  l  p   t  a  a  a   g  l  l   l  l  a   a  q  p  a   m  a  d   
                                 pelB leader 
 
 71  tccaactggt gcagtcaggg gctgaagtga aaaaacctgg ggcctcagtg aaggtgtcct gcaaggcttc   
      v  q  l   v  q  s  g   a  e  v   k  k  p   g  a  s  v   k  v  s   c  k  a   
 
141  tggctacacc tttactaggt acacgatgca ctgggtaagg caggcacctg gacagggtct ggaatggatt   
     s  g  y  t   f  t  r   y  t  m   h  w  v  r   q  a  p   g  q  g   l  e  w  i   
 
211  ggatacatta atcctagccg tggttatact aattacgcag acagcgtcaa gggccgcttc acaatcacta   
       g  y  i   n  p  s   r  g  y  t   n  y  a   d  s  v   k  g  r  f   t  i  t   
 
281  cagacaaatc caccagcaca gcctacatgg aactgagcag cctgcgttct gaggacactg caacctatta   
      t  d  k   s  t  s  t   a  y  m   e  l  s   s  l  r  s   e  d  t   a  t  y   
 
351  ctgtgcaaga tattatgatg atcattactg ccttgactac tggggccaag gcaccacggt caccgtctcc   
     y  c  a  r   y  y  d   d  h  y   c  l  d  y   w  g  q   g  t  t   v  t  v  s   
 
                          AgeI .  
                   SpeI .  
421  tcaggcgaag gtactagtac cggttctggt ggaagtggag gttcaggtgg agcagacgac attgtactga   
       s  g  e   g  t  s   t  g  s  g   g  s  g   g  s  g   g  a  d  d   i  v  l   
                               18 aa linker 
 
491  cccagtctcc agcaactctg tctctgtctc caggggagcg tgccaccctg agctgcagag ccagtcaaag   
      t  q  s   p  a  t  l   s  l  s   p  g  e   r  a  t  l   s  c  r   a  s  q   
 
561  tgtaagttac atgaactggt accagcagaa gccgggcaag gcacccaaaa gatggattta tgacacatcc   
     s  v  s  y   m  n  w   y  q  q   k  p  g  k   a  p  k   r  w  i   y  d  t  s   
 
631  aaagtggctt ctggagtccc tgctcgcttc agtggcagtg ggtctgggac cgactactct ctcacaatca   
       k  v  a   s  g  v   p  a  r  f   s  g  s   g  s  g   t  d  y  s   l  t  i   
 
701  acagcttgga ggctgaagat gctgccactt attactgcca acagtggagt agtaacccgc tcacgttcgg   
      n  s  l   e  a  e  d   a  a  t   y  y  c   q  q  w  s   s  n  p   l  t  f   
 
                                         NotI  .  
                                 BamHI .  
771  tggcgggacc aaggtggaga tcaaaggatc cgcggccgcc gattacaagg atgacgacga taagggaggt   
     g  g  g  t   k  v  e   i  k  g   s  a  a  a   d  y  k   d  d  d   d  k  g  g   
                                                          Flag tag 
 
                                EcoRI           
841  catcaccatc atcaccatta ataagaattc   
       h  h  h   h  h  h   *  *   















                                                                      NcoI .  SpeI… 
  1  atgaaatacc tattgcctac ggcagccgct ggattgttat tactcgcggc ccagccggcc atggccacta   
       m  k  y   l  l  p   t  a  a  a   g  l  l   l  l  a   a  q  p  a   m  a  t   
                                 pelB leader 
 
       . 
 71  gtactggtca ggtgcagctg gtggaaagcg gtggcggact ggtgcagccg ggcggcagcc tgaaactgag   
      s  t  g   q  v  q  l   v  e  s   g  g  g   l  v  q  p   g  g  s   l  k  l   
 
141  ctgtgccgcc agcggttttg attttagccg ttattggatg agctgggtgc gtcaggcgcc gggcaaaggc   
     s  c  a  a   s  g  f   d  f  s   r  y  w  m   s  w  v   r  q  a   p  g  k  g   
 
211  ctggaatgga ttggcgaaat taacccgacc agcagcacca ttaactttac cccgagcctg aaagataaag   
       l  e  w   i  g  e   i  n  p  t   s  s  t   i  n  f   t  p  s  l   k  d  k   
 
281  tgtttattag ccgtgataac gcgaaaaaca ccctgtatct gcagatgagc aaagtgcgta gcgaagatac   
      v  f  i   s  r  d  n   a  k  n   t  l  y   l  q  m  s   k  v  r   s  e  d   
 
351  cgcgctgtat tattgcgcgc gtggcaacta ttatcgttat ggcgatgcga tggattattg gggccagggc   
     t  a  l  y   y  c  a   r  g  n   y  y  r  y   g  d  a   m  d  y   w  g  q  g   
 
                                                                     AgeI .  
421  accagcgtga ccgtgagcgg tggaggaggt tcaggaggag gtggttcagg aggaggtacc ggtgatattg   
       t  s  v   t  v  s   g  g  g  g   s  g  g   g  g  s   g  g  g  t   g  d  i   
                                   (G4S)2-G3-TG-linker (15 aa) 
 
491  ttctgaccca gagcccggcg agcctggcgg ttagcctggg tcagcgtgcc accattagct gccgtgcgag   
      v  l  t   q  s  p  a   s  l  a   v  s  l   g  q  r  a   t  i  s   c  r  a   
 
561  caaaagcgtg agcaccagcg gctatagcta tctgcattgg tatcagcaga aaccgggcca gcctccaaaa   
     s  k  s  v   s  t  s   g  y  s   y  l  h  w   y  q  q   k  p  g   q  p  p  k   
 
631  ctgctgattt atctggccag caacctggaa agcggtgtgc cggcccgttt tagcggcagc ggcagcggta   
       l  l  i   y  l  a   s  n  l  e   s  g  v   p  a  r   f  s  g  s   g  s  g   
 
701  ccgattttac cctgaacatt catccggtgg aagaagaaga tgcggcgacc tattattgcc agcatagccg   
      t  d  f   t  l  n  i   h  p  v   e  e  e   d  a  a  t   y  y  c   q  h  s   
 
                                                          NotI  .  
771  tgaactgccg tttacctttg gcagcggcac caaactggaa attaaagcgg ccgccgatta caaggatgac   
     r  e  l  p   f  t  f   g  s  g   t  k  l  e   i  k  a   a  a  d   y  k  d  d   
                                                                        Flag tag… 
 
841  gacgataagg gaggtcatca ccatcatcac cattaataa 
       d  d  k   g  g  h   h  h  h  h   h  *  * 

















                                                                      NcoI .  
  1  atgaaatacc tattgcctac ggcagccgct ggattgttat tactcgcggc ccagccggcc atggcaagca   
       m  k  y   l  l  p   t  a  a  a   g  l  l   l  l  a   a  q  p  a   m  a  s   
                                 pelB leader 
 
 71  gccatcacca tcatcaccat agcgattaca aggatgacga cgataagagc ggcctggtgc cgcgcggcag   
      s  h  h   h  h  h  h   s  d  y   k  d  d   d  d  k  s   g  l  v   p  r  g_ .    
             His tag                  Flag tag                            TCS… 
 
       AgeI .  
141  caccggtgat attgttctga cccagagccc ggcgagcctg gcggttagcc tgggtcagcg tgccaccatt   
     s  t  g  d   i  v  l   t  q  s   p  a  s  l   a  v  s   l  g  q   r  a  t  i   
 
 
211  agctgccgtg cgagcaaaag cgtgagcacc agcggctata gctatctgca ttggtatcag cagaaaccgg   
       s  c  r   a  s  k   s  v  s  t   s  g  y   s  y  l   h  w  y  q   q  k  p   
 
281  gccagcctcc aaaactgctg atttatctgg ccagcaacct ggaaagcggt gtgccggccc gttttagcgg   
      g  q  p   p  k  l  l   i  y  l   a  s  n   l  e  s  g   v  p  a   r  f  s   
 
351  cagcggcagc ggtaccgatt ttaccctgaa cattcatccg gtggaagaag aagatgcggc gacctattat   
     g  s  g  s   g  t  d   f  t  l   n  i  h  p   v  e  e   e  d  a   a  t  y  y   
 
421  tgccagcata gccgtgaact gccgtttacc tttggcagcg gcaccaaact ggaaattaaa aagatctctg   
       c  q  h   s  r  e   l  p  f  t   f  g  s   g  t  k   l  e  i  k   k  i  s .  
 
 
491  gtggcggcgg ctcgggtggt ggtgggtcgg gcggcggcgg ctcgagccag gtgcagctgg tggaaagcgg   
      g  g  g   g  s  g  g   g  g  s   g  g  g   g  s  s  q   v  q  l   v  e  s   
          …KIS-(G4S)3-S-linker (19 aa) 
 
561  tggcggactg gtgcagccgg gcggcagcct gaaactgagc tgtgccgcca gcggttttga ttttagccgt   
     g  g  g  l   v  q  p   g  g  s   l  k  l  s   c  a  a   s  g  f   d  f  s  r   
 
631  tattggatga gctgggtgcg tcaggcgccg ggcaaaggcc tggaatggat tggcgaaatt aacccgacca   
       y  w  m   s  w  v   r  q  a  p   g  k  g   l  e  w   i  g  e  i   n  p  t   
 
701  gcagcaccat taactttacc ccgagcctga aagataaagt gtttattagc cgtgataacg cgaaaaacac   
      s  s  t   i  n  f  t   p  s  l   k  d  k   v  f  i  s   r  d  n   a  k  n   
 
771  cctgtatctg cagatgagca aagtgcgtag cgaagatacc gcgctgtatt attgcgcgcg tggcaactat   
     t  l  y  l   q  m  s   k  v  r   s  e  d  t   a  l  y   y  c  a   r  g  n  y   
 
                                                                           EcoRI           
841  tatcgttatg gcgatgcgat ggattattgg ggccagggca ccagcgtgac cgtgagctaa taagaattc 


















                                                                      NcoI .  
  1  atgaaatacc tattgcctac ggcagccgct ggattgttat tactcgcggc ccagccggcc atggcccagg   
       m  k  y   l  l  p   t  a  a  a   g  l  l   l  l  a   a  q  p  a   m  a  q   
                                 pelB leader 
 
 71  tgcagctggt gcagtctggg ggaggcgtgg tccagcctgg ggggtccctg agagtctcct gtgcagcgtc   
      v  q  l   v  q  s  g   g  g  v   v  q  p   g  g  s  l   r  v  s   c  a  a   
 
141  tggggtcacc ctcagtgatt atggcatgca ttgggtccgc caggctccag gcaaggggct ggagtggatg   
     s  g  v  t   l  s  d   y  g  m   h  w  v  r   q  a  p   g  k  g   l  e  w  m   
 
211  gcttttatac ggaatgatgg aagtgataaa tattatgcag actccgtgaa gggccgattc accatctcca   
       a  f  i   r  n  d   g  s  d  k   y  y  a   d  s  v   k  g  r  f   t  i  s   
 
281  gagacaactc caagaaaaca gtgtctctgc aaatgagcag tctcagagct gaagacacgg ctgtgtatta   
      r  d  n   s  k  k  t   v  s  l   q  m  s   s  l  r  a   e  d  t   a  v  y   
 
351  ctgtgcgaaa aatggcgaat ctgggccttt ggactactgg tacttcgatc tctggggccg tggcaccctg   
     y  c  a  k   n  g  e   s  g  p   l  d  y  w   y  f  d   l  w  g   r  g  t  l   
 
421  gtcaccgtgt cgagtggtgg aggcggttca ggcggaggtg gctctggcgg tggcggatcg gatgttgtga   
       v  t  v   s  s  g   g  g  g  s   g  g  g   g  s  g   g  g  g  s   d  v  v   
                                   (G4S)3-linker (15 aa) 
 
491  tgactcagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc atcacttgcc aggcgagtca   
      m  t  q   s  p  s  s   l  s  a   s  v  g   d  r  v  t   i  t  c   q  a  s   
 
561  ggacattagc aactatttaa attggtatca gcagaaacca gggaaagccc ctaagctcct gatctacgat   
     q  d  i  s   n  y  l   n  w  y   q  q  k  p   g  k  a   p  k  l   l  i  y  d   
 
631  gcatccaatt tggaaacagg ggtcccatca aggttcagtg gaagtggatc tgggacagat tttactttca   
       a  s  n   l  e  t   g  v  p  s   r  f  s   g  s  g   s  g  t  d   f  t  f   
 
701  ccatcagcag cctgcagcct gaggattttg caacttatta ctgccaacaa tatagtagtt ttccgctcac   
      t  i  s   s  l  q  p   e  d  f   a  t  y   y  c  q  q   y  s  s   f  p  l   
 
                                             NotI  .  
771  tttcggcgga gggaccaaag tggatatcaa acgtgcggcc gcagaacaaa aactcatctc agaagaggat   
     t  f  g  g   g  t  k   v  d  i   k  r  a  a   a  e  q   k  l  i   s  e  e  d  
                                                                      myc tag… 
 
                                                EcoRI .          
841  ctgaatgggg ccgcacatca ccatcatcac cattaataag aattc 
       l  n  g   a  a  h   h  h  h  h   h  *  * 













Agnes Banaszek 119 
8.6 His-taFvAChR-CD3 
(in pBM1.1) 
VLAChR VHAChR VHCD3 VLCD3 
 
 
   1  atgaaatacc tgctgccgac cgctgctgct ggtctgctgc tcctcgctgc ccagccggcg atggccatgg   
        m  k  y   l  l  p   t  a  a  a   g  l  l   l  l  a   a  q  p  a   m  a  m   
                                 pelB leader 
 
  71  gccatcatca tcatcatcat catcatcatc acagcagcgg ccatatcgac gacgacgaca agcatatgaa   
       g  h  h   h  h  h  h   h  h  h   h  s  s   g  h  i  d   d  d  d   k  h  m   
                   His cluster                                  ECS 
 
 141  gcttatggcc cagccggccg tgatgaccca gtctccatcc tccctgtctg catctgtagg agacagagtc   
      k  l  m  a   q  p  a   v  m  t   q  s  p  s   s  l  s   a  s  v   g  d  r  v   
 
 211  accatcgctt gccgggcaag tcagaccatt agcaactatt taaattggta tcagcagaaa ccagggaaag   
        t  i  a   c  r  a   s  q  t  i   s  n  y   l  n  w   y  q  q  k   p  g  k   
 
 281  cccctaagct cctgatctat ggtgcatcca gtttgcaaag tggggtccca tcaaggttca gtggcagtgg   
       a  p  k   l  l  i  y   g  a  s   s  l  q   s  g  v  p   s  r  f   s  g  s   
 
 351  atctgggaca gatttcactc tcaccatcag cagtctgcaa cctgaagatt ttgcaactta ctactgtcaa   
      g  s  g  t   d  f  t   l  t  i   s  s  l  q   p  e  d   f  a  t   y  y  c  q   
 
 421  cagagttaca gtacccctcc gacgtacact tttggccagg ggaccaagct ggagatcaaa ggtggcggtg   
        q  s  y   s  t  p   p  t  y  t   f  g  q   g  t  k   l  e  i  k   g  g  g .  
 
 
 491  gctcgggcgg tggtgggtcg ggtggcagcg gatcatcggg gggcgacttg gtccagccgg gggggtccct   
       g  s  g   g  g  g  s   g  g  s   g  s  s   g  g  d  l   v  q  p   g  g  s   
        …(G4S)2-G2S-GS-linker (15 aa) 
 
 561  gagagtctcc tgtgtagcct ctggatttac atttaggacc tatgtgatga actgggtccg ccaggctcca   
      l  r  v  s   c  v  a   s  g  f   t  f  r  t   y  v  m   n  w  v   r  q  a  p   
 
 631  ggaaaggggc tggagtgggt ggcccacata agtccagagg gaactgaaga atactatgcg gaccctgtga   
        g  k  g   l  e  w   v  a  h  i   s  p  e   g  t  e   e  y  y  a   d  p  v   
 
 701  agggccgatt taccgtctcc agagacaacg cgaagaattc agtatttctg caaatgaata gtctgagagg   
       k  g  r   f  t  v  s   r  d  n   a  k  n   s  v  f  l   q  m  n   s  l  r   
 
 771  cgaggacacg gctgtgtatt attgcgcgag agtccgacgc tatggtccct ctacgctcag tccgttcacc   
      g  e  d  t   a  v  y   y  c  a   r  v  r  r   y  g  p   s  t  l   s  p  f  t   
 
                                                                             NotI…. 
 841  tggaaggaca atcactacgc catggacgtc tggggccaag ggacaacggt caccgtctct ccagcggccg   
        w  k  d   n  h  y   a  m  d  v   w  g  q   g  t  t   v  t  v  s   p  a  a .  
 
       . 
 911  caggtggttc agacgtccaa ctggtgcagt caggggctga agtgaaaaaa cctggggcct cagtgaaggt   
       a  g  g   s  d  v  q   l  v  q   s  g  a   e  v  k  k   p  g  a   s  v  k   
      …6 aa linker 
 
 981  gtcctgcaag gcttctggct acacctttac taggtacacg atgcactggg taaggcaggc acctggacag   
      v  s  c  k   a  s  g   y  t  f   t  r  y  t   m  h  w   v  r  q   a  p  g  q   
 
1051  ggtctggaat ggattggata cattaatcct agccgtggtt atactaatta cgcagacagc gtcaagggcc   
        g  l  e   w  i  g   y  i  n  p   s  r  g   y  t  n   y  a  d  s   v  k  g   
 
1121  gcttcacaat cactacagac aaatccacca gcacagccta catggaactg agcagcctgc gttctgagga   
       r  f  t   i  t  t  d   k  s  t   s  t  a   y  m  e  l   s  s  l   r  s  e   
 
1191  cactgcaacc tattactgtg caagatatta tgatgatcat tactgccttg actactgggg ccaaggcacc   
      d  t  a  t   y  y  c   a  r  y   y  d  d  h   y  c  l   d  y  w   g  q  g  t   
 
 Sequences 
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1261  acggtcaccg tctcctcagg cgaaggtact agtaccggtt ctggtggaag tggaggttca ggtggagcag   
        t  v  t   v  s  s   g  e  g  t   s  t  g   s  g  g   s  g  g  s   g  g  a .  
                                                         18 aa linker… 
 
1331  acgacattgt actgacccag tctccagcaa ctctgtctct gtctccaggg gagcgtgcca ccctgagctg   
       d  d  i   v  l  t  q   s  p  a   t  l  s   l  s  p  g   e  r  a   t  l  s   
 
 
1401  cagagccagt caaagtgtaa gttacatgaa ctggtaccag cagaagccgg gcaaggcacc caaaagatgg   
      c  r  a  s   q  s  v   s  y  m   n  w  y  q   q  k  p   g  k  a   p  k  r  w   
 
1471  atttatgaca catccaaagt ggcttctgga gtccctgctc gcttcagtgg cagtgggtct gggaccgact   
        i  y  d   t  s  k   v  a  s  g   v  p  a   r  f  s   g  s  g  s   g  t  d   
 
1541  actctctcac aatcaacagc ttggaggctg aagatgctgc cacttattac tgccaacagt ggagtagtaa   
       y  s  l   t  i  n  s   l  e  a   e  d  a   a  t  y  y   c  q  q   w  s  s   
 
                                                          SacI .   
1611  cccgctcacg ttcggtggcg ggaccaaggt ggagatcaaa taataagagc tc 






VLAChR VHAChR VHCD3 VLCD3 
 
                                                              SfiI     .  
   1  atgaaatacc tattgcctac ggcagccgct ggattgttat tactcgcggc ccagccggcc atggccgtga   
        m  k  y   l  l  p   t  a  a  a   g  l  l   l  l  a   a  q  p  a   m  a  v   
                                 pelB leader 
 
  71  tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc atcgcttgcc gggcaagtca   
       m  t  q   s  p  s  s   l  s  a   s  v  g   d  r  v  t   i  a  c   r  a  s   
 
 141  gaccattagc aactatttaa attggtatca gcagaaacca gggaaagccc ctaagctcct gatctatggt   
      q  t  i  s   n  y  l   n  w  y   q  q  k  p   g  k  a   p  k  l   l  i  y  g   
 
 211  gcatccagtt tgcaaagtgg ggtcccatca aggttcagtg gcagtggatc tgggacagat ttcactctca   
        a  s  s   l  q  s   g  v  p  s   r  f  s   g  s  g   s  g  t  d   f  t  l   
 
 281  ccatcagcag tctgcaacct gaagattttg caacttacta ctgtcaacag agttacagta cccctccgac   
       t  i  s   s  l  q  p   e  d  f   a  t  y   y  c  q  q   s  y  s   t  p  p   
 
 351  gtacactttt ggccagggga ccaagctgga gatcaaaggt ggcggtggct cgggcggtgg tgggtcgggt   
      t  y  t  f   g  q  g   t  k  l   e  i  k  g   g  g  g   s  g  g   g  g  s  g   
                                                      (G4S)2-G2S-GS-linker (15 aa)… 
 
 421  ggcagcggat catcgggggg cgacttggtc cagccggggg ggtccctgag agtctcctgt gtagcctctg   
        g  s  g   s  s  g   g  d  l  v   q  p  g   g  s  l   r  v  s  c   v  a  s   
 
 
 491  gatttacatt taggacctat gtgatgaact gggtccgcca ggctccagga aaggggctgg agtgggtggc   
       g  f  t   f  r  t  y   v  m  n   w  v  r   q  a  p  g   k  g  l   e  w  v   
 
 561  ccacataagt ccagagggaa ctgaagaata ctatgcggac cctgtgaagg gccgatttac cgtctccaga   
      a  h  i  s   p  e  g   t  e  e   y  y  a  d   p  v  k   g  r  f   t  v  s  r   
 
 631  gacaacgcga agaattcagt atttctgcaa atgaatagtc tgagaggcga ggacacggct gtgtattatt   
        d  n  a   k  n  s   v  f  l  q   m  n  s   l  r  g   e  d  t  a   v  y  y   
 
 701  gcgcgagagt ccgacgctat ggtccctcta cgctcagtcc gttcacctgg aaggacaatc actacgccat   




Agnes Banaszek 121 
                                                             SacI .   
 771  ggacgtctgg ggccaaggga caacggtcac cgtctctcca gcggccgcag agctcggtga cgtccaactg   
      m  d  v  w   g  q  g   t  t  v   t  v  s  p   a  a  a   e  l  g   d  v  q  l   
                                                      6 aa linker 
 
 841  gtgcagtcag gggctgaagt gaaaaaacct ggggcctcag tgaaggtgtc ctgcaaggct tctggctaca   
        v  q  s   g  a  e   v  k  k  p   g  a  s   v  k  v   s  c  k  a   s  g  y   
 
 911  cctttactag gtacacgatg cactgggtaa ggcaggcacc tggacagggt ctggaatgga ttggatacat   
       t  f  t   r  y  t  m   h  w  v   r  q  a   p  g  q  g   l  e  w   i  g  y   
 
 981  taatcctagc cgtggttata ctaattacgc agacagcgtc aagggccgct tcacaatcac tacagacaaa   
      i  n  p  s   r  g  y   t  n  y   a  d  s  v   k  g  r   f  t  i   t  t  d  k   
 
1051  tccaccagca cagcctacat ggaactgagc agcctgcgtt ctgaggacac tgcaacctat tactgtgcaa   
        s  t  s   t  a  y   m  e  l  s   s  l  r   s  e  d   t  a  t  y   y  c  a   
 
1121  gatattatga tgatcattac tgccttgact actggggcca aggcaccacg gtcaccgtct cctcaggcga   
       r  y  y   d  d  h  y   c  l  d   y  w  g   q  g  t  t   v  t  v   s  s  g  .   
 
 
1191  aggtactagt accggttctg gtggaagtgg aggttcaggt ggagcagacg acattgtact gacccagtct   
      e  g  t  s   t  g  s   g  g  s   g  g  s  g   g  a  d   d  i  v   l  t  q  s   
            …18 aa linker 
 
1261  ccagcaactc tgtctctgtc tccaggggag cgtgccaccc tgagctgcag agccagtcaa agtgtaagtt   
        p  a  t   l  s  l   s  p  g  e   r  a  t   l  s  c   r  a  s  q   s  v  s   
 
1331  acatgaactg gtaccagcag aagccgggca aggcacccaa aagatggatt tatgacacat ccaaagtggc   
       y  m  n   w  y  q  q   k  p  g   k  a  p   k  r  w  i   y  d  t   s  k  v   
 
1401  ttctggagtc cctgctcgct tcagtggcag tgggtctggg accgactact ctctcacaat caacagcttg   
      a  s  g  v   p  a  r   f  s  g   s  g  s  g   t  d  y   s  l  t   i  n  s  l   
 
1471  gaggctgaag atgctgccac ttattactgc caacagtgga gtagtaaccc gctcacgttc ggtggcggga   
        e  a  e   d  a  a   t  y  y  c   q  q  w   s  s  n   p  l  t  f   g  g  g   
 
                                  NotI  .  
1541  ccaaggtgga gatcaaagga tccgcggccg ccgattacaa ggatgacgac gataagggag gtcatcacca   
       t  k  v   e  i  k  g   s  a  a   a  d  y   k  d  d  d   d  k  g   g  h  h  .  
                                                  Flag tag 
 
1611  tcatcaccat taataa 
      h  h  h  h   *  * 






VHCD3 VLCD3 VLAChR VHAChR 
 
 
   1  atgaaatacc tgctgccgac cgctgctgct ggtctgctgc tcctcgctgc ccagccggcg atggccatgg   
        m  k  y   l  l  p   t  a  a  a   g  l  l   l  l  a   a  q  p  a   m  a  m   
                                 pelB leader 
   
                                                                           HindIII…  
  71  gccatcatca tcatcatcat catcatcatc acagcagcgg ccatatcgac gacgacgaca agcatatgaa   
       g  h  h   h  h  h  h   h  h  h   h  s  s   g  h  i  d   d  d  d   k  h  m   
                   His cluster                                  ECS 
          . 
 141  gcttgacgtc caactggtgc agtcaggggc tgaagtgaaa aaacctgggg cctcagtgaa ggtgtcctgc   
      k  l  d  v   q  l  v   q  s  g   a  e  v  k   k  p  g   a  s  v   k  v  s  c   
 
 Sequences 
Agnes Banaszek 122 
 211  aaggcttctg gctacacctt tactaggtac acgatgcact gggtaaggca ggcacctgga cagggtctgg   
        k  a  s   g  y  t   f  t  r  y   t  m  h   w  v  r   q  a  p  g   q  g  l   
 
 281  aatggattgg atacattaat cctagccgtg gttatactaa ttacgcagac agcgtcaagg gccgcttcac   
       e  w  i   g  y  i  n   p  s  r   g  y  t   n  y  a  d   s  v  k   g  r  f   
 
 351  aatcactaca gacaaatcca ccagcacagc ctacatggaa ctgagcagcc tgcgttctga ggacactgca   
      t  i  t  t   d  k  s   t  s  t   a  y  m  e   l  s  s   l  r  s   e  d  t  a   
 
 421  acctattact gtgcaagata ttatgatgat cattactgcc ttgactactg gggccaaggc accacggtca   
        t  y  y   c  a  r   y  y  d  d   h  y  c   l  d  y   w  g  q  g   t  t  v   
 
 491  ccgtctcctc aggcgaaggt actagtaccg gttctggtgg aagtggaggt tcaggtggag cagacgacat   
       t  v  s   s  g  e  g   t  s  t   g  s  g   g  s  g  g   s  g  g   a  d  d   
                                         18 aa linker 
 
 561  tgtactgacc cagtctccag caactctgtc tctgtctcca ggggagcgtg ccaccctgag ctgcagagcc   
      i  v  l  t   q  s  p   a  t  l   s  l  s  p   g  e  r   a  t  l   s  c  r  a   
 
 631  agtcaaagtg taagttacat gaactggtac cagcagaagc cgggcaaggc acccaaaaga tggatttatg   
        s  q  s   v  s  y   m  n  w  y   q  q  k   p  g  k   a  p  k  r   w  i  y   
 
 701  acacatccaa agtggcttct ggagtccctg ctcgcttcag tggcagtggg tctgggaccg actactctct   
       d  t  s   k  v  a  s   g  v  p   a  r  f   s  g  s  g   s  g  t   d  y  s   
 
 771  cacaatcaac agcttggagg ctgaagatgc tgccacttat tactgccaac agtggagtag taacccgctc   
      l  t  i  n   s  l  e   a  e  d   a  a  t  y   y  c  q   q  w  s   s  n  p  l   
 
                                                 SfiI     .  
 841  acgttcggtg gcgggaccaa ggtggagatc aaatcggccc agccggccgt gatgacccag tctccatcct   
        t  f  g   g  g  t   k  v  e  i   k  s  a   q  p  a   v  m  t  q   s  p  s   
                                             5 aa linker 
 
 911  ccctgtctgc atctgtagga gacagagtca ccatcgcttg ccgggcaagt cagaccatta gcaactattt   
       s  l  s   a  s  v  g   d  r  v   t  i  a   c  r  a  s   q  t  i   s  n  y   
 
 981  aaattggtat cagcagaaac cagggaaagc ccctaagctc ctgatctatg gtgcatccag tttgcaaagt   
      l  n  w  y   q  q  k   p  g  k   a  p  k  l   l  i  y   g  a  s   s  l  q  s   
 
1051  ggggtcccat caaggttcag tggcagtgga tctgggacag atttcactct caccatcagc agtctgcaac   
        g  v  p   s  r  f   s  g  s  g   s  g  t   d  f  t   l  t  i  s   s  l  q   
 
1121  ctgaagattt tgcaacttac tactgtcaac agagttacag tacccctccg acgtacactt ttggccaggg   
       p  e  d   f  a  t  y   y  c  q   q  s  y   s  t  p  p   t  y  t   f  g  q   
 
1191  gaccaagctg gagatcaaag gtggcggtgg ctcgggcggt ggtgggtcgg gtggcagcgg atcatcgggg   
      g  t  k  l   e  i  k   g  g  g   g  s  g  g   g  g  s   g  g  s   g  s  s  g   
                                     (G4S)2-G2S-GS-linker (15 aa) 
 
1261  ggcgacttgg tccagccggg ggggtccctg agagtctcct gtgtagcctc tggatttaca tttaggacct   
        g  d  l   v  q  p   g  g  s  l   r  v  s   c  v  a   s  g  f  t   f  r  t   
 
1331  atgtgatgaa ctgggtccgc caggctccag gaaaggggct ggagtgggtg gcccacataa gtccagaggg   
       y  v  m   n  w  v  r   q  a  p   g  k  g   l  e  w  v   a  h  i   s  p  e   
 
1401  aactgaagaa tactatgcgg accctgtgaa gggccgattt accgtctcca gagacaacgc gaagaattca   
      g  t  e  e   y  y  a   d  p  v   k  g  r  f   t  v  s   r  d  n   a  k  n  s   
 
1471  gtatttctgc aaatgaatag tctgagaggc gaggacacgg ctgtgtatta ttgcgcgaga gtccgacgct   
        v  f  l   q  m  n   s  l  r  g   e  d  t   a  v  y   y  c  a  r   v  r  r   
 
1541  atggtccctc tacgctcagt ccgttcacct ggaaggacaa tcactacgcc atggacgtct ggggccaagg   
       y  g  p   s  t  l  s   p  f  t   w  k  d   n  h  y  a   m  d  v   w  g  q   
 
1611  gacaacggtc accgtctctc cagcggccgc agagctctag atgattagct agatgattag   
      g  t  t  v   t  v  s   p  a  a   a  e  l  *             *   
                                                     *            *   
                                                         *            *   
                                                    stop in 3 frames 
 Sequences 
Agnes Banaszek 123 
8.9 taFvCD3-AChR-FlagHis 
(in pUC119) 
VHCD3 VLCD3 VLAChR VHAChR 
                                                                       NcoI .  
                                                              SfiI     .  
   1  atgaaatacc tattgcctac ggcagccgct ggattgttat tactcgcggc ccagccggcc atggccgacg   
        m  k  y   l  l  p   t  a  a  a   g  l  l   l  l  a   a  q  p  a   m  a  d   
                                 pelB leader 
 
  71  tccaactggt gcagtcaggg gctgaagtga aaaaacctgg ggcctcagtg aaggtgtcct gcaaggcttc   
       v  q  l   v  q  s  g   a  e  v   k  k  p   g  a  s  v   k  v  s   c  k  a   
 
 141  tggctacacc tttactaggt acacgatgca ctgggtaagg caggcacctg gacagggtct ggaatggatt   
      s  g  y  t   f  t  r   y  t  m   h  w  v  r   q  a  p   g  q  g   l  e  w  i   
 
 211  ggatacatta atcctagccg tggttatact aattacgcag acagcgtcaa gggccgcttc acaatcacta   
        g  y  i   n  p  s   r  g  y  t   n  y  a   d  s  v   k  g  r  f   t  i  t   
 
 281  cagacaaatc caccagcaca gcctacatgg aactgagcag cctgcgttct gaggacactg caacctatta   
       t  d  k   s  t  s  t   a  y  m   e  l  s   s  l  r  s   e  d  t   a  t  y   
 
 351  ctgtgcaaga tattatgatg atcattactg ccttgactac tggggccaag gcaccacggt caccgtctcc   
      y  c  a  r   y  y  d   d  h  y   c  l  d  y   w  g  q   g  t  t   v  t  v  s   
 
 421  tcaggcgaag gtactagtac cggttctggt ggaagtggag gttcaggtgg agcagacgac attgtactga   
        s  g  e   g  t  s   t  g  s  g   g  s  g   g  s  g   g  a  d  d   i  v  l   
                                18 aa linker 
 
 491  cccagtctcc agcaactctg tctctgtctc caggggagcg tgccaccctg agctgcagag ccagtcaaag   
       t  q  s   p  a  t  l   s  l  s   p  g  e   r  a  t  l   s  c  r   a  s  q   
 
 561  tgtaagttac atgaactggt accagcagaa gccgggcaag gcacccaaaa gatggattta tgacacatcc   
      s  v  s  y   m  n  w   y  q  q   k  p  g  k   a  p  k   r  w  i   y  d  t  s   
 
 631  aaagtggctt ctggagtccc tgctcgcttc agtggcagtg ggtctgggac cgactactct ctcacaatca   
        k  v  a   s  g  v   p  a  r  f   s  g  s   g  s  g   t  d  y  s   l  t  i   
 
 701  acagcttgga ggctgaagat gctgccactt attactgcca acagtggagt agtaacccgc tcacgttcgg   
       n  s  l   e  a  e  d   a  a  t   y  y  c   q  q  w  s   s  n  p   l  t  f   
 
                                  BamHI . 
 771  tggcgggacc aaggtggaga tcaaaggatc cggtggaggt tcagtgatga cccagtctcc atcctccctg   
      g  g  g  t   k  v  e   i  k  g   s  g  g  g   s  v  m   t  q  s   p  s  s  l   
                                      6 aa linker 
 
 841  tctgcatctg taggagacag agtcaccatc gcttgccggg caagtcagac cattagcaac tatttaaatt   
        s  a  s   v  g  d   r  v  t  i   a  c  r   a  s  q   t  i  s  n   y  l  n   
 
 911  ggtatcagca gaaaccaggg aaagccccta agctcctgat ctatggtgca tccagtttgc aaagtggggt   
       w  y  q   q  k  p  g   k  a  p   k  l  l   i  y  g  a   s  s  l   q  s  g   
 
 981  cccatcaagg ttcagtggca gtggatctgg gacagatttc actctcacca tcagcagtct gcaacctgaa   
      v  p  s  r   f  s  g   s  g  s   g  t  d  f   t  l  t   i  s  s   l  q  p  e   
 
1051  gattttgcaa cttactactg tcaacagagt tacagtaccc ctccgacgta cacttttggc caggggacca   
        d  f  a   t  y  y   c  q  q  s   y  s  t   p  p  t   y  t  f  g   q  g  t   
 
1121  agctggagat caaaggtggc ggtggctcgg gcggtggtgg gtcgggtggc agcggatcat cggggggcga   
       k  l  e   i  k  g  g   g  g  s   g  g  g   g  s  g  g   s  g  s   s  g  g   
                                     (G4S)2-G2S-GS-linker (15 aa) 
 
1191  cttggtccag ccgggggggt ccctgagagt ctcctgtgta gcctctggat ttacatttag gacctatgtg   
      d  l  v  q   p  g  g   s  l  r   v  s  c  v   a  s  g   f  t  f   r  t  y  v   
 
1261  atgaactggg tccgccaggc tccaggaaag gggctggagt gggtggccca cataagtcca gagggaactg   
        m  n  w   v  r  q   a  p  g  k   g  l  e   w  v  a   h  i  s  p   e  g  t   
 Sequences 
Agnes Banaszek 124 
 
1331  aagaatacta tgcggaccct gtgaagggcc gatttaccgt ctccagagac aacgcgaaga attcagtatt   
       e  e  y   y  a  d  p   v  k  g   r  f  t   v  s  r  d   n  a  k   n  s  v   
 
1401  tctgcaaatg aatagtctga gaggcgagga cacggctgtg tattattgcg cgagagtccg acgctatggt   
      f  l  q  m   n  s  l   r  g  e   d  t  a  v   y  y  c   a  r  v   r  r  y  g   
 
1471  ccctctacgc tcagtccgtt cacctggaag gacaatcact acgccatgga cgtctggggc caagggacaa   
        p  s  t   l  s  p   f  t  w  k   d  n  h   y  a  m   d  v  w  g   q  g  t   
 
                           NotI  .  
1541  cggtcaccgt ctctccagcg gccgccgatt acaaggatga cgacgataag ggaggtcatc accatcatca   
       t  v  t   v  s  p  a   a  a  d   y  k  d   d  d  d  k   g  g  h   h  h  h  .   
                                           Flag tag                       His tag… 
 
1611  ccattaataa   




8.10 taFvCD3-HLA-A2-FlagHis / -mycHis 
(in pUC119) 
VHCD3 VLCD3 VHHLA-A2 VLHLA-A2 
                                                                       NcoI .  
                                                              SfiI     .  
   1  atgaaatacc tattgcctac ggcagccgct ggattgttat tactcgcggc ccagccggcc atggccgacg   
        m  k  y   l  l  p   t  a  a  a   g  l  l   l  l  a   a  q  p  a   m  a  d   
                                 pelB leader 
 
  71  tccaactggt gcagtcaggg gctgaagtga aaaaacctgg ggcctcagtg aaggtgtcct gcaaggcttc   
       v  q  l   v  q  s  g   a  e  v   k  k  p   g  a  s  v   k  v  s   c  k  a   
 
 141  tggctacacc tttactaggt acacgatgca ctgggtaagg caggcacctg gacagggtct ggaatggatt   
      s  g  y  t   f  t  r   y  t  m   h  w  v  r   q  a  p   g  q  g   l  e  w  i   
 
 211  ggatacatta atcctagccg tggttatact aattacgcag acagcgtcaa gggccgcttc acaatcacta   
        g  y  i   n  p  s   r  g  y  t   n  y  a   d  s  v   k  g  r  f   t  i  t   
 
 281  cagacaaatc caccagcaca gcctacatgg aactgagcag cctgcgttct gaggacactg caacctatta   
       t  d  k   s  t  s  t   a  y  m   e  l  s   s  l  r  s   e  d  t   a  t  y   
 
 351  ctgtgcaaga tattatgatg atcattactg ccttgactac tggggccaag gcaccacggt caccgtctcc   
      y  c  a  r   y  y  d   d  h  y   c  l  d  y   w  g  q   g  t  t   v  t  v  s   
 
 421  tcaggcgaag gtactagtac cggttctggt ggaagtggag gttcaggtgg agcagacgac attgtactga   
        s  g  e   g  t  s   t  g  s  g   g  s  g   g  s  g   g  a  d  d   i  v  l   
                                18 aa linker 
 
 491  cccagtctcc agcaactctg tctctgtctc caggggagcg tgccaccctg agctgcagag ccagtcaaag   
       t  q  s   p  a  t  l   s  l  s   p  g  e   r  a  t  l   s  c  r   a  s  q   
 
 561  tgtaagttac atgaactggt accagcagaa gccgggcaag gcacccaaaa gatggattta tgacacatcc   
      s  v  s  y   m  n  w   y  q  q   k  p  g  k   a  p  k   r  w  i   y  d  t  s   
 
 631  aaagtggctt ctggagtccc tgctcgcttc agtggcagtg ggtctgggac cgactactct ctcacaatca   
        k  v  a   s  g  v   p  a  r  f   s  g  s   g  s  g   t  d  y  s   l  t  i   
 
 701  acagcttgga ggctgaagat gctgccactt attactgcca acagtggagt agtaacccgc tcacgttcgg   
       n  s  l   e  a  e  d   a  a  t   y  y  c   q  q  w  s   s  n  p   l  t  f   
 
                                  BamHI .  
 771  tggcgggacc aaggtggaga tcaaaggatc cggtggagga ggttcacagg tgcagctggt gcagtctggg   
      g  g  g  t   k  v  e   i  k  g   s  g  g  g   g  s  q   v  q  l   v  q  s  g   
                                      7 aa linker 
 
 Sequences 
Agnes Banaszek 125 
 841  ggaggcgtgg tccagcctgg ggggtccctg agagtctcct gtgcagcgtc tggggtcacc ctcagtgatt   
        g  g  v   v  q  p   g  g  s  l   r  v  s   c  a  a   s  g  v  t   l  s  d   
 
 911  atggcatgca ttgggtccgc caggctccag gcaaggggct ggagtggatg gcttttatac ggaatgatgg   
       y  g  m   h  w  v  r   q  a  p   g  k  g   l  e  w  m   a  f  i   r  n  d   
 
 981  aagtgataaa tattatgcag actccgtgaa gggccgattc accatctcca gagacaactc caagaaaaca   
      g  s  d  k   y  y  a   d  s  v   k  g  r  f   t  i  s   r  d  n   s  k  k  t   
 
1051  gtgtctctgc aaatgagcag tctcagagct gaagacacgg ctgtgtatta ctgtgcgaaa aatggcgaat   
        v  s  l   q  m  s   s  l  r  a   e  d  t   a  v  y   y  c  a  k   n  g  e   
 
1121  ctgggccttt ggactactgg tacttcgatc tctggggccg tggcaccctg gtcaccgtgt cgagtggtgg   
       s  g  p   l  d  y  w   y  f  d   l  w  g   r  g  t  l   v  t  v   s  s  g  .   
 
 
1191  aggcggttca ggcggaggtg gctctggcgg tggcggatcg gatgttgtga tgactcagtc tccatcctcc   
      g  g  g  s   g  g  g   g  s  g   g  g  g  s   d  v  v   m  t  q   s  p  s  s   
          …(G4S)3-linker (15 aa) 
 
1261  ctgtctgcat ctgtaggaga cagagtcacc atcacttgcc aggcgagtca ggacattagc aactatttaa   
        l  s  a   s  v  g   d  r  v  t   i  t  c   q  a  s   q  d  i  s   n  y  l   
 
1331  attggtatca gcagaaacca gggaaagccc ctaagctcct gatctacgat gcatccaatt tggaaacagg   
       n  w  y   q  q  k  p   g  k  a   p  k  l   l  i  y  d   a  s  n   l  e  t   
 
1401  ggtcccatca aggttcagtg gaagtggatc tgggacagat tttactttca ccatcagcag cctgcagcct   
      g  v  p  s   r  f  s   g  s  g   s  g  t  d   f  t  f   t  i  s   s  l  q  p   
 
1471  gaggattttg caacttatta ctgccaacaa tatagtagtt ttccgctcac tttcggcgga gggaccaaag   
        e  d  f   a  t  y   y  c  q  q   y  s  s   f  p  l   t  f  g  g   g  t  k   
 
                        NotI  .  
1541  tggatatcaa acgtgcggcc gccgattaca aggatgacga cgataaggga ggtcatcacc atcatcacca   
       v  d  i   k  r  a  a   a  d  y   k  d  d   d  d  k  g   g  h  h   h  h  h  .   
                                        Flag tag                          His tag… 
 
1611  ttaataa 






...    
 
 
                        NotI  .  
1541  tggatatcaa acgtgcggcc gcagaacaaa aactcatctc agaagaggat ctgaatgggg ccgcacatca   
       v  d  i   k  r  a  a   a  e  q   k  l  i   s  e  e  d   l  n  g   a  a  h  .   
                                            myc tag  
 
1611  ccatcatcac cattaataa 
      h  h  h  h   h  *  * 
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8.11 taFvHLA-A2-CD3-FlagHis / -mycHis 
(in pUC119) 
VHHLA-A2 VLHLA-A2 VHCD3 VLCD3 
                                                                       NcoI .  
                                                              SfiI     .  
   1  atgaaatacc tattgcctac ggcagccgct ggattgttat tactcgcggc ccagccggcc atggcccagg   
        m  k  y   l  l  p   t  a  a  a   g  l  l   l  l  a   a  q  p  a   m  a  q   
                                 pelB leader 
 
  71  tgcagctggt gcagtctggg ggaggcgtgg tccagcctgg ggggtccctg agagtctcct gtgcagcgtc   
       v  q  l   v  q  s  g   g  g  v   v  q  p   g  g  s  l   r  v  s   c  a  a   
 
 141  tggggtcacc ctcagtgatt atggcatgca ttgggtccgc caggctccag gcaaggggct ggagtggatg   
      s  g  v  t   l  s  d   y  g  m   h  w  v  r   q  a  p   g  k  g   l  e  w  m   
 
 211  gcttttatac ggaatgatgg aagtgataaa tattatgcag actccgtgaa gggccgattc accatctcca   
        a  f  i   r  n  d   g  s  d  k   y  y  a   d  s  v   k  g  r  f   t  i  s   
 
 281  gagacaactc caagaaaaca gtgtctctgc aaatgagcag tctcagagct gaagacacgg ctgtgtatta   
       r  d  n   s  k  k  t   v  s  l   q  m  s   s  l  r  a   e  d  t   a  v  y   
 
 351  ctgtgcgaaa aatggcgaat ctgggccttt ggactactgg tacttcgatc tctggggccg tggcaccctg   
      y  c  a  k   n  g  e   s  g  p   l  d  y  w   y  f  d   l  w  g   r  g  t  l   
 
 421  gtcaccgtgt cgagtggtgg aggcggttca ggcggaggtg gctctggcgg tggcggatcg gatgttgtga   
        v  t  v   s  s  g   g  g  g  s   g  g  g   g  s  g   g  g  g  s   d  v  v   
                                   (G4S)3-linker (15 aa) 
 
 491  tgactcagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc atcacttgcc aggcgagtca   
       m  t  q   s  p  s  s   l  s  a   s  v  g   d  r  v  t   i  t  c   q  a  s   
 
 561  ggacattagc aactatttaa attggtatca gcagaaacca gggaaagccc ctaagctcct gatctacgat   
      q  d  i  s   n  y  l   n  w  y   q  q  k  p   g  k  a   p  k  l   l  i  y  d   
 
 631  gcatccaatt tggaaacagg ggtcccatca aggttcagtg gaagtggatc tgggacagat tttactttca   
        a  s  n   l  e  t   g  v  p  s   r  f  s   g  s  g   s  g  t  d   f  t  f   
 
 701  ccatcagcag cctgcagcct gaggattttg caacttatta ctgccaacaa tatagtagtt ttccgctcac   
       t  i  s   s  l  q  p   e  d  f   a  t  y   y  c  q  q   y  s  s   f  p  l   
 
                                                      SacI . 
 771  tttcggcgga gggaccaaag tggatatcaa acgtggtggc ggagagctcg gtgacgtcca actggtgcag   
      t  f  g  g   g  t  k   v  d  i   k  r  g  g   g  e  l   g  d  v   q  l  v  q   
                                                6 aa linker 
 
 841  tcaggggctg aagtgaaaaa acctggggcc tcagtgaagg tgtcctgcaa ggcttctggc tacaccttta   
        s  g  a   e  v  k   k  p  g  a   s  v  k   v  s  c   k  a  s  g   y  t  f   
 
 911  ctaggtacac gatgcactgg gtaaggcagg cacctggaca gggtctggaa tggattggat acattaatcc   
       t  r  y   t  m  h  w   v  r  q   a  p  g   q  g  l  e   w  i  g   y  i  n   
 
 981  tagccgtggt tatactaatt acgcagacag cgtcaagggc cgcttcacaa tcactacaga caaatccacc   
      p  s  r  g   y  t  n   y  a  d   s  v  k  g   r  f  t   i  t  t   d  k  s  t   
 
1051  agcacagcct acatggaact gagcagcctg cgttctgagg acactgcaac ctattactgt gcaagatatt   
        s  t  a   y  m  e   l  s  s  l   r  s  e   d  t  a   t  y  y  c   a  r  y   
 
1121  atgatgatca ttactgcctt gactactggg gccaaggcac cacggtcacc gtctcctcag gcgaaggtac   
       y  d  d   h  y  c  l   d  y  w   g  q  g   t  t  v  t   v  s  s   g  e  g  .   
 
 
1191  tagtaccggt tctggtggaa gtggaggttc aggtggagca gacgacattg tactgaccca gtctccagca   
      t  s  t  g   s  g  g   s  g  g   s  g  g  a   d  d  i   v  l  t   q  s  p  a   
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1261  actctgtctc tgtctccagg ggagcgtgcc accctgagct gcagagccag tcaaagtgta agttacatga   
        t  l  s   l  s  p   g  e  r  a   t  l  s   c  r  a   s  q  s  v   s  y  m   
 
1331  actggtacca gcagaagccg ggcaaggcac ccaaaagatg gatttatgac acatccaaag tggcttctgg   
       n  w  y   q  q  k  p   g  k  a   p  k  r   w  i  y  d   t  s  k   v  a  s   
 
1401  agtccctgct cgcttcagtg gcagtgggtc tgggaccgac tactctctca caatcaacag cttggaggct   
      g  v  p  a   r  f  s   g  s  g   s  g  t  d   y  s  l   t  i  n   s  l  e  a   
 
1471  gaagatgctg ccacttatta ctgccaacag tggagtagta acccgctcac gttcggtggc gggaccaagg   
        e  d  a   a  t  y   y  c  q  q   w  s  s   n  p  l   t  f  g  g   g  t  k   
 
                           NotI  .  
1541  tggagatcaa aggatccgcg gccgccgatt acaaggatga cgacgataag ggaggtcatc accatcatca   
       v  e  i   k  g  s  a   a  a  d   y  k  d   d  d  d  k   g  g  h   h  h  h  .   
                                        Flag tag                          His tag… 
 
1611  ccattaataa   






...    
 
 
                           NotI  .  
1541  tggagatcaa aggatccgcg gccgcagaac aaaaactcat ctcagaagag gatctgaatg gggccgcaca   
       v  e  i   k  g  s  a   a  a  e   q  k  l   i  s  e  e   d  l  n   g  a  a__   
                                                myc tag  
 
1611  tcaccatcat caccattaat aa 
      h  h  h  h   h  h  *   * 
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8.12 VHCD3-scFvCD45(VH-VL)-FlagHis 
(in pUC119) 
VHCD3 VHCD45 VLCD45 
 
 
   1  atgaaatacc tattgcctac ggcagccgct ggattgttat tactcgcggc ccagccggcc atggccgacg   
        m  k  y   l  l  p   t  a  a  a   g  l  l   l  l  a   a  q  p  a   m  a  d   
                                 pelB leader 
 
  71  tccaactggt gcagtcaggg gctgaagtga aaaaacctgg ggcctcagtg aaggtgtcct gcaaggcttc   
       v  q  l   v  q  s  g   a  e  v   k  k  p   g  a  s  v   k  v  s   c  k  a   
 
 141  tggctacacc tttactaggt acacgatgca ctgggtaagg caggcacctg gacagggtct ggaatggatt   
      s  g  y  t   f  t  r   y  t  m   h  w  v  r   q  a  p   g  q  g   l  e  w  i   
 
 211  ggatacatta atcctagccg tggttatact aattacgcag acagcgtcaa gggccgcttc acaatcacta   
        g  y  i   n  p  s   r  g  y  t   n  y  a   d  s  v   k  g  r  f   t  i  t   
 
 281  cagacaaatc caccagcaca gcctacatgg aactgagcag cctgcgttct gaggacactg caacctatta   
       t  d  k   s  t  s  t   a  y  m   e  l  s   s  l  r  s   e  d  t   a  t  y   
 
 351  ctgtgcaaga tattatgatg atcattactg ccttgactac tggggccaag gcaccacggt caccgtctcc   
      y  c  a  r   y  y  d   d  h  y   c  l  d  y   w  g  q   g  t  t   v  t  v  s   
 
                    SpeI . 
 421  tcaggcgaag gtactagtac tggtcaggtg cagctggtgg aaagcggtgg cggactggtg cagccgggcg   
        s  g  e   g  t  s   t  g  q  v   q  l  v   e  s  g   g  g  l  v   q  p  g   
               7 aa linker 
 
 491  gcagcctgaa actgagctgt gccgccagcg gttttgattt tagccgttat tggatgagct gggtgcgtca   
       g  s  l   k  l  s  c   a  a  s   g  f  d   f  s  r  y   w  m  s   w  v  r   
 
 561  ggcgccgggc aaaggcctgg aatggattgg cgaaattaac ccgaccagca gcaccattaa ctttaccccg   
      q  a  p  g   k  g  l   e  w  i   g  e  i  n   p  t  s   s  t  i   n  f  t  p   
 
 631  agcctgaaag ataaagtgtt tattagccgt gataacgcga aaaacaccct gtatctgcag atgagcaaag   
        s  l  k   d  k  v   f  i  s  r   d  n  a   k  n  t   l  y  l  q   m  s  k   
 
 701  tgcgtagcga agataccgcg ctgtattatt gcgcgcgtgg caactattat cgttatggcg atgcgatgga   
       v  r  s   e  d  t  a   l  y  y   c  a  r   g  n  y  y   r  y  g   d  a  m   
 
 771  ttattggggc cagggcacca gcgtgaccgt gagcggtgga ggaggttcag gaggaggtgg ttcaggagga   
      d  y  w  g   q  g  t   s  v  t   v  s  g  g   g  g  s   g  g  g   g  s  g  g   
                                                     (G4S)2-G3-TG-linker (15 aa)… 
 
 841  ggtaccggtg atattgttct gacccagagc ccggcgagcc tggcggttag cctgggtcag cgtgccacca   
        g  t  g   d  i  v   l  t  q  s   p  a  s   l  a  v   s  l  g  q   r  a  t   
 
 
 911  ttagctgccg tgcgagcaaa agcgtgagca ccagcggcta tagctatctg cattggtatc agcagaaacc   
       i  s  c   r  a  s  k   s  v  s   t  s  g   y  s  y  l   h  w  y   q  q  k   
 
 981  gggccagcct ccaaaactgc tgatttatct ggccagcaac ctggaaagcg gtgtgccggc ccgttttagc   
      p  g  q  p   p  k  l   l  i  y   l  a  s  n   l  e  s   g  v  p   a  r  f  s   
 
1051  ggcagcggca gcggtaccga ttttaccctg aacattcatc cggtggaaga agaagatgcg gcgacctatt   
        g  s  g   s  g  t   d  f  t  l   n  i  h   p  v  e   e  e  d  a   a  t  y   
 
1121  attgccagca tagccgtgaa ctgccgttta cctttggcag cggcaccaaa ctggaaatta aagcggccgc   
       y  c  q   h  s  r  e   l  p  f   t  f  g   s  g  t  k   l  e  i   k  a  a   
 
1191  cgattacaag gatgacgacg ataagggagg tcatcaccat catcaccatt aataa 
      a  d  y  k   d  d  d   d  k  g   g  h  h  h   h  h  h   *  * 
                Flag tag                      His tag 
 Sequences 
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8.13 VHCD3-scFvCD45(VL-VH)-FlagHis 
(in pUC119) 
VHCD3 VLCD45 VHCD45 
                                                                       NcoI .  
                                                              SfiI     .  
   1  atgaaatacc tattgcctac ggcagccgct ggattgttat tactcgcggc ccagccggcc atggccgacg   
        m  k  y   l  l  p   t  a  a  a   g  l  l   l  l  a   a  q  p  a   m  a  d   
                                 pelB leader 
 
  71  tccaactggt gcagtcaggg gctgaagtga aaaaacctgg ggcctcagtg aaggtgtcct gcaaggcttc   
       v  q  l   v  q  s  g   a  e  v   k  k  p   g  a  s  v   k  v  s   c  k  a   
 
 141  tggctacacc tttactaggt acacgatgca ctgggtaagg caggcacctg gacagggtct ggaatggatt   
      s  g  y  t   f  t  r   y  t  m   h  w  v  r   q  a  p   g  q  g   l  e  w  i   
 
 211  ggatacatta atcctagccg tggttatact aattacgcag acagcgtcaa gggccgcttc acaatcacta   
        g  y  i   n  p  s   r  g  y  t   n  y  a   d  s  v   k  g  r  f   t  i  t   
 
 281  cagacaaatc caccagcaca gcctacatgg aactgagcag cctgcgttct gaggacactg caacctatta   
       t  d  k   s  t  s  t   a  y  m   e  l  s   s  l  r  s   e  d  t   a  t  y   
 
 351  ctgtgcaaga tattatgatg atcattactg ccttgactac tggggccaag gcaccacggt caccgtctcc   
      y  c  a  r   y  y  d   d  h  y   c  l  d  y   w  g  q   g  t  t   v  t  v  s  
  
                           AgeI . 
 421  tcaggcgaag gtactagtac cggtgatatt gttctgaccc agagcccggc gagcctggcg gttagcctgg   
        s  g  e   g  t  s   t  g  d  i   v  l  t   q  s  p   a  s  l  a   v  s  l   
               7 aa linker 
 
 491  gtcagcgtgc caccattagc tgccgtgcga gcaaaagcgt gagcaccagc ggctatagct atctgcattg   
       g  q  r   a  t  i  s   c  r  a   s  k  s   v  s  t  s   g  y  s   y  l  h   
 
 561  gtatcagcag aaaccgggcc agcctccaaa actgctgatt tatctggcca gcaacctgga aagcggtgtg   
      w  y  q  q   k  p  g   q  p  p   k  l  l  i   y  l  a   s  n  l   e  s  g  v   
 
 631  ccggcccgtt ttagcggcag cggcagcggt accgatttta ccctgaacat tcatccggtg gaagaagaag   
        p  a  r   f  s  g   s  g  s  g   t  d  f   t  l  n   i  h  p  v   e  e  e   
 
 701  atgcggcgac ctattattgc cagcatagcc gtgaactgcc gtttaccttt ggcagcggca ccaaactgga   
       d  a  a   t  y  y  c   q  h  s   r  e  l   p  f  t  f   g  s  g   t  k  l   
 
 771  aattaaaaag atctctggtg gcggcggctc gggtggtggt gggtcgggcg gcggcggctc gagccaggtg   
      e  i  k  k   i  s  g   g  g  g   s  g  g  g   g  s  g   g  g  g   s  s  q  v   
                              KIS-(G4S)3-S-linker (19 aa) 
 
 841  cagctggtgg aaagcggtgg cggactggtg cagccgggcg gcagcctgaa actgagctgt gccgccagcg   
        q  l  v   e  s  g   g  g  l  v   q  p  g   g  s  l   k  l  s  c   a  a  s   
 
 911  gttttgattt tagccgttat tggatgagct gggtgcgtca ggcgccgggc aaaggcctgg aatggattgg   
       g  f  d   f  s  r  y   w  m  s   w  v  r   q  a  p  g   k  g  l   e  w  i   
 
 981  cgaaattaac ccgaccagca gcaccattaa ctttaccccg agcctgaaag ataaagtgtt tattagccgt   
      g  e  i  n   p  t  s   s  t  i   n  f  t  p   s  l  k   d  k  v   f  i  s  r   
 
1051  gataacgcga aaaacaccct gtatctgcag atgagcaaag tgcgtagcga agataccgcg ctgtattatt   
        d  n  a   k  n  t   l  y  l  q   m  s  k   v  r  s   e  d  t  a   l  y  y   
 
1121  gcgcgcgtgg caactattat cgttatggcg atgcgatgga ttattggggc cagggcacca gcgtgaccgt   
       c  a  r   g  n  y  y   r  y  g   d  a  m   d  y  w  g   q  g  t   s  v  t   
 
             NotI  .                                                         EcoRI… 
1191  gagcgcggcc gccgattaca aggatgacga cgataaggga ggtcatcacc atcatcacca ttaataagaa   
      v  s  a  a   a  d  y   k  d  d   d  d  k  g   g  h  h   h  h  h   h  *  *     
                            Flag tag                       His tag 
         . 
1261  ttc 
 Sequences 
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8.14 VHCD3-scFvHLA-A2-FlagHis 
(in pUC119) 
VHCD3 VHHLA-A2 VLHLA-A2 
 
                                                                       NcoI .  
   1  atgaaatacc tattgcctac ggcagccgct ggattgttat tactcgcggc ccagccggcc atggccgacg   
        m  k  y   l  l  p   t  a  a  a   g  l  l   l  l  a   a  q  p  a   m  a  d   
                                 pelB leader 
 
  71  tccaactggt gcagtcaggg gctgaagtga aaaaacctgg ggcctcagtg aaggtgtcct gcaaggcttc   
       v  q  l   v  q  s  g   a  e  v   k  k  p   g  a  s  v   k  v  s   c  k  a   
 
 141  tggctacacc tttactaggt acacgatgca ctgggtaagg caggcacctg gacagggtct ggaatggatt   
      s  g  y  t   f  t  r   y  t  m   h  w  v  r   q  a  p   g  q  g   l  e  w  i   
 
 211  ggatacatta atcctagccg tggttatact aattacgcag acagcgtcaa gggccgcttc acaatcacta   
        g  y  i   n  p  s   r  g  y  t   n  y  a   d  s  v   k  g  r  f   t  i  t   
 
 281  cagacaaatc caccagcaca gcctacatgg aactgagcag cctgcgttct gaggacactg caacctatta   
       t  d  k   s  t  s  t   a  y  m   e  l  s   s  l  r  s   e  d  t   a  t  y   
 
 351  ctgtgcaaga tattatgatg atcattactg ccttgactac tggggccaag gcaccacggt caccgtctcc   
      y  c  a  r   y  y  d   d  h  y   c  l  d  y   w  g  q   g  t  t   v  t  v  s   
 
          BamHI   
 421  tcaggatccg gtggaggagg ttcacaggtg cagctggtgc agtctggggg aggcgtggtc cagcctgggg   
        s  g  s   g  g  g   g  s  q  v   q  l  v   q  s  g   g  g  v  v   q  p  g   
               7 aa linker 
 
 491  ggtccctgag agtctcctgt gcagcgtctg gggtcaccct cagtgattat ggcatgcatt gggtccgcca   
       g  s  l   r  v  s  c   a  a  s   g  v  t   l  s  d  y   g  m  h   w  v  r   
 
 561  ggctccaggc aaggggctgg agtggatggc ttttatacgg aatgatggaa gtgataaata ttatgcagac   
      q  a  p  g   k  g  l   e  w  m   a  f  i  r   n  d  g   s  d  k   y  y  a  d   
 
 631  tccgtgaagg gccgattcac catctccaga gacaactcca agaaaacagt gtctctgcaa atgagcagtc   
        s  v  k   g  r  f   t  i  s  r   d  n  s   k  k  t   v  s  l  q   m  s  s   
 
 701  tcagagctga agacacggct gtgtattact gtgcgaaaaa tggcgaatct gggcctttgg actactggta   
       l  r  a   e  d  t  a   v  y  y   c  a  k   n  g  e  s   g  p  l   d  y  w   
 
 771  cttcgatctc tggggccgtg gcaccctggt caccgtgtcg agtggtggag gcggttcagg cggaggtggc   
      y  f  d  l   w  g  r   g  t  l   v  t  v  s   s  g  g   g  g  s   g  g  g  g   
                                                             (G4S)3-linker (15 aa)… 
 
 841  tctggcggtg gcggatcgga tgttgtgatg actcagtctc catcctccct gtctgcatct gtaggagaca   
        s  g  g   g  g  s   d  v  v  m   t  q  s   p  s  s   l  s  a  s   v  g  d   
 
 
 911  gagtcaccat cacttgccag gcgagtcagg acattagcaa ctatttaaat tggtatcagc agaaaccagg   
       r  v  t   i  t  c  q   a  s  q   d  i  s   n  y  l  n   w  y  q   q  k  p   
 
 981  gaaagcccct aagctcctga tctacgatgc atccaatttg gaaacagggg tcccatcaag gttcagtgga   
      g  k  a  p   k  l  l   i  y  d   a  s  n  l   e  t  g   v  p  s   r  f  s  g   
 
1051  agtggatctg ggacagattt tactttcacc atcagcagcc tgcagcctga ggattttgca acttattact   
        s  g  s   g  t  d   f  t  f  t   i  s  s   l  q  p   e  d  f  a   t  y  y  
  
                                                                            NotI  .  
1121  gccaacaata tagtagtttt ccgctcactt tcggcggagg gaccaaagtg gatatcaaac gtgcggccgc   
       c  q  q   y  s  s  f   p  l  t   f  g  g   g  t  k  v   d  i  k   r  a  a   
 
1191  cgattacaag gatgacgacg ataagggagg tcatcaccat catcaccatt aataa 
      a  d  y  k   d  d  d   d  k  g   g  h  h  h   h  h  h   *  * 
                Flag tag                       His tag 
 
 Sequences 
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8.15 VHCD3-scFvHLA-A2-mycHis 
(in pUC119) 
VHCD3 VHHLA-A2 VLHLA-A2 
 
                                                                       NcoI .  
   1  atgaaatacc tattgcctac ggcagccgct ggattgttat tactcgcggc ccagccggcc atggccgacg   
        m  k  y   l  l  p   t  a  a  a   g  l  l   l  l  a   a  q  p  a   m  a  d   
                                 pelB leader 
 
  71  tccaactggt gcagtcaggg gctgaagtga aaaaacctgg ggcctcagtg aaggtgtcct gcaaggcttc   
       v  q  l   v  q  s  g   a  e  v   k  k  p   g  a  s  v   k  v  s   c  k  a   
 
 141  tggctacacc tttactaggt acacgatgca ctgggtaagg caggcacctg gacagggtct ggaatggatt   
      s  g  y  t   f  t  r   y  t  m   h  w  v  r   q  a  p   g  q  g   l  e  w  i   
 
 211  ggatacatta atcctagccg tggttatact aattacgcag acagcgtcaa gggccgcttc acaatcacta   
        g  y  i   n  p  s   r  g  y  t   n  y  a   d  s  v   k  g  r  f   t  i  t   
 
 281  cagacaaatc caccagcaca gcctacatgg aactgagcag cctgcgttct gaggacactg caacctatta   
       t  d  k   s  t  s  t   a  y  m   e  l  s   s  l  r  s   e  d  t   a  t  y   
 
 351  ctgtgcaaga tattatgatg atcattactg ccttgactac tggggccaag gcaccacggt caccgtctcc   
      y  c  a  r   y  y  d   d  h  y   c  l  d  y   w  g  q   g  t  t   v  t  v  s   
 
          BamHI   
 421  tcaggatccg gtggaggagg ttcacaggtg cagctggtgc agtctggggg aggcgtggtc cagcctgggg   
        s  g  s   g  g  g   g  s  q  v   q  l  v   q  s  g   g  g  v  v   q  p  g   
               7 aa linker 
 
 491  ggtccctgag agtctcctgt gcagcgtctg gggtcaccct cagtgattat ggcatgcatt gggtccgcca   
       g  s  l   r  v  s  c   a  a  s   g  v  t   l  s  d  y   g  m  h   w  v  r   
 
 561  ggctccaggc aaggggctgg agtggatggc ttttatacgg aatgatggaa gtgataaata ttatgcagac   
      q  a  p  g   k  g  l   e  w  m   a  f  i  r   n  d  g   s  d  k   y  y  a  d   
 
 631  tccgtgaagg gccgattcac catctccaga gacaactcca agaaaacagt gtctctgcaa atgagcagtc   
        s  v  k   g  r  f   t  i  s  r   d  n  s   k  k  t   v  s  l  q   m  s  s   
 
 701  tcagagctga agacacggct gtgtattact gtgcgaaaaa tggcgaatct gggcctttgg actactggta   
       l  r  a   e  d  t  a   v  y  y   c  a  k   n  g  e  s   g  p  l   d  y  w   
 
 771  cttcgatctc tggggccgtg gcaccctggt caccgtgtcg agtggtggag gcggttcagg cggaggtggc   
      y  f  d  l   w  g  r   g  t  l   v  t  v  s   s  g  g   g  g  s   g  g  g  g   
                                                             (G4S)3-linker (15 aa)… 
 
 841  tctggcggtg gcggatcgga tgttgtgatg actcagtctc catcctccct gtctgcatct gtaggagaca   
        s  g  g   g  g  s   d  v  v  m   t  q  s   p  s  s   l  s  a  s   v  g  d   
 
 
 911  gagtcaccat cacttgccag gcgagtcagg acattagcaa ctatttaaat tggtatcagc agaaaccagg   
       r  v  t   i  t  c  q   a  s  q   d  i  s   n  y  l  n   w  y  q   q  k  p   
 
 981  gaaagcccct aagctcctga tctacgatgc atccaatttg gaaacagggg tcccatcaag gttcagtgga   
      g  k  a  p   k  l  l   i  y  d   a  s  n  l   e  t  g   v  p  s   r  f  s  g   
 
1051  agtggatctg ggacagattt tactttcacc atcagcagcc tgcagcctga ggattttgca acttattact   
        s  g  s   g  t  d   f  t  f  t   i  s  s   l  q  p   e  d  f  a   t  y  y  
  
                                                                            NotI  .  
1121  gccaacaata tagtagtttt ccgctcactt tcggcggagg gaccaaagtg gatatcaaac gtgcggccgc   
       c  q  q   y  s  s  f   p  l  t   f  g  g   g  t  k  v   d  i  k   r  a  a   
 
1191  agaacaaaaa ctcatctcag aagaggatct gaatggggcc gcacatcacc atcatcacca ttaataa 
      a  e  q  k   l  i  s   e  e  d   l  n  g  a   a  h  h   h  h  h   h  *  * 
                    myc tag                                 His tag 
 
 Sequences 
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8.16 VLCD3-scFvHLA-A2-mycHis 
(in pUC119) 
VLCD3 VHHLA-A2 VLHLA-A2 
 
                                                                       NcoI .  
   1  atgaaatacc tattgcctac ggcagccgct ggattgttat tactcgcggc ccagccggcc atggccgaca   
        m  k  y   l  l  p   t  a  a  a   g  l  l   l  l  a   a  q  p  a   m  a  d   
                                 pelB leader 
 
  71  ttgtactgac ccagtctcca gcaactctgt ctctgtctcc aggggagcgt gccaccctga gctgcagagc   
       i  v  l   t  q  s  p   a  t  l   s  l  s   p  g  e  r   a  t  l   s  c  r   
 
 141  cagtcaaagt gtaagttaca tgaactggta ccagcagaag ccgggcaagg cacccaaaag atggatttat   
      a  s  q  s   v  s  y   m  n  w   y  q  q  k   p  g  k   a  p  k   r  w  i  y   
 
 211  gacacatcca aagtggcttc tggagtccct gctcgcttca gtggcagtgg gtctgggacc gactactctc   
        d  t  s   k  v  a   s  g  v  p   a  r  f   s  g  s   g  s  g  t   d  y  s   
 
 281  tcacaatcaa cagcttggag gctgaagatg ctgccactta ttactgccaa cagtggagta gtaacccgct   
       l  t  i   n  s  l  e   a  e  d   a  a  t   y  y  c  q   q  w  s   s  n  p  
  
                                            BamHI   
 351  cacgttcggt ggcgggacca aggtggagat caaaggatcc ggtggaggag gttcacaggt gcagctggtg   
      l  t  f  g   g  g  t   k  v  e   i  k  g  s   g  g  g   g  s  q   v  q  l  v   
                                                 7 aa linker 
 
 421  cagtctgggg gaggcgtggt ccagcctggg gggtccctga gagtctcctg tgcagcgtct ggggtcaccc   
        q  s  g   g  g  v   v  q  p  g   g  s  l   r  v  s   c  a  a  s   g  v  t   
 
 491  tcagtgatta tggcatgcat tgggtccgcc aggctccagg caaggggctg gagtggatgg cttttatacg   
       l  s  d   y  g  m  h   w  v  r   q  a  p   g  k  g  l   e  w  m   a  f  i   
 
 561  gaatgatgga agtgataaat attatgcaga ctccgtgaag ggccgattca ccatctccag agacaactcc   
      r  n  d  g   s  d  k   y  y  a   d  s  v  k   g  r  f   t  i  s   r  d  n  s   
 
 631  aagaaaacag tgtctctgca aatgagcagt ctcagagctg aagacacggc tgtgtattac tgtgcgaaaa   
        k  k  t   v  s  l   q  m  s  s   l  r  a   e  d  t   a  v  y  y   c  a  k   
 
 701  atggcgaatc tgggcctttg gactactggt acttcgatct ctggggccgt ggcaccctgg tcaccgtgtc   
       n  g  e   s  g  p  l   d  y  w   y  f  d   l  w  g  r   g  t  l   v  t  v   
 
 771  gagtggtgga ggcggttcag gcggaggtgg ctctggcggt ggcggatcgg atgttgtgat gactcagtct   
      s  s  g  g   g  g  s   g  g  g   g  s  g  g   g  g  s   d  v  v   m  t  q  s   
                       (G4S)3-linker (15 aa) 
 
 841  ccatcctccc tgtctgcatc tgtaggagac agagtcacca tcacttgcca ggcgagtcag gacattagca   
        p  s  s   l  s  a   s  v  g  d   r  v  t   i  t  c   q  a  s  q   d  i  s   
 
 911  actatttaaa ttggtatcag cagaaaccag ggaaagcccc taagctcctg atctacgatg catccaattt   
       n  y  l   n  w  y  q   q  k  p   g  k  a   p  k  l  l   i  y  d   a  s  n   
 
 981  ggaaacaggg gtcccatcaa ggttcagtgg aagtggatct gggacagatt ttactttcac catcagcagc   
      l  e  t  g   v  p  s   r  f  s   g  s  g  s   g  t  d   f  t  f   t  i  s  s   
 
1051  ctgcagcctg aggattttgc aacttattac tgccaacaat atagtagttt tccgctcact ttcggcggag   
        l  q  p   e  d  f   a  t  y  y   c  q  q   y  s  s   f  p  l  t   f  g  g  
  
                                  NotI  .   
1121  ggaccaaagt ggatatcaaa cgtgcggccg cagaacaaaa actcatctca gaagaggatc tgaatggggc   
       g  t  k   v  d  i  k   r  a  a   a  e  q   k  l  i  s   e  e  d   l  n  g   
                                                                                 myc tag 
 
1191  cgcacatcac catcatcacc attaataa 
      a  a  h  h   h  h  h   h  *  * 
                 His tag 
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Parts of the present study were submitted for publication as part of the following 
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11 Supplementary Notes 
The experimental work for this dissertation was performed from 1st December 2008 to 
31st May 2012 under the direction of Dr. med. Gernot Stuhler at the Department of 
Internal Medicine II, but principally at the laboratories of Prof. Dr. rer. nat. Harald 
Wajant at the Division of Molecular Internal Medicine, Julius-Maximilians-Universität 
Würzburg. 
 
The data and results of this thesis regarding the trispecific antibody were substantially 
used as a proof of concept in the following patent specification: Dual antigen-induced 
bipartite functional complementation. Julius-Maximilians-Universität Würzburg. Patent 
No. WO 2013/104804. 
 
Furthermore, the development of the trispecific antibody concept presented by this 
study helped to win the m4 Award 2013: “Neuartige bi-molekulare T-Zell aktivierende 
Antikörper für die zielgerichtete kombinatorische Tumor-Immuntherapie (bi-ATAK)”. 
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